<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.2.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art520.dtd?><?SourceDTD.Version 5.2.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_IJWD113 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEgr7 jpg ?><?FILEgr8 jpg ?><?FILEgr9 jpg ?><?FILEgr10 jpg ?><?FILEgr11 jpg ?><?FILEgr12 jpg ?><?FILEgr13 jpg ?><?FILEgr14 jpg ?><?FILEgr15 jpg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Womens Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Womens Dermatol</journal-id><journal-title-group><journal-title>International Journal of Women's Dermatology</journal-title></journal-title-group><issn pub-type="epub">2352-6475</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5419061</article-id><article-id pub-id-type="publisher-id">S2352-6475(17)30016-3</article-id><article-id pub-id-type="doi">10.1016/j.ijwd.2017.02.006</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Updates in the understanding and treatments of skin &#x00026; hair disorders in women of color<sup><xref ref-type="fn" rid="d31e994">&#x02606;</xref></sup><sup><xref ref-type="fn" rid="d31e999">&#x02606;&#x02606;</xref></sup><sup><xref ref-type="fn" rid="d31e1004">&#x02605;</xref></sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lawson</surname><given-names>Christina N.</given-names></name><degrees>MD</degrees><email>clawson2011@gmail.com</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Hollinger</surname><given-names>Jasmine</given-names></name><degrees>MD</degrees><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Sethi</surname><given-names>Sumit</given-names></name><degrees>MD</degrees><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Rodney</surname><given-names>Ife</given-names></name><degrees>MD</degrees><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Sarkar</surname><given-names>Rashmi</given-names></name><degrees>MD</degrees><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Dlova</surname><given-names>Ncoza</given-names></name><degrees>MBChB, FCDerm (SA)</degrees><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Callender</surname><given-names>Valerie D.</given-names></name><degrees>MD</degrees><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Department of Dermatology, Howard University College of Medicine, Washington, District of Columbia</aff><aff id="af0010"><label>b</label>Callender Dermatology &#x00026; Cosmetic Center, Glenn Dale, Maryland</aff><aff id="af0015"><label>c</label>Department of Dermatology, Maulana Azad Medical College and Associated Hospitals, New Delhi, India</aff><aff id="af0020"><label>d</label>Department of Dermatology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Address correspondence and reprint requests to: Christina N. Lawson, MD, Howard University Hospital, Department of Dermatology, 2041 Georgia Avenue NW, Suite 2107, Washington, DC 20060. Tel.: +&#x000a0;1 202 865 6725; fax: +&#x000a0;1 202 865 1757. <email>clawson2011@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>16</day><month>2</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>3</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>16</day><month>2</month><year>2017</year></pub-date><volume>3</volume><issue>1 Suppl</issue><fpage>S21</fpage><lpage>S37</lpage><history><date date-type="received"><day>22</day><month>12</month><year>2014</year></date><date date-type="rev-recd"><day>15</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 The Author(s)</copyright-statement><copyright-year>2015</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="ab0005"><p>Skin of color comprises a diverse and expanding population of individuals. In particular, women of color represent an increasing subset of patients who frequently seek dermatologic care. Acne, melasma, and alopecia are among the most common skin disorders seen in this patient population. Understanding the differences in the basic science of skin and hair is imperative in addressing their unique needs. Despite the paucity of conclusive data on racial and ethnic differences in skin of color, certain biologic differences do exist, which affect the disease presentations of several cutaneous disorders in pigmented skin. While the overall pathogenesis and treatments for acne in women of color are similar to Caucasian men and women, individuals with darker skin types present more frequently with dyschromias from acne, which can be difficult to manage. Melasma is an acquired pigmentary disorder seen commonly in women with darker skin types and is strongly associated with ultraviolet (UV) radiation, genetic factors, and hormonal influences. Lastly, certain hair care practices and hairstyles are unique among women of African descent, which may contribute to specific types of hair loss seen in this population, such as traction alopecia, trichorrhexis nodosa and central centrifugal cicatricial alopecia (CCCA).</p></abstract></article-meta></front><body><sec id="s0005"><title>Introduction</title><p>Skin of color, which refers to individuals with Fitzpatrick skin types (FST) IV through VI, represents a rapidly expanding population in the United States as well as in many nations across the world. It includes Asians, Latinos (Hispanics), Africans, African-Americans, Afro-Caribbeans, Middle Easterners, Native Americans, Alaskan natives, Pacific Islanders, Native Hawaiians and Mediterraneans. In the United States alone, just over one third of the United States population reported their race and ethnicity as something other than non-Hispanic white in the 2010 census (<xref rid="bb0005" ref-type="bibr">US Census Bureau, 2010</xref>). As this patient population increases, it is critical to recognize the vast clinical presentations of skin and hair disorders in patients with pigmented skin. The epidemiology of skin diseases in individuals of color has not been extensively studied (<xref rid="bb0010" ref-type="bibr">Taylor, 2003</xref>). <xref rid="t0005" ref-type="table">Table&#x000a0;1</xref> provides recent nationally representative data from dermatology practice surveys among skin of color patients (<xref rid="bb0015" ref-type="bibr">Davis et al., 2012</xref>). While acne and unspecified dermatitis or eczema are in the top five cutaneous diagnoses for all major U.S. racial and ethnic groups, dyschromia also remains a leading condition among African Americans and Hispanics (<xref rid="bb0015" ref-type="bibr">Davis et al., 2012</xref>). African Americans are unique in that alopecia remains a top diagnosis within this ethnic group (<xref rid="bb0015" ref-type="bibr">Davis et al., 2012</xref>). In particular, there are unique challenges specific to treating skin and hair conditions in women of color. Delays in treatment or misdiagnoses may lead to possible sequelae, such as postinflammatory hyperpigmentation (PIH), hypertrophic scarring, keloid formation, and permanent alopecia. The optimal treatments for women of color seeking dermatologic care continue to evolve over time. It is the authors&#x02019; aim that a better understanding of the common skin and hair disorders afflicted by women of color will ultimately lead to more satisfactory outcomes in this patient population.</p></sec><sec id="s0010"><title>Structure &#x00026; function of skin of color</title><p>The heterogeneity seen among persons of color can be best explained via the differences in the structure, function, and physiology of the skin and hair. Literature on ethnic and racial differences in skin and hair structure, physiology, and function is lacking. Although data in this area is limited, the literature does offer some insight on the physiologic and structural variations that exist. It is important to understand these differences since disease presentations are influenced by these variations and several cutaneous disorders are much more commonly seen in skin of color (<xref rid="bb0015" ref-type="bibr">Davis et al., 2012</xref>).</p><sec id="s0015"><title>Melanocyte biology</title><p>It is well known that ethnic and racial differences in skin color are not due to the number of melanocytes, but rather are due to variations in the size, number, and aggregation of melanosomes within keratinocytes and melanocytes (<xref rid="bb0020" ref-type="bibr">Taylor, 2002</xref>). Melanocytes synthesize melanin in melanosomes which are specialized organelles. Pigmented melanosomes are transferred from one melanocyte to between 30&#x02013;35 adjacent keratinocytes in the basal layer. Two types of melanin exist: eumelanin, a dark brown&#x02013;black pigment and pheomelanin, a yellow&#x02013;reddish pigment. The constitutive levels of pheomelanin and eumelanin are generally believed to be due to genetics (<xref rid="bb0020" ref-type="bibr">Taylor, 2002</xref>). Eumelanin is more important in determining the degree of pigmentation than pheomelanin (<xref rid="bb0025" ref-type="bibr">Wakamatsu et al., 2006</xref>). Lighter melanocytes have higher pheomelanin content than dark melanocytes (<xref rid="bb0025" ref-type="bibr">Wakamatsu et al., 2006</xref>). In one study by Wakamatsu et al, Caucasians had the least amount of eumelanin, Asian Indians had more, and African-Americans had the highest amount (<xref rid="bb0025" ref-type="bibr">Wakamatsu et al., 2006</xref>). Paracrine factors secreted from fibroblasts and keratinocytes have also been shown to play important roles in the regulation of skin pigmentation. In particular, neuregulin-1 (NRG1) which is highly expressed and secreted by fibroblasts derived from Fitzpatrick type VI skin has been found by Choi et al to play an important role in regulating the constitutive pigmentation of human skin by increasing the proliferation and pigmentation of melanocytes (<xref rid="bb0030" ref-type="bibr">Choi et al., 2012</xref>). These authors subsequently characterized the bioactive motif of NRG1 that is involved in modulating melanin production in melanocytes by increasing melanin production (<xref rid="bb0030" ref-type="bibr">Choi et al., 2012</xref>).</p><p>Melanosomes also differ among races. In black skin, they are larger and more active in producing melanin and are packaged, distributed, and broken down differently than in Caucasian skin (<xref rid="bb0020" ref-type="bibr">Taylor, 2002</xref>). The number of melanosomes transferred to keratinocytes has also been shown to be significantly higher in skin of African descent versus white skin as made evident by higher expression of the RAB27A melanosome transport molecule in darkly pigmented melanocytes (<xref rid="bb0035" ref-type="bibr">Yoshida-Amano et al., 2012</xref>). Protease-activated receptor 2 (PAR-2) is another contributor to skin pigmentation. This receptor is involved in various biologic processes including cutaneous pigmentation since its activation stimulates production of pigment (<xref rid="bb0040" ref-type="bibr">Babiarz-Magee et al., 2004</xref>). In addition, its expression has been found to be different in Caucasian skin when compared to darker skin. One study demonstrated that PAR-2 and its activator trypsin are expressed in higher levels in darker skin and was also found to have higher cleavage ability in highly pigmented skin (<xref rid="bb0040" ref-type="bibr">Babiarz-Magee et al., 2004</xref>).</p><p>Melanin provides protection from ultraviolet (UV) light. Fitzpatrick skin phototypes IV&#x02013;VI are less susceptible to photoaging, which is most likely due to the photoprotective properties of melanin. Previous studies have illustrated that the mean UVA transmission through the epidermis is 17.5% in pigmented skin and is 55.5% for Caucasian skin (<xref rid="bb0045" ref-type="bibr">Kligman, 1994</xref>). The UVB transmission through the epidermis is 5.7% for pigmented skin compared to 29.4% for Caucasian skin (<xref rid="bb0045" ref-type="bibr">Kligman, 1994</xref>).</p></sec><sec id="s0020"><title>Biology of the epidermis and dermis</title><p>The structure and function of the epidermis and dermis is similar among various races and ethnicities, but important differences do exist.</p><p>The stratum corneum (SC) serves as the skin&#x02019;s mechanical barrier and prevents water loss. Over the years, there has been conflicting data in the literature regarding racial differences in the SC. Early studies have shown that the stratum corneum of black skin is more compact than that of white skin (<xref rid="bb0020" ref-type="bibr">Taylor, 2002</xref>). In one study conducted by Chu and Kollias, corneocyte detachment was more prevalent with age and was found to be more severe on the dorsal forearm in Caucasian subjects (<xref rid="bb0050" ref-type="bibr">Chu and Kollias, 2011</xref>). In addition, corneocyte detachment values were lower for African-Americans than for Caucasians (<xref rid="bb0050" ref-type="bibr">Chu and Kollias, 2011</xref>). The authors also concluded that the SC appears different between body sites of different exposures, ages, and persons of different pigmentation groups, but there are minimal differences in water-handling properties (<xref rid="bb0050" ref-type="bibr">Chu and Kollias, 2011</xref>). In a study investigating differences in SC lipids among different ethnicities, the ceramide/cholesterol ratio was highest in Asians, whites had intermediate values, and Africans had the lowest values (<xref rid="bb0055" ref-type="bibr">Jungersted et al., 2010</xref>). Another study showed that East Asian and to some extent Caucasian skin had low maturation and relatively weak skin barrier (<xref rid="bb0060" ref-type="bibr">Muizzuddin et al., 2010</xref>). African American skin had low ceramide levels and high protein cohesion in the uppermost layers of the SC (<xref rid="bb0060" ref-type="bibr">Muizzuddin et al., 2010</xref>). Transepidermal water loss (TEWL) is defined as the amount of water vapor loss from the skin, excluding sweat. The difference in TEWL between different races has yet to be established due to conflicting studies. TEWL has been found to be greater in black skin compared to white skin in the majority of studies, but the opposite has also been reported (<xref rid="bb0060" ref-type="bibr">Muizzuddin et al., 2010</xref>).</p><p>The dermis of blacks is thicker and more compact than that of white skin (<xref rid="bb0065" ref-type="bibr">Girardeau-Hubert et al., 2012</xref>). The papillary and reticular layers of the dermis are more distinct, contain larger collagen fiber bundles, and the fiber fragments are sparse in whites. In contrast, the dermis of black skin contains closely stacked, smaller collagen fiber bundles with a surrounding ground substance (<xref rid="bb0065" ref-type="bibr">Girardeau-Hubert et al., 2012</xref>). Girardeau-Hubert et al showed on histology that African skin had greater convoluted appearance of the dermal epidermal junction (DEJ) than Caucasian skin and on immunostaining laminin 332, type IV and VII collagens, and nidogen proteins at the DEJ were lower in African skin compared with Caucasian skin (<xref rid="bb0065" ref-type="bibr">Girardeau-Hubert et al., 2012</xref>).</p></sec><sec id="s0025"><title>Hair biology</title><p>Three major categories of hair exist according to ethnic origin: Asian, Caucasian, and African. Genetics are thought to be responsible for the majority of variations seen across races and ethnic groups in hair morphology. It has been previously noted that the four hair types are helical, spiral, straight, and wavy (<xref rid="bb0020" ref-type="bibr">Taylor, 2002</xref>). The majority of blacks have the spiral hair type (<xref rid="bb0020" ref-type="bibr">Taylor, 2002</xref>). This impart explains why African hair is more difficult to comb than Caucasian hair. Regarding hair shape, Asian and Caucasian hair is more cylindrical in contrast to African hair, which resembles an oval twisted rod that has frequent twists that have random reversals in direction and pronounced flattening. Asian hair has the greatest diameter with circular geometry while black hair shows an elliptic section along the shaft and a high degree of irregularity in the hair diameter. Caucasian hair is intermediate in diameter and section shape. Black hair breaks more easily than Caucasian hair due to the lesser tensile strength and also has lower moisture content (<xref rid="bb0070" ref-type="bibr">Ji et al., 2013</xref>). A study by Ji et al evaluated the change of integral hair lipids after UVR in Africans, Asians, and Europeans. The study found that Asian hair had more integral hair lipids than European and African hair, but lipid composition overall was similar across the groups (<xref rid="bb0070" ref-type="bibr">Ji et al., 2013</xref>). African hair in general showed the most hair surface damage (<xref rid="bb0070" ref-type="bibr">Ji et al., 2013</xref>). The study also revealed that after UV irradiation, European and African hair exhibited more damage because they had less integral hair lipids when compared to Asian hair, which had less damage (<xref rid="bb0070" ref-type="bibr">Ji et al., 2013</xref>). As measured by high-performance thin-layer chromatography, integral hair lipids in whole hair follicles are composed of fatty acid, phytosphingosine, ceramide, cholesterol, cholesterol sulfate, and cholesterol oleate in decreasing order (<xref rid="bb0075" ref-type="bibr">Lee et al., 2005</xref>). These findings reiterate the importance of hair care in blacks as this hair type is naturally more brittle and more susceptible to breakage. Although keratins and their respective amino acids have been reported to be similar across the three groups, one study showed high variation in keratin protein expression among Kenyans, Koreans, Caucasians, African Americans allowing identification of individual profiles (<xref rid="bb0080" ref-type="bibr">Laatsch et al., 2014</xref>). On the contrary, differences between these groups were less marked and relied largely on levels of keratin-associated proteins (<xref rid="bb0080" ref-type="bibr">Laatsch et al., 2014</xref>). <xref rid="t0010" ref-type="table">Table&#x000a0;2</xref> summarizes the most established differences in the structure and function of the skin and hair between Caucasians and African Americans (<xref rid="bb0025" ref-type="bibr">Wakamatsu et al., 2006</xref>, <xref rid="bb0035" ref-type="bibr">Yoshida-Amano et al., 2012</xref>, <xref rid="bb0050" ref-type="bibr">Chu and Kollias, 2011</xref>, <xref rid="bb0055" ref-type="bibr">Jungersted et al., 2010</xref>, <xref rid="bb0065" ref-type="bibr">Girardeau-Hubert et al., 2012</xref>, <xref rid="bb0070" ref-type="bibr">Ji et al., 2013</xref>, <xref rid="bb0085" ref-type="bibr">Badreshia-Bansal and Taylor, 2009</xref>, <xref rid="bb9000" ref-type="bibr">Weigand et al., 1974</xref>, <xref rid="bb9010" ref-type="bibr">La Ruche and Cesarini, 1992</xref>, <xref rid="bb9005" ref-type="bibr">Lindelof et al., 1998</xref>).</p></sec></sec><sec id="s0030"><title>Adult-Female acne</title><p>Acne vulgaris is the most commonly reported dermatological complaint among non-Caucasian patients (<xref rid="bb0090" ref-type="bibr">Halder et al., 1983a</xref>, <xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0100" ref-type="bibr">Callender et al., 2014a</xref>). Adult acne is traditionally defined as the presence of acne beyond the age of 25 years and is divided into persistent and late-onset acne (<xref rid="bb0100" ref-type="bibr">Callender et al., 2014a</xref>). Although once previously regarded as a disease of adolescence, acne vulgaris may persist from adolescence beyond the age of 25 years (&#x0201c;persistent acne&#x0201d;) or manifest itself for the first time beyond the age of 25 years (&#x0201c;late-onset adult acne&#x0201d;) (<xref rid="bb0105" ref-type="bibr">Khunger and Kumar, 2012</xref>). Among adult cases of acne, women tend to be affected more frequently than men; 12-22% of US women have adult acne, compared to 3% of US men (<xref rid="bb0110" ref-type="bibr">Goulden et al., 1999</xref>). One photographic study found clinical acne to be highly prevalent in African American (37%), Hispanic/Latinas (32%), Asian (30%), and Continental Indian (23%) women (<xref rid="bb0115" ref-type="bibr">Perkins et al., 2011</xref>). Another study reported that adult subjects with acne (mostly women) comprised the majority of dermatologic office visits (61.9%) while adolescents (aged 15-17 years old) comprised only 36.5% of visits (<xref rid="bb0120" ref-type="bibr">Yentzer et al., 2010</xref>). In addition, females account for two-thirds of dermatologic visits for acne and one-third of all office visits for acne are by women over the age of 25 years old (<xref rid="bb0120" ref-type="bibr">Yentzer et al., 2010</xref>).</p><p>A recent cross-sectional, web-based survey of 208 women with adult facial acne was performed to evaluate the racial differences in clinical characteristics, perceptions, behaviors and psychosocial impact of acne. In this study, non-Caucasian women experienced substantially more PIH than Caucasian women (<xref rid="bb0100" ref-type="bibr">Callender et al., 2014a</xref>). In addition, lesion clearance was the most important aspect of acne clearing for Caucasian women (57.9% vs non-Caucasian 31.7%), whereas clearance of PIH was most important for many non-Caucasian females (41.6% vs Caucasian 8.4%) (<xref rid="bb0100" ref-type="bibr">Callender et al., 2014a</xref>). These findings further emphasize the importance of developing an individualized, tailored treatment approach when caring for women of color with acne.</p><p>Several previous studies have suggested that adult female acne has a significant negative psychosocial impact in women. A recent cross-sectional, web-based survey reported the facial acne in adult women negatively affected their overall health-related quality of life, was associated with mild to moderate symptoms of depression and/or anxiety, and impacted their ability to concentrate on work or school (<xref rid="bb0125" ref-type="bibr">Tanghetti et al., 2014</xref>). Taken together, these findings demonstrate the crucial role dermatologists serve in addressing the symptom burden of acne in adult women.</p><sec id="s0035"><title>Pathogenesis</title><p>The multifactorial pathogenesis of acne vulgaris in women of color is similar to that of Caucasian women and men. The four key components central to acne pathophysiology include follicular hyperkeratinization, sebum production, <italic>Propionibacterium acnes</italic> overgrowth, and inflammation (<xref rid="bb0130" ref-type="bibr">Fisk et al., 2014</xref>). In addition, many previous studies have evaluated differences in skin biology characteristics between racial ethnic groups. For example, one small study of 60 women found an overall higher density of <italic>P. acnes</italic> in African American subjects (<xref rid="bb0135" ref-type="bibr">Warrier et al., 1996</xref>). Another study demonstrated that pore size was positively correlated with acne in African American, Asian and Continental Indian women (<xref rid="bb0115" ref-type="bibr">Perkins et al., 2011</xref>). However, to date, results from studies evaluating potential differences in sebaceous gland activity and size and sebum production between racial groups remain contradictory. Additional factors such as genetics, diet, cosmetics, tobacco, stress, medications, and hormonal influences from estrogens and androgens also play a role in adult women with acne (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0130" ref-type="bibr">Fisk et al., 2014</xref>).</p></sec><sec id="s0040"><title>Clinical features</title><p>Acne vulgaris in the adult female patient typically presents with primary lesions on the lower one-third of the face, especially near the jaw line and chin (<xref rid="bb0140" ref-type="bibr">Kamangar and Shinkai, 2012</xref>) (<xref rid="f0005" ref-type="fig">Fig.&#x000a0;1</xref>). Clinical features that are more frequently encountered in women of color include dyspigmentation and scarring (<xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>). In one study, these aforementioned events were more common in African Americans and Hispanic women than all other ethnicities (<xref rid="bb0115" ref-type="bibr">Perkins et al., 2011</xref>).</p><p>PIH is often the presenting complaint among women of color with darker skin types with acne (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>) (<xref rid="f0010" ref-type="fig">Fig.&#x000a0;2</xref>). While epidermal lesions may persist for up to one year, dermal pigmentation may persist for years and may be a cause of significant distress (<xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>). In 2013, a new instrument to measure PIH from acne vulgaris, known as the postacne hyperpigmentation index (PAHPI), was developed and found to have good reliability and validity in skin of color subjects (<xref rid="bb0150" ref-type="bibr">Savory et al., 2014</xref>).</p><p>A study performed by <xref rid="bb0155" ref-type="bibr">Halder et al. (1996)</xref> demonstrated histopathological evidence of marked inflammation in all types of acne lesions on biopsy specimens, including comedones that lacked evidence of inflammation clinically. This intensified level of inflammation on histopathology in skin of color subjects may account for their increased propensity to develop PIH. Other complications of acne seen more commonly in women of color include keloidal scarring and persistent erythema.</p><p>Women of color with acne may also develop distinctive subtypes of acne secondary to unique cultural practices integral to their ethnic background. Pomade acne, commonly seen in African Americans, presents as closed comedones and papules along the frontal hairline, forehead, and temples (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>) (<xref rid="f0015" ref-type="fig">Fig.&#x000a0;3</xref>). Pomade acne occurs secondary to long-term daily use of oils and thick emollients used for moisturizing ethnic hair. Acne cosmetica is also frequently encountered among women of color and presents as comedones due to the use of certain cosmetic products that are used to conceal acne lesions and PIH (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>). In addition, steroid acne may be seen in patients using skin-lightening agents that contain potent topical corticosteroids in efforts to improve PIH (<xref rid="bb0160" ref-type="bibr">Callender, 2004</xref>).</p></sec><sec id="s0045"><title>Treatment</title><p>The treatment of acne in women of color is generally similar to that of Caucasian patients. However, an appropriate understanding of the sequelae of acne is the key distinguishing characteristic in women of color. Potential sequelae, such as PIH and keloid scarring, occur more frequently in individuals with skin of color (<xref rid="bb0165" ref-type="bibr">Shah and Alexis, 2010</xref>). More severe forms of acne (especially truncal) can be associated with keloids and may be long lasting or permanent (<xref rid="bb0165" ref-type="bibr">Shah and Alexis, 2010</xref>). Therefore, early and efficacious anti-inflammatory agents to minimize pigmentary abnormalities and keloid scarring must be balanced with their potential for adverse effects (e.g. avoidance of potentially irritating topical agents that might further aggravate pre-existing PIH.) As with all acne patients, one must first determine the predominant type of acne lesion(s) and obtain a history of the patient&#x02019;s skin type (normal, oily, dry or combination). An acne/PIH algorithm is provided in <xref rid="f0020" ref-type="fig">Fig.&#x000a0;4</xref> (<xref rid="bb0170" ref-type="bibr">Taylor et al., 2011</xref>).</p></sec><sec id="s0050"><title>Topical retinoids</title><p>Topical retinoids, which include adapalene, tretinoin, and tazarotene, are the mainstay of treatment in mild to moderate acne vulgaris in women of color. Retinoids are beneficial for women of color as they treat not only the active acne lesions, but also help ameliorate PIH (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>). Their mechanism of action includes inhibition of toll-like receptor (TLR)-2, reduction of the formation of hyperproliferative keratins, and inhibition of AP-1 pathway, thereby reducing inflammation (<xref rid="bb0175" ref-type="bibr">Taylor and Summers, 2009</xref>). An additional property of topical retinoids that makes these agents appealing for use in skin of color patients is their ability to improve PIH by inhibition of melanosome transfer and facilitating melanin dispersion and removal (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>).</p><p>A major concern with the use of topical retinoids in skin of color includes the potential for inducing a retinoid dermatitis, which is characterized by xerosis, peeling, and erythema of the skin (<xref rid="bb0175" ref-type="bibr">Taylor and Summers, 2009</xref>). There are several practical tips that may mitigate this adverse effect and prevent further worsening of PIH. These include initiating patients on lower concentrations of topical retinoids, choosing cream or lotion (over gel), instructing an every-other-day application regimen with increased frequency as tolerated by the patient, and the addition of a topical gentle moisturizer (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>, <xref rid="bb0175" ref-type="bibr">Taylor and Summers, 2009</xref>).</p><p>A study of 171 Mexican subjects with FST III and IV were evaluated in a single-center, randomized, double-blinded, placebo-controlled clinical trial evaluating the efficacy and safety of adapalene and tretinoin (<xref rid="bb0180" ref-type="bibr">Tirado-Sanchez et al., 2013</xref>). The authors found that adapalene 0.3% gel and tretinoin 0.05% gel were comparable in efficacy in reducing both inflammatory and noninflammatory lesions, while tolerance was better with adapalene 0.1% gel than with adapalene 0.3% and tretinoin 0.05% gel in Mexican subjects.</p><p><xref rid="bb0185" ref-type="bibr">Grimes and Callender (2006)</xref> performed a randomized, double-blinded, vehicle-controlled study consisting of 74 subjects of darker racial ethnic groups with acne to assess the efficacy of tazarotene in the treatment of PIH. In this study, once-daily application of tazarotene 0.1% cream achieved significant reduction in overall PIH disease severity compared with vehicle and in the intensity and area of hyperpigmentation within 18 weeks (<xref rid="bb0185" ref-type="bibr">Grimes and Callender, 2006</xref>).</p></sec><sec id="s0055"><title>Topical antimicrobials</title><p>Benzoyl peroxide is effective in treating acne due to its suppression of bacterial proliferation, hyperkeratinization and inflammation (<xref rid="bb0130" ref-type="bibr">Fisk et al., 2014</xref>). It may be used as monotherapy or in combination with topical retinoids and antimicrobials. A recent, multicenter, randomized, double blind, placebo controlled study (<xref rid="bb0190" ref-type="bibr">Alexis et al., 2014</xref>) was performed in black subjects with moderate acne to evaluate the efficacy and safety of adapalene 0.1%/benzoyl peroxide (BPO) 2.5% combination gel. The authors reported that significantly more black subjects had decreased median total, inflammatory and noninflammatory lesion counts with adapalene-BPO combination than with vehicle and significant reductions were detected as early as week 1. In addition, adapalene-BPO was safely tolerated in the black subjects and no cases of treatment-induced PIH were observed in this study (<xref rid="bb0190" ref-type="bibr">Alexis et al., 2014</xref>).</p><p>Topical antimicrobials such as clindamycin and erythromycin are used primarily for inflammatory acne in women of color. Due to the potential development of resistant strains of <italic>P. acnes</italic> to these agents, they are often recommended for use in combination with other topical agents such as BPO or retinoids (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>). A recent, multi-center, 12-week, double-blinded study consisting of 797 subjects with moderate to severe acne was performed to assess the efficacy and cutaneous tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel among FST I through III as compared with FST IV through VI (<xref rid="bb0195" ref-type="bibr">Callender, 2012</xref>). Treatment success and median reductions in inflammatory, noninflammatory and total lesions at week 12 were comparable between both groups. Subjects with FST IV through VI were not found to be more susceptible to cutaneous irritation from this combination treatment as compared to FST I through III (<xref rid="bb0195" ref-type="bibr">Callender, 2012</xref>).</p><p>A recent, randomized, double-blinded, placebo-controlled clinical trial consisting of 33 subjects with FST IV through VI was performed to evaluate the efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced PIH (<xref rid="bb0200" ref-type="bibr">Callender et al., 2012a</xref>). The authors concluded that this combination gel was safe and effective for skin of color patients with acne.</p></sec><sec id="s0060"><title>Azelaic acid</title><p>Topical azelaic acid, a dicarboxyclic acid, minimizes both inflammatory and noninflammatory lesions in acne vulgaris. It is an excellent treatment option for women of color with acne-induced PIH given its ability to inhibit tyrosinase (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0130" ref-type="bibr">Fisk et al., 2014</xref>). In a pilot study by Kircik, azelaic acid 15% gel applied twice daily for 16 weeks was found to improve both acne and PIH in subjects with FST IV through VI (<xref rid="bb0205" ref-type="bibr">Kircik, 2011</xref>).</p></sec><sec id="s0065"><title>Dapsone</title><p>Topical dapsone is an effective treatment for acne vulgaris due to its anti-inflammatory and antimicrobial properties (<xref rid="bb0210" ref-type="bibr">Draelos et al., 2007</xref>). A double-blinded, randomized, vehicle-controlled crossover study of 64 subjects, consisting mostly of African Americans, was undertaken to evaluate the risk of hemolysis in acne patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) who were treated with dapsone 5% gel vs vehicle gel (<xref rid="bb0215" ref-type="bibr">Piette et al., 2008</xref>). The authors reported only a 0.32 g/dL decrease in hemoglobin levels from baseline to 2 weeks; however, this was not accompanied by alterations in other laboratory parameters indicative of hemolysis (<xref rid="bb0215" ref-type="bibr">Piette et al., 2008</xref>). The authors concluded that the risk of hemolytic anemia with topical dapsone 5% gel is minimal in patients with G6PD deficiency.</p></sec><sec id="s0070"><title>Oral agents</title><p>Similar to the general population, oral antibiotics are indicated in women of color for moderate to severe inflammatory acne given their anti-inflammatory and anti-microbial properties (<xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>). The most common classes of antibiotics used include macrolides and tetracyclines. Fleischer et al (<xref rid="bb0220" ref-type="bibr">Fleischer et al., 2006</xref>) evaluated an extended release formulation of minocycline hydrochloride for its safety and efficacy in a phase 2 dose finding study and two phase 3 safety and efficacy trials. The designs were prospective, multicenter, randomized, double-blinded, and placebo-controlled and included 1038 participants with moderate to severe acne. Study participants received minocycline 1 mg/kg daily or placebo over 12 weeks. The number of inflammatory lesions was reduced and significant improvement was noted in the Evaluator&#x02019;s Global Severity Assessment scores (<xref rid="bb0220" ref-type="bibr">Fleischer et al., 2006</xref>). In both the placebo and treatment groups, acute vestibular adverse events (AVAEs) were comparable. The authors concluded that extended release minocycline reduces dose dependent AVAEs, inflammatory lesions, and improves overall appearance of acne patients.</p><p>Recently, a randomized controlled trial (RCT) comparing the efficacy of oral doxycycline and oral azithromycin in acne treatment showed that doxycycline is the better treatment option for acne (<xref rid="bb0225" ref-type="bibr">Ullah et al., 2014</xref>). Subjects with moderate acne received either azithromycin 500 mg daily before meals for 4 consecutive days monthly for 3 months or doxycycline 100 mg daily after meals for 3 months and followed up after 3 months. An excellent response was noted in 3.1% and a good response was observed in 22.8% in the azithromycin group subjects. In the doxycycline group, 11.4% had excellent and 55.4% had a good response (<xref rid="bb0225" ref-type="bibr">Ullah et al., 2014</xref>).</p><p>Another recent non-inferiority RCT by <xref rid="bb0230" ref-type="bibr">Tan et al. (2014)</xref> compared the efficacy and safety of oral isotretinoin vs. doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) in severe nodular acne over 20 weeks. The authors found that D+A/BPO showed a favorable composite efficacy/safety profile compared with isotretinoin and concluded that this combination can be used as an alternative to isotretinoin in severe nodular acne (<xref rid="bb0230" ref-type="bibr">Tan et al., 2014</xref>).</p><p>Both doxycycline and minocycline have been associated with gastrointestinal side effects, photosensitivity and photo-onycholysis (<xref rid="bb0235" ref-type="bibr">Kircik, 2010</xref>). Three distinct types of cutaneous minocycline-induced pigmentation have been described, which include blue-black pigmentation confined to sites of scarring or inflammation on the face (Type I), blue-gray circumscribed pigmentation of normal skin on the lower legs and forearms (Type II), and diffuse muddy brown pigmentation of normal skin accentuated in sun-exposed areas (Type III) (<xref rid="bb0240" ref-type="bibr">Mouton et al., 2004</xref>). Minocycline-induced cutaneous hyperpigmentation ranges in frequency from 2.4% to 14.8% in several longitudinal studies (<xref rid="bb0245" ref-type="bibr">Soung et al., 2007</xref>). In addition, minocycline has been associated with the development of autoantibodies, including anti-nuclear antibody (ANA), anti-neutrophil cytoplasmic antibody (ANCA), and anti-phospholipid antibodies with or without associated clinical symptoms (<xref rid="bb0235" ref-type="bibr">Kircik, 2010</xref>). Of note, minocycline has been recently associated with drug-induced lupus, with the majority of cases (84%) occurring in young women taking minocycline for acne (<xref rid="bb0235" ref-type="bibr">Kircik, 2010</xref>). Therefore, in women of color, one must carefully weigh the benefits and risks of these agents, paying particular attention to the risk of photosensitivity, gastrointestinal concerns, skin hyperpigmentation, and autoimmune and hypersensitivity syndromes (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>).</p><p>Any adult female patient with difficult-to-treat acne should be evaluated for a possible underlying endocrine disorder, especially hyperandrogenism. Polycystic ovarian syndrome (PCOS) is the most common cause of hyperandrogenism and cutaneous signs of PCOS include acne, hirsutism, androgenetic alopecia, seborrhea and acanthosis nigricans (<xref rid="bb0140" ref-type="bibr">Kamangar and Shinkai, 2012</xref>). One recent study supports the concept that women often report worsening of acne prior to the onset of their menses, with 65% of all participants reporting perimenstrual acne flare (<xref rid="bb0250" ref-type="bibr">Geller et al., 2014</xref>). The subset of women with acne exacerbations related to their menstrual cycle may be the best candidates to benefit from hormonal therapy such as oral contraceptive pills.</p><p>Isotretinoin, an oral retinoid approved by the US Food and Drug Administration, is the treatment of choice for severe nodulocystic acne in skin of color (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>). Special attention and education is mandatory for women of childbearing age given its serious systemic toxicities, which include teratogenicity (pregnancy category X), dyslipidemia, pancreatitis, hepatotoxicity, and pseudotumor cerebri (<xref rid="bb0095" ref-type="bibr">Davis and Callender, 2010</xref>, <xref rid="bb0145" ref-type="bibr">Yin and McMichael, 2014</xref>). An interesting study done by <xref rid="bb0255" ref-type="bibr">Kelly and Sampson (1987)</xref> was performed to evaluate the response of African American patients with recalcitrant nodulocystic acne to isotretinoin treatment. Of the 10 subjects studied, the author reported an early onset flare in areas of the face that were initially devoid of lesions prior to treatment. In addition, the author also reported an improvement in PIH at the completion of the study (<xref rid="bb0255" ref-type="bibr">Kelly and Sampson, 1987</xref>). The subjects in this study were also noted to develop a temporary ashen or grayish facial hue between the second and eighth week of therapy, which was likely attributed to the drying and desquamative effects of isotretinoin. In order to avoid non-compliance and treatment failures, it is critical to educate patients with darker skin prior to initiation of isotretinoin that dyschromia may occur.</p></sec><sec id="s0075"><title>Cosmetic therapies</title><p>Atrophic acne scarring is another potential sequela of acne in skin of color patients that presents a therapeutic challenge (<xref rid="bb0165" ref-type="bibr">Shah and Alexis, 2010</xref>). A study consisting of 30 subjects with atrophic ice pick scars was performed to assess the efficacy and safety of the chemical reconstruction of skin scars (CROSS) technique in FST IV and V using high strength trichloroacetic acid (TCA) focally into the depth of the scar to induce collagen production (<xref rid="bb0260" ref-type="bibr">Khunger et al., 2011</xref>). The subjects were initially primed for two weeks before the procedure with hydroquinone 4% cream in the morning and tretinoin 0.025% cream in the night. Focal application of 100% TCA with a wooden toothpick in each individual scar at two weekly intervals for four sessions resulted in excellent improvement in 73.3% of subjects. Transient hypopigmentation was observed in one subject and hyperpigmentation in two subjects. At three-month follow-up, no significant adverse effects such as prolonged pigmentary changes or scarring were noted. However, given the increased risk of dyschromias and keloid scarring in skin of color patients, the current authors emphasize that concentrations of TCA greater than 35% should be used with extreme caution in such patients as higher concentrations are thought to be melanotoxic.</p><p>Laser technology can also be an effective adjunct therapy in the management of acne in women of color. Gold performed an evaluation on five subjects with using a novel superficial and deep carbon dioxide (CO<sub>2</sub>) fractional laser in FST IV and V with acne scarring (<xref rid="bb0265" ref-type="bibr">Gold, 2012</xref>). Although this study included a small sample size, all subjects had clinically significant improvement in their skin and no reports of PIH were noted. A recent single-center prospective study assessed the clinical efficacy and safety of the 1450-nm diode laser for the treatment of acne scarring in patients with FST IV to VI (<xref rid="bb0270" ref-type="bibr">Semchyshyn et al., 2013</xref>). While the authors found the nonablative 1450-nm diode laser to be effective in improving the appearance of atrophic acne scars in these subjects, PIH was noted in 56% of the subjects (<xref rid="bb0270" ref-type="bibr">Semchyshyn et al., 2013</xref>). Therefore, while lasers may be beneficial in treating acne-related scarring, similar to most other surgical procedures, caution must be utilized with use of lasers in women of color given the risks of postinflammatory hyper- and hypopigmentation and scarring.</p><p>Recently, the efficacy and safety of polymethylmethacrylate (PMMA) suspended in bovine collagen was evaluated for the correction of atrophic facial acne scars in a study by <xref rid="bb0275" ref-type="bibr">Karnik et al. (2014)</xref>. The study was a multicenter, double blind, RCT that included 147 participants with more than 20% reporting Fitzpatrick skin types V and VI. Those with at least 4 moderate to severe rolling, atrophic scars were included. Subjects were randomized to PMMA-collagen or saline injections and underwent 2 injection sessions. Follow up was for 6 months. Scar severity was assessed using the Acne Scar Rating Scale (ASRS). The study included 1288 scars with 863 in the PMMA-collagen group and 425 in the control group. Successful results were achieved in 64% of the PMMA-collagen group compared with 33% of the control group. The study found no significant differences in efficacy or safety for darker skin types. Upon assessment of adverse events (particularly those concerning for darker skin types which include hypertrophic scarring, hypopigmentation, or hyperpigmentation), none were seen. Overall, the authors concluded that PMMA-collagen is an effective treatment for facial atrophic acne scars and maintains an excellent safety profile (<xref rid="bb0275" ref-type="bibr">Karnik et al., 2014</xref>). With regards to darker skin types, the authors highlight that the complete lack of dyspigmentation along with excellent treatment outcomes makes PMMA-collagen a great treatment modality for darker skin types (<xref rid="bb0275" ref-type="bibr">Karnik et al., 2014</xref>).</p><p>A summary of clinical studies on acne in skin of color is provided in <xref rid="t0015" ref-type="table">Table&#x000a0;3</xref>.</p></sec></sec><sec id="s0080"><title>Melasma</title><p>Melasma is an acquired hypermelanosis of the skin characterized by hyperpigmented macules and patches distributed symmetrically on sun-exposed areas of the body, particularly on the face. Most cases occur in women of reproductive age with darker skin tones (Fitzpatrick skin type IV&#x02013;VI) living in areas of intense ultraviolet (UV) radiation, but people of all ages, races, and skin colors may be affected. Its pathogenesis is not completely understood. The majority of cases have been associated with identifiable risk factors such as genetic predisposition, ultraviolet (UV) radiation and hormonal influences including oral contraceptives and pregnancy, anti-seizure and phototoxic medications, and thyroid disease (<xref rid="bb0280" ref-type="bibr">Grimes, 1995</xref>, <xref rid="bb0285" ref-type="bibr">Sheth and Pandya, 2011a</xref>). In fair skinned individuals, the pigmentation may reduce or resolve completely after parturition, whereas, it may persist in women with darker skin.</p><p>Based on the distribution of the facial lesions, melasma is classified into malar, centrofacial, mandibular and combination patterns of these (<xref rid="f0025" ref-type="fig">Fig.&#x000a0;5</xref>, <xref rid="f0030" ref-type="fig">Fig.&#x000a0;6</xref>). In the Indian subcontinent, a majority of patients show a malar distribution compared with disease pattern in Western population where centrofacial pattern predominates (<xref rid="bb0285" ref-type="bibr">Sheth and Pandya, 2011a</xref>, <xref rid="bb0290" ref-type="bibr">Sardesai et al., 2013</xref>). Based on Wood's lamp examination, it has been classified as epidermal, dermal, mixed, and indeterminate variants in Type IV-VI skin (<xref rid="bb0280" ref-type="bibr">Grimes, 1995</xref>, <xref rid="bb0285" ref-type="bibr">Sheth and Pandya, 2011a</xref>). While a Wood&#x02019;s lamp examination was previously thought to precisely predict epidermal versus dermal pigment deposition, recent studies have shown that dermal melanin deposition is common and may be underrecognized given that many patients often exhibit a mixed pattern (<xref rid="bb0280" ref-type="bibr">Grimes, 1995</xref>, <xref rid="bb0285" ref-type="bibr">Sheth and Pandya, 2011a</xref>, <xref rid="bb0290" ref-type="bibr">Sardesai et al., 2013</xref>).</p><sec id="s0085"><title>Medical management</title><p>A broad-spectrum UVA- and UVB-protective sunscreen with a sun protection factor (SPF) of at least 30 along with a physical blocker, such as titanium dioxide or zinc oxide, should be applied daily in patients with melasma. In addition to protection from ultraviolet radiation (UVR), visible light protection is also warranted as it also impacts pigmentation. Recently, it has been shown that short wavelengths of visible light (415 nm) can induce prolonged hyperpigmentation in comparison to long wavelengths (630 nm), which do not impact pigmentation in healthy volunteers (<xref rid="bb0295" ref-type="bibr">Boukari et al., 2015</xref>). <xref rid="bb0295" ref-type="bibr">Boukari et al. (2015)</xref> recently conducted a RCT in real-life settings during the spring and summer evaluating the protective properties against melasma relapses of a sunscreen protecting against UVA/UVB and the shorter wavelengths of visible light compared to a sunscreen with UVA/UVB protection but without visible light protection. The study included 40 melasma patients representing FST III &#x02013;V. Subjects were randomized to receive either Formula A (tinted and contained iron oxides) or Formula B, which were initially analyzed with photospectrometric analysis to assess the absorption potential of visible light. Patients applied 1 dose of the respective product twice daily and an additional dose every 2 hours, and 30 minutes before exposure to daylight. Patients were instructed to apply 1 teaspoon of sunscreen to the face. The main clinical assessment was the Melasma Area and Severity Index (MASI) score. The median increase of the MASI score from baseline to month 6 was more important with Formula B than with Formula A. Also, the tinted sunscreen only provided a partial protection in the targeted visible wavelengths according to the photospectrometric analysis. Given their results, the authors emphasize the impact that visible light has on melasma pathogenesis. Thus, they note the importance of developing more effective filters that protect against these wavelengths (<xref rid="bb0295" ref-type="bibr">Boukari et al., 2015</xref>). Additional sun protective measures, such as limited time outdoors, use of protective clothing and hats, and sun avoidance when possible are also essential to the treatment of melasma.</p><p>Currently, there is no single universally effective therapeutic agent for the treatment of melasma as the condition is recurrent and challenging. Conventional treatment of melasma includes elimination of any possible causative factors coupled with the use of a broad-spectrum sunscreen and skin lightening agents such as topical retinoids, hydroquinone, kojic acid, azelaic acid, deoxyarbutin, or ascorbic acid as monotherapy or in combination formulations using the modified Kligman&#x02019;s formula.</p><p>Triple combination (TC) therapy, comprised of hydroquinone, a retinoid, and a fluorinated corticosteroid, is considered to be a highly effective and safe treatment for melasma in skin of color (<xref rid="bb0300" ref-type="bibr">Rivas and Pandya, 2013</xref>). One of the most successful TC therapy regimens consists of a fixed combination of 4% hydroquinone, 0.05% tretinoin and 0.01% fluocinolone acetonide (<xref rid="bb0305" ref-type="bibr">Sheth and Pandya, 2011b</xref>). <xref rid="bb0310" ref-type="bibr">Taylor et al. (2003)</xref> conducted one of the initial studies demonstrating the high efficacy of this TC by comparing nightly use of TC cream with nightly use of three dual-combination creams (4% hydroquinone plus 0.05% tretinoin, 0.05% plus 0.01% fluocinolone acetonide, and 4% hydroquinone plus 0.01% fluocinolone acetonide). After 8 weeks, complete clearance was achieved in 26.1% of subjects treated with TC cream in comparison with 9.5% of subjects using hydroquinone plus tretinoin, 1.9% of subjects using tretinoin plus fluocinolone, and 2.5% of subjects using hydroquinone plus fluocinolone (<xref rid="bb0310" ref-type="bibr">Taylor et al., 2003</xref>). In addition, complete or near complete clearance was achieved in 77% of patients on the TC therapy versus a maximum of 46.8% in subjects using the dual combination preparations. Adverse effects such as erythema, peeling, irritation and dryness were highest in the combination regimens containing tretinoin, however, these side effects were transient and mild (<xref rid="bb0310" ref-type="bibr">Taylor et al., 2003</xref>). Several additional publications have subsequently demonstrated the safety and efficacy of this TC cream, particularly in darker-skinned racial ethnic groups (<xref rid="bb0315" ref-type="bibr">Torok, 2006</xref>, <xref rid="bb0320" ref-type="bibr">Torok et al., 2005a</xref>, <xref rid="bb0325" ref-type="bibr">Chan et al., 2008</xref>).</p><p>Given the relapsing nature of melasma, maintenance regimens are often necessary to sustain efficacy after initial stabilization. A study conducted by <xref rid="bb0330" ref-type="bibr">Arellano et al. (2012)</xref> was performed to determine the maintenance therapy for patients in whom TC therapy had shown to be effective. The authors found that the twice-weekly TC therapy group had a lower relapse rate compared with the tapering regimen group (3 times weekly for the first month, twice weekly for the second month and once weekly for the fourth month) (<xref rid="bb0330" ref-type="bibr">Arellano et al., 2012</xref>). <xref rid="bb0335" ref-type="bibr">Torok et al. (2005b)</xref> conducted a 12-month extension of an 8-week multicenter RCT consisting of 327 subjects evaluating the safety and efficacy of once daily TC cream in facial melasma. The study concluded that TC cream had a favorable safety profile and when applied intermittently over a long time period is tolerable, safe, and effective for moderate to severe facial melasma (<xref rid="bb0335" ref-type="bibr">Torok et al., 2005b</xref>).</p><p>Other combination creams have also been studied and show promising results. In a randomized study conducted by Lim, 40 Chinese female subjects were treated with 2% kojic acid in a gel containing 10% glycolic acid and 2% hydroquinone (<xref rid="bb0340" ref-type="bibr">Lim, 1999</xref>). The gel was applied to one-half of the face twice daily and compared with a gel containing only 10% glycolic acid and 2% hydroquinone applied to the other half of the face twice daily for 12 weeks. The authors found that in 60% of the subjects in the kojic acid group, more than 50% of melasma lesions had cleared versus 47.5% of subjects in the 10% glycolic acid and 2% hydroquinone group (<xref rid="bb0340" ref-type="bibr">Lim, 1999</xref>). More recently, a hydroquinone-free, multimodal complex skin lightening agent has been developed to address dyschromias such as melasma. This agent acts via targeting multiple pathways in melanin synthesis including reduction in melanocyte activation, melanin synthesis, melanin transfer to keratinocytes, and epidermal melanin (<xref rid="bb0345" ref-type="bibr">Makino et al., 2013</xref>). <xref rid="bb0350" ref-type="bibr">Grimes (2014)</xref> presented a case report of six female subjects with Fitzpatrick skin types IV - V with moderate epidermal facial melasma treated with a hydroquinone-free, multimodality skin brightener. Patients applied the agent twice daily and were evaluated at 4, 8, and 12 weeks. The Investigator Overall Hyperpigmentation scores improved by an average of 22% and the MASI scores improved by an average 38%. In addition, 100% of the participants showed at week 12 at least a 25% increase in Global Improvement. The skin brightener was well tolerated without pruritus, erythema, edema, scaling, or burning/stinging reported (<xref rid="bb0350" ref-type="bibr">Grimes, 2014</xref>).</p><p>In summary, it is recommended that patients with mild melasma use non-phenolic therapy such as azelaic acid (AZ), arbutin, kojic acid, tretinoin, adapalene and glycolic acid or any combination of these or 4% hydroquinone as monotherapy. For moderate to severe melasma, TC therapy is the gold standard. These agents are often used in concurrence with other physical therapies.</p></sec><sec id="s0090"><title>Chemical peels</title><p>A wide variety of agents are available for chemical peels, however, the choice is rather limited while treating a patient with Fitzpatrick skin type IV - VI. Use of medium-depth peels is advised with caution and deep phenol peels are avoided owing to risk of scarring and prolonged hyperpigmentation (<xref rid="bb0355" ref-type="bibr">Sarkar et al., 2012</xref>, <xref rid="bb0360" ref-type="bibr">Salam et al., 2013</xref>). Among the superficial peels, 20&#x02013;30% salicylic acid in ethanol is widely considered to be the safest peel in the ethnic skin population (<xref rid="bb0360" ref-type="bibr">Salam et al., 2013</xref>). Based on current available evidence, glycolic acid peels (20-70%) every 4-6 weeks are a useful adjunctive therapy in refractory cases of epidermal melasma (<xref rid="bb0305" ref-type="bibr">Sheth and Pandya, 2011b</xref>, <xref rid="bb0355" ref-type="bibr">Sarkar et al., 2012</xref>, <xref rid="bb0360" ref-type="bibr">Salam et al., 2013</xref>). It is the most widely utilized peeling agent in skin of color and has proven safety as well as efficacy. Superficial trichloroacetic acid (TCA) peels (10-25%) should be used with caution in darker skin types due to the risk of pigment dyschromias and scarring. The most common sequela with the use of chemical peels for melasma in ethnic skin is PIH, which can either occur between the treatment sessions or after stopping treatment. Pre-peel priming with hydroquinone and tretinoin for 2-4 weeks enhances the effect of the peeling agent apart from decreasing the PIH, with hydroquinone considered superior to tretinoin as a priming agent (<xref rid="bb0365" ref-type="bibr">Nanda et al., 2004</xref>). Recommendations of chemical peels for melasma in skin of color are provided in <xref rid="t0020" ref-type="table">Table&#x000a0;4</xref>.</p></sec><sec id="s0095"><title>Light and laser therapy (<xref rid="bb0370" ref-type="bibr">Arora et al., 2012</xref>, <xref rid="bb0375" ref-type="bibr">Sardana and Garg, 2014</xref>)</title><p>Published data or recommendations on the safety and effectiveness of lasers in Fitzpatrick skin types V &#x02013; VI are limited by complications of post procedure hyper- or hypopigmentation. Several of the lasers utilized as options for the treatment of melasma, including the pigment-specific lasers (Q-switched, long-pulsed lasers and intense pulsed light or IPL), ablative lasers (Er:YAG) and fractional lasers have had conflicting results and are anecdotal. Most of the studies reported in Asians have been performed on Fitzpatrick skin types III &#x02013; IV and demonstrate that lasers may cause worsening of the disease, minimally improve it, or produce unwanted PIH (<xref rid="bb0380" ref-type="bibr">Jang et al., 2011</xref>).</p><p>A recent 2013 evidence-based review of treatments for melasma demonstrated overall that laser and light therapy yields varied results and that relapse is a frequent occurrence after treatment (<xref rid="bb0300" ref-type="bibr">Rivas and Pandya, 2013</xref>). While IPL therapy has been shown to be effective in improving melasma, it is characterized by a high relapse rate (<xref rid="bb0385" ref-type="bibr">Wang et al., 2004</xref>). QS-Nd:YAG lasers are associated with an increased risk of rebound hyperpigmentation and a very high rate of relapse following treatment (<xref rid="bb0390" ref-type="bibr">Wattanakrai et al., 2012</xref>). In general, laser and light therapies are considered third-line agents for the treatment of melasma and further research is needed. Most physicians recommend priming the patient&#x02019;s skin with triple combination prior to laser therapy and continue to use this regimen after treatment sessions. Low fluence and low treatment density non-ablative fractional lasers and Q-switched 1064 nm can be considered as third-line treatment for patients who have not improved sufficiently after 3&#x02013;6 months of topical treatment (<xref rid="t0025" ref-type="table">Table&#x000a0;5</xref>).</p></sec></sec><sec id="s0100"><title>Alopecia</title><sec id="s0105"><title>Hair care practices</title><p>Hair and scalp disorders in women of African descent are particularly challenging, partially due to a paucity of research into the pathophysiology of these disorders, and also because of poor understanding of the basic hair care practices in this patient population. Below we discuss some of the more common grooming practices that could significantly impact the clinical presentation of hair and scalp disorders, and compliance with treatment regimens.</p><p>Several hairstyles common in people of African descent result in tension at the root of the hair follicles. These include cornrows (formed by braiding the hair tightly into individual sections) and dreadlocks (a type of styling allows the hair to knot into individual twistlike structures) (<xref rid="bb0465" ref-type="bibr">Ogunleye et al., 2014</xref>). In either of these styles, human or synthetic hair may be added for increased length and volume (<xref rid="bb0470" ref-type="bibr">Callender et al., 2004</xref>). Hair weaving is another common hairstyle, where the hair is cornrowed and additional hair is sewn or glued to the cornrows. These methods of styling have all been associated with traction alopecia or marginal scalp hair loss (<xref rid="bb0475" ref-type="bibr">Grimes, 2000</xref>).</p><p>Straightening of the hair has traditionally been the style of choice in black women, as it is thought to increase styling options and manageability of the hair (<xref rid="bb0465" ref-type="bibr">Ogunleye et al., 2014</xref>, <xref rid="bb0480" ref-type="bibr">Callender, 2002</xref>). This can be achieved via thermal straightening or chemical straightening. Thermal straightening, also known as hot combing or pressing, involves temporarily rearranging hydrogen bonds within the hair shafts (<xref rid="bb0470" ref-type="bibr">Callender et al., 2004</xref>). The hair is coated with a lubricating oil and then combed with a hot metal comb heated to 300 to 500&#x000b0;F (<xref rid="bb0485" ref-type="bibr">LoPresti et al., 1968</xref>). An alternative to the hot comb is the flat iron. Here, the hair is placed between 2 hot smooth, ceramic plates with temperatures ranging from 180 to 450&#x000b0;F (<xref rid="f0035" ref-type="fig">Fig.&#x000a0;7</xref>).</p><p>Chemical relaxers produce permanent hair straightening by rearranging disulfide bonds within the shaft; using sodium hydroxide in lye relaxers, and guanidine hydroxide in no-lye relaxers (<xref rid="f0040" ref-type="fig">Fig.&#x000a0;8</xref>). These often result in irritant contact dermatitis, trichorrhexis nodosa, and fragile, easily damaged hair (<xref rid="bb0490" ref-type="bibr">Swee et al., 2000</xref>). A newer method of hair straightening, known as the Brazilian keratin treatment, is a process in which a liquid keratin solution is sealed into the hair using a flat iron. Formaldehyde, the preservative used in this process, can be a significant health concern to both stylists and clients.</p><p>In terms of hair cleansing, African American women tend to shampoo less frequently than other ethnicities, approximately once every 1 to 2 weeks (<xref rid="bb0495" ref-type="bibr">Hall et al., 2013</xref>). This is partially due to lower levels of sebum on the hair shaft, with resulting dryness and breakage if shampooed too frequently. Also, the hairstyles described above are time consuming and costly, and so the hair is washed infrequently in an attempt to maintain these hairstyles for longer periods of time (<xref rid="bb0480" ref-type="bibr">Callender, 2002</xref>, <xref rid="bb0500" ref-type="bibr">McMichael, 2003</xref>).</p></sec><sec id="s0110"><title>Traction Alopecia</title><p>Traction alopecia (TA) is a form of alopecia loss caused by repetitive or prolonged tension to the hair. Although early disease is non-scarring, longstanding TA can lead to permanent hair loss. TA is most frequently reported in individuals of African descent (<xref rid="bb0505" ref-type="bibr">Khumalo et al., 2007a</xref>, <xref rid="bb0510" ref-type="bibr">Khumalo et al., 2007b</xref>) and is closely linked to the unique hair grooming practices and increased susceptibility of the hair follicles in this patient population (<xref rid="bb0515" ref-type="bibr">Mulinari-Brenner and Bregfeld, 2001</xref>).</p><p>The earliest clinical sign of traction on the scalp is perifollicular erythema, which may progress to follicular papules and pustules. Eventually, yellow-white cylinders, known as peri-pilar casts, encircle the hair shaft at sites of traction (<xref rid="bb0520" ref-type="bibr">Samrao et al., 2011</xref>, <xref rid="bb0525" ref-type="bibr">Rollins, 1961</xref>, <xref rid="bb0530" ref-type="bibr">Fox et al., 2007</xref>, <xref rid="bb0535" ref-type="bibr">Tosti et al., 2010</xref>). Subsequently, clinically apparent alopecia develops, with decreased follicular markings in late stage disease (<xref rid="bb0520" ref-type="bibr">Samrao et al., 2011</xref>).</p><p>TA often affects the frontal and temporal scalp, as well as anterior and superior to the ears (<xref rid="f0045" ref-type="fig">Fig.&#x000a0;9</xref>). Patients usually report a history of tight braids, weaves, cornrows, ponytails, chignons or religious head coverings. There is a significantly higher risk of developing TA when traction is applied to chemically treated hair, such as relaxers and dyes; but does not appear to be affected by the frequency of relaxer application (<xref rid="bb0505" ref-type="bibr">Khumalo et al., 2007a</xref>, <xref rid="bb0540" ref-type="bibr">Khumalo et al., 2008</xref>). The presence of retained hairs along the frontal and/or temporal hairline, termed the &#x0201c;fringe sign,&#x0201d; is a common finding in patients with TA of the marginal hairline, and can help in making a clinical diagnosis of TA (<xref rid="bb0520" ref-type="bibr">Samrao et al., 2011</xref>).</p><p>As the early stage of TA is reversible, it is very important that the public be educated on the increased risk of TA in patients with symptomatic traction an combined hairstyles, such as the tight braiding of relaxed hair. It has been suggested that to influence the practice of at risk individuals, scientific data should be translated into simple messages like "tolerate pain from a hairstyle and risk hair loss" and "no braids or weaves on relaxed hair" (<xref rid="bb0545" ref-type="bibr">Mirmirani and Khumalo, 2014</xref>).</p><p>An unusual variant of TA resulting from the use of wefted hair extensions, termed the &#x0201c;horseshoe&#x0201d; pattern, has been reported (<xref rid="bb0550" ref-type="bibr">Ahdout and Mirmirani, 2012</xref>). Wefts consist of multiple strands of hair held together by a band of fine threads, and are attached directly to the hairline by being sewn, bonded, glued, or clipped. TA has also been reported in Hispanic women with long hair who wear tight ponytails, and in Japanese women and ballerinas who frequently wear their hair in a tight bun. In these cases, the hair loss may be confined to the occipital or temporal scalp (<xref rid="bb0555" ref-type="bibr">Trueb, 1995</xref>, <xref rid="bb0560" ref-type="bibr">Samrao et al., 2010a</xref>).</p><p>In patients who give a remote or unclear history of tight hairstyles, the clinical differential diagnosis includes androgenetic alopecia, telogen effluvium, trichotillomania and central centrifugal cicatricial alopecia. When TA is localized to the marginal hairline, frontal fibrosing alopecia and the ophiasis pattern of alopecia areata should be considered (<xref rid="bb0565" ref-type="bibr">Heath and Taylor, 2012</xref>).</p><p>Treatment options for TA depend on duration of the disease process. Firstly, patients should be advised that TA may lead to permanent progressive alopecia (<xref rid="bb0570" ref-type="bibr">James et al., 2007</xref>). In early disease, the hairstyle should be loosened, and chemicals, heat and combined hairstyles should be avoided. Intralesional corticosteroids directed at the periphery of hair loss, suppress peri-follicular inflammation (<xref rid="bb0470" ref-type="bibr">Callender et al., 2004</xref>). Oral or topical antibiotics may also be used in early disease for their anti-inflammatory effect (<xref rid="bb0470" ref-type="bibr">Callender et al., 2004</xref>). Topical minoxidil may also be considered in conjunction with intralesional corticosteroids (<xref rid="bb0575" ref-type="bibr">Khumalo and Ngwanya, 2007</xref>). In longstanding disease, dermal scarring leads to permanent alopecia. In these advanced cases, surgical options such as hair transplantation may be considered (<xref rid="bb0470" ref-type="bibr">Callender et al., 2004</xref>, <xref rid="bb0580" ref-type="bibr">Ozcelik, 2005</xref>).</p></sec><sec id="s0115"><title>Acquired Trichorrhexis Nodosa</title><p>Trichorrhexis nodosa (TN), a hair shaft disorder, is characterized by fragility and nodes along the shaft. The hair appears lusterless and dry and patients may complain of &#x0201c;whitish spots&#x0201d; along the hair (<xref rid="bb0585" ref-type="bibr">Martin and Sugathan, 2011</xref>) (<xref rid="f0050" ref-type="fig">Fig.&#x000a0;10</xref>). The underlying pathogenic mechanism seems to be the loss of cuticle cells along the shaft. As a result, the cortical fibers lose their protection, and split longitudinally into numerous small fibers. On microscopic examination, there is cuticular cell disruption and fraying and breaking of the cortical fibers, with the resulting appearance likened to two paint brushes crushed against each other, hence the description &#x0201c;paint brush fracture&#x0201d; (<xref rid="bb0590" ref-type="bibr">Mart&#x000ed;nez de Lagr&#x000e1;n et al., 2009</xref>, <xref rid="bb0595" ref-type="bibr">Rudnicka et al., 2013</xref>, <xref rid="bb0600" ref-type="bibr">Miyamoto et al., 2009</xref>).</p><p>TN may be congenital or acquired. Acquired TN results from repeated trauma to the hair (<xref rid="bb0505" ref-type="bibr">Khumalo et al., 2007a</xref>, <xref rid="bb0510" ref-type="bibr">Khumalo et al., 2007b</xref>, <xref rid="bb0540" ref-type="bibr">Khumalo et al., 2008</xref>, <xref rid="bb0515" ref-type="bibr">Mulinari-Brenner and Bregfeld, 2001</xref>, <xref rid="bb0560" ref-type="bibr">Samrao et al., 2010a</xref>, <xref rid="bb0520" ref-type="bibr">Samrao et al., 2011</xref>, <xref rid="bb0525" ref-type="bibr">Rollins, 1961</xref>, <xref rid="bb0530" ref-type="bibr">Fox et al., 2007</xref>, <xref rid="bb0535" ref-type="bibr">Tosti et al., 2010</xref>, <xref rid="bb0545" ref-type="bibr">Mirmirani and Khumalo, 2014</xref>, <xref rid="bb0550" ref-type="bibr">Ahdout and Mirmirani, 2012</xref>, <xref rid="bb0555" ref-type="bibr">Trueb, 1995</xref>, <xref rid="bb0565" ref-type="bibr">Heath and Taylor, 2012</xref>, <xref rid="bb0570" ref-type="bibr">James et al., 2007</xref>, <xref rid="bb0470" ref-type="bibr">Callender et al., 2004</xref>, <xref rid="bb0575" ref-type="bibr">Khumalo and Ngwanya, 2007</xref>, <xref rid="bb0580" ref-type="bibr">Ozcelik, 2005</xref>, <xref rid="bb0585" ref-type="bibr">Martin and Sugathan, 2011</xref>), such as from harsh hair combing practices, chemical trauma, excessive brushing, and application of heat. While acquired TN usually affects the distal shaft, there has been a recently reported case of recurrent generalized proximal trichorrhexis nodosa in a Nigerian female with a history of severe atopic dermatitis, affecting the scalp (<xref rid="bb0605" ref-type="bibr">Ogunbiyi et al., 2014</xref>). Occasionally, acquired TN may also result from iron deficiency or hypothyroidism (<xref rid="bb0610" ref-type="bibr">Lurie et al., 1996</xref>).</p><p>Chemical trauma to the hair includes excessive exposure to bleaching, perming, shampooing and dyeing. In African type hair, chemical &#x0201c;relaxers&#x0201d; are used to straighten the tightly curled hair. In addition to disrupting the hair cuticle, these relaxers also reduce cysteine levels within the hair shaft (<xref rid="bb0615" ref-type="bibr">Khumalo et al., 2010</xref>). Cysteine is a component of the disulfide bonds that are responsible for the inherent strength of hair (<xref rid="bb0615" ref-type="bibr">Khumalo et al., 2010</xref>).</p><p>Heating devices such as hot combs and flat irons are used, not only in African Americans, but in all ethnic groups, to obtain sleek, straight hair (<xref rid="bb0615" ref-type="bibr">Khumalo et al., 2010</xref>). Here, hydrogen bonds in the cortex of the hair shaft are temporarily broken and then reform (<xref rid="bb0625" ref-type="bibr">Bolduc and Shapiro, 2001</xref>, <xref rid="bb0630" ref-type="bibr">Quinn et al., 2003</xref>). Unfortunately, damage to the protective cuticle is a common consequence; with hair breakage reported in up to 18% of African American women using a hot comb (<xref rid="bb0475" ref-type="bibr">Grimes, 2000</xref>).</p><p>Treatment of acquired trichorrhexis nodosa focuses on avoiding the offending agents. Patients should be advised to use combs with straight elongated bristles, along with hair oils and conditioners, to minimize tension and friction along the hair shaft. In chemical induced TN, hair relaxers and dyes should be applied only by a licensed professional. Patients should be advised of the significantly increased risk of hair breakage when dyeing chemically straightened hair. Also, hot combs and flat irons should be used no more frequently than once per week, on dry hair only, at temperatures below 175&#x000b0;C (<xref rid="bb0620" ref-type="bibr">Mirmirani, 2010</xref>, <xref rid="bb0635" ref-type="bibr">Detwiler et al., 1994</xref>, <xref rid="bb0640" ref-type="bibr">Ruetsch and Kamath, 2004</xref>).</p></sec><sec id="s0120"><title>Central Centrifugal Cicatricial Alopecia</title><p>Central Centrifugal Cicatricial Alopecia (CCCA), a chronic, progressive and inflammatory form of hair loss, seen more commonly in women of African descent and rarely in men (<xref rid="bb0645" ref-type="bibr">Sperling and Sau, 1992</xref>). It has been previously known as &#x0201c;follicular degeneration syndrome,<sup>&#x0201d; &#x0201c;</sup>hot comb alopecia,&#x0201d; and chemically induced scarring alopecia (<xref rid="bb0645" ref-type="bibr">Sperling and Sau, 1992</xref>, <xref rid="bb0485" ref-type="bibr">LoPresti et al., 1968</xref>, <xref rid="bb0650" ref-type="bibr">Nicholson et al., 1993</xref>). The currently recognized term, CCCA, was later coined by the North American Hair Research Society (NAHRS) (<xref rid="bb0655" ref-type="bibr">Olsen et al., 2003</xref>).</p><p>The true prevalence of this condition is still unknown but may vary from 2.7% to 5.7% and increases with age (<xref rid="bb0465" ref-type="bibr">Ogunleye et al., 2014</xref>). However, it has been reported that CCCA patients are among the top five reasons why African- Americans seek dermatologic evaluation (<xref rid="bb0660" ref-type="bibr">Halder et al., 1983b</xref>, <xref rid="bb0665" ref-type="bibr">Alexis et al., 2007</xref>). The true etiology of CCCA remains to be elucidated and is most likely multifactorial. Possible contributing factors include intense heat and traction to the scalp, the application of chemical relaxers, the intrinsically curly nature of African hair follicles and the decreased number of dermal elastic fibers in African hair compared with that of white individuals (<xref rid="bb0650" ref-type="bibr">Nicholson et al., 1993</xref>, <xref rid="bb0670" ref-type="bibr">Gathers et al., 2009</xref>, <xref rid="bb0675" ref-type="bibr">Nnoruka, 2005</xref>, <xref rid="bb0680" ref-type="bibr">Ackerman et al., 2000</xref>, <xref rid="bb0685" ref-type="bibr">Montagna and Carlisle, 1991</xref>). Genetics also appears to play a significant role, and an autosomal dominant inheritance pattern with partial penetrance has been proposed (<xref rid="bb0690" ref-type="bibr">Dlova and Forder, 2012</xref>, <xref rid="bb0695" ref-type="bibr">Dlova et al., 2014</xref>). Lastly, the intrinsically curly nature of African hair follicles likely plays a role in CCCA development. African hair is elliptical in nature, with frequent twists and decreased tensile strength (<xref rid="bb0700" ref-type="bibr">Franbourg et al., 2003</xref>). This intrinsic risk for breakage is compounded with harsh hair grooming practices which force the hair to flow in an unnatural direction for prolonged periods of time (<xref rid="bb0705" ref-type="bibr">Callender and Onwudiwe, 2011</xref>).</p><p>In CCCA, the scarring alopecia occurs mainly on the vertex of the scalp with symmetric spread in a centrifugal pattern (<xref rid="f0055" ref-type="fig">Fig.&#x000a0;11</xref>, <xref rid="f0060" ref-type="fig">Fig.&#x000a0;12</xref>, <xref rid="f0065" ref-type="fig">Fig.&#x000a0;13</xref>). The clinical presentation and distribution of hair loss may mimic that of androgenetic alopecia, but the lack of follicular openings indicates a scarring process (<xref rid="f0070" ref-type="fig">Fig.&#x000a0;14</xref>). Possible signs and symptoms include papules, pustules, tenderness or pruritus of the scalp and may be totally asymptomatic. A sign of early or occult CCCA may present as hair breakage (<xref rid="bb0710" ref-type="bibr">Callender et al., 2012b</xref>). While patients may not have frank alopecia at presentation, a history of short, broken hair should prompt further investigation and a confirmatory biopsy. Dermatoscopic evaluation may aid in identifying the optimal site from which to obtain a biopsy specimen. On dermoscopy, the presence of a peripilar white halo is a feature that suggests CCCA in an African American patient with mild central thinning. The peripilar white halo corresponds on pathology to the lamellar fibrosis surrounding the outer root sheath (<xref rid="bb0720" ref-type="bibr">Miteva and Tosti, 2013</xref>, <xref rid="bb0715" ref-type="bibr">Miteva and Tosti, 2014</xref>).</p><p>In terms of associated disorders and hair grooming practices, results of a cross-sectional survey by Kyei et al found a statistically significant correlation with type 2 diabetes mellitus, bacterial skin infections and hairstyles like braids and weaves. Interestingly, no significant difference was noted in the use of chemical relaxers and hot combs. There was also a strong positive correlation between the age of the subjects and degree of hair loss (<xref rid="bb0725" ref-type="bibr">Kyei et al., 2011</xref>). A study by Olsen et al found no significant correlation between chemical relaxer and hot comb use, seborrheic dermatitis, or bacterial infections (<xref rid="bb0730" ref-type="bibr">Olsen et al., 2011</xref>).</p><p>Treatment of CCCA is focused on attempting to terminate the progression of disease with hopes of possible regrowth if permanent scarring has not occurred. Firstly, discontinuation of potentially damaging hair-grooming practices should be encouraged. High potency topical corticosteroids or intralesional corticosteroid injections may help with symptom alleviation. For active spreading disease, anti-inflammatory antibiotics such as doxycycline and antimalarials such as hydroxychloroquine may slow disease activity (<xref rid="bb0735" ref-type="bibr">Summers et al., 2011</xref>).</p><p>In patients with stable disease controlled with medical therapy for at least one year, and who also display a lack of inflammation on scalp biopsy, hair transplantation can be a safe well-tolerated procedure for CCCA in women of color (<xref rid="bb0740" ref-type="bibr">Callender et al., 2014b</xref>). However, it is important to note that the presence of scarring can decrease the transplanted graft survival rate, and regrowth of the transplanted hair is slow (<xref rid="bb0745" ref-type="bibr">Callender, 2006</xref>, <xref rid="bb0750" ref-type="bibr">Callender and Young, 2008</xref>). Counseling includes styles that seek to camouflage the injury including wigs, color sticks/crayons or micropigmentation (<xref rid="bb0470" ref-type="bibr">Callender et al., 2004</xref>).</p></sec><sec id="s0125"><title>Frontal Fibrosing Alopecia</title><p>Frontal fibrosing alopecia (FFA), first described in 1994 (<xref rid="bb0755" ref-type="bibr">Kossard, 1994</xref>), is a primary scarring alopecia that is considered a clinical variant of lichen planopilaris (<xref rid="bb0760" ref-type="bibr">Kossard et al., 1997</xref>). It occurs mainly in postmenopausal women (<xref rid="bb0755" ref-type="bibr">Kossard, 1994</xref>), although premenopausal women (<xref rid="bb0765" ref-type="bibr">Moreno-Ramirez and Camacho Martinez, 2005</xref>, <xref rid="bb0770" ref-type="bibr">Faulkner et al., 2002</xref>, <xref rid="bb0775" ref-type="bibr">Banka et al., 2014</xref>, <xref rid="bb0780" ref-type="bibr">Va&#x000f1;&#x000f3;-Galv&#x000e1;n et al., 2014</xref>) and men (<xref rid="bb0785" ref-type="bibr">Kossard and Shiell, 2005</xref>, <xref rid="bb0790" ref-type="bibr">Nusbaum and Nusbaum, 2010</xref>, <xref rid="bb0795" ref-type="bibr">Stockmeier et al., 2002</xref>, <xref rid="bb0800" ref-type="bibr">Dlova and Goh, 2013</xref>, <xref rid="bb0805" ref-type="bibr">Ramaswamy et al., 2012</xref>) may also be affected.</p><p>Most data on FFA comes from studies and case reports including a majority of white and Asian patients. It is important to note that, although uncommon, FFA does occur in individuals of African descent (<xref rid="bb0810" ref-type="bibr">Miteva et al., 2012</xref>, <xref rid="bb0815" ref-type="bibr">Dlova et al., 2013</xref>). This lack of data on FFA in black patients may be due to misdiagnosis as traction alopecia (<xref rid="bb0810" ref-type="bibr">Miteva et al., 2012</xref>), which has overlapping clinical features with FFA and is a very common entity in this patient population.</p><p>On presentation, there is follicular hyperkeratosis, perifollicular erythema and scarring of the frontotemporal hairline (<xref rid="f0075" ref-type="fig">Fig.&#x000a0;15</xref>). Up to 75% of patients may also complaint of eyebrow loss, which may be the initial complaint at presentation (<xref rid="bb0820" ref-type="bibr">Ladizinski et al., 2013</xref>, <xref rid="bb0825" ref-type="bibr">Tan and Messenger, 2009</xref>, <xref rid="bb0830" ref-type="bibr">Samrao et al., 2010b</xref>). Other affected areas include the eyelashes, axillary and pubic regions, the occipital scalp, and vellus hairs, which may present as facial noninflammatory papules, or follicular red dots in the glabellar region (<xref rid="bb0820" ref-type="bibr">Ladizinski et al., 2013</xref>, <xref rid="bb0825" ref-type="bibr">Tan and Messenger, 2009</xref>, <xref rid="bb0830" ref-type="bibr">Samrao et al., 2010b</xref>, <xref rid="bb0835" ref-type="bibr">Chew et al., 2010</xref>, <xref rid="bb0840" ref-type="bibr">Molina et al., 2011</xref>, <xref rid="bb0845" ref-type="bibr">Pirmez et al., 2014</xref>). Furthermore, it has been proposed that the triad of eyelash loss, body hair involvement, and facial papules is associated with severe FFA, and may be used to predict prognosis and to highlight patients who would require systemic therapy (<xref rid="bb0780" ref-type="bibr">Va&#x000f1;&#x000f3;-Galv&#x000e1;n et al., 2014</xref>).</p><p>An interesting clinical finding of FFA is termed the &#x0201c;lonely hair sign&#x0201d; (<xref rid="bb0850" ref-type="bibr">Tosti et al., 2011</xref>). There has been debate as to whether this sign is specific to FFA, as it is common to see hairs that are spared from the inflammatory processes in all types of cicatricial alopecias (<xref rid="bb0855" ref-type="bibr">Camacho, 2012</xref>). However, it is important to note that this term describes the presence of one or few isolated terminal hairs, particularly in the middle of the forehead; as FFA is the only cicatricial alopecia characterized by progressive recession of the frontotemporal hairline (<xref rid="bb0860" ref-type="bibr">Tosti, 2012</xref>). Another useful tool in the diagnosis of FFA is dermoscopy (<xref rid="bb0865" ref-type="bibr">Inui et al., 2008</xref>); which shows loss of follicular orifices and perifollicular erythema, a direct marker of FFA activity (<xref rid="bb0870" ref-type="bibr">Toledo-Pastrana et al., 2013</xref>).</p><p>Several disorders reported to possibly be associated with FFA include thyroid disease, vitiligo, lichen planus pigmentosus, lupus erythematosus (<xref rid="bb0875" ref-type="bibr">MacDonald et al., 2012</xref>, <xref rid="bb0880" ref-type="bibr">Miteva et al., 2011</xref>, <xref rid="bb0885" ref-type="bibr">Berliner et al., 2014</xref>, <xref rid="bb0890" ref-type="bibr">Del Rei et al., 2014</xref>, <xref rid="bb0895" ref-type="bibr">Khan et al., 2013</xref>, <xref rid="bb0900" ref-type="bibr">Dlova, 2013</xref>, <xref rid="bb0905" ref-type="bibr">Gaffney et al., 2013</xref>). Lichen planus pigmentosus has been identified as a herald sign for imminent FFA in black South African patients (<xref rid="bb0900" ref-type="bibr">Dlova, 2013</xref>). Because of the significant prevalence of hypothyroidism in FFA subjects in the their study, Va&#x000f1;&#x000f3;-Galv&#x000e1;n et al strongly suggest including thyroid hormone laboratory studies in the initial workup of patients with FFA (<xref rid="bb0780" ref-type="bibr">Va&#x000f1;&#x000f3;-Galv&#x000e1;n et al., 2014</xref>).</p><p>While there are presently no clinical trials for the management of FFA, several treatments have been reported. These include topical and intralesional corticosteroids, topical calcineurin inhibitors, hydroxychloroqine, mycophenolate mofetil and oral 5-alpha reductase inhibitors (5aRi) (<xref rid="bb0765" ref-type="bibr">Moreno-Ramirez and Camacho Martinez, 2005</xref>, <xref rid="bb0830" ref-type="bibr">Samrao et al., 2010b</xref>, <xref rid="bb0910" ref-type="bibr">Tan et al., 2004</xref>, <xref rid="bb0915" ref-type="bibr">Katoulis et al., 2009</xref>, <xref rid="bb0920" ref-type="bibr">Chiang et al., 2010</xref>, <xref rid="bb0925" ref-type="bibr">Cho et al., 2010</xref>). The efficacy of these treatment modalities are inconsistent. In patients who do not undergo any treatment, recession of the anterior hairline ranges from 0.95-1.08 cm per year (<xref rid="bb0870" ref-type="bibr">Toledo-Pastrana et al., 2013</xref>, <xref rid="bb0930" ref-type="bibr">Miteva and Tosti, 2012</xref>). Before initiating treatment, it is important that the patient understands that the main goal is to halt progression of hair loss. In reported cases of improvement, hair regrowth was minimal, and always located at the hairline.</p><p>In recently published reviews, oral finasteride or dutasteride showed good response in 44-47% (<xref rid="bb0780" ref-type="bibr">Va&#x000f1;&#x000f3;-Galv&#x000e1;n et al., 2014</xref>, <xref rid="bb0935" ref-type="bibr">Racz et al., 2013</xref>). This was followed by intralesional steroids and oral antimalarials. Therefore, it has been suggested that 5aRi may be a useful maintenance treatment to stabilize FFA (<xref rid="bb0820" ref-type="bibr">Ladizinski et al., 2013</xref>), and can be used together with intralesional corticosteroids when signs of activity such as perifollicular erythema or follicular hyperkeratosis are present (<xref rid="bb0780" ref-type="bibr">Va&#x000f1;&#x000f3;-Galv&#x000e1;n et al., 2014</xref>).</p></sec></sec><sec id="s0130"><title>Conclusion</title><p>People of color constitute a large group that will continue to expand. This article has reviewed the most updated, evidence-based literature regarding the pathophysiology and treatment of disorders prevalent in women of color, particularly acne, melasma and alopecia. Important biological differences in skin and hair structure do exist in individuals of color and this may account for the increased incidence of keloids and pigmentary disorders. Prompt diagnosis and initiation of targeted therapy is imperative as these steps may prevent the potential sequelae common in women of color such as dyschromias and scarring.</p><p>In general, the pathogenesis and treatments for acne in women of color are similar to the general population; however, there are a few special considerations. Given the increased risk of PIH and keloid scarring in women with darker skin types, early aggressive reduction of inflammation is essential in treatment. Therefore, dermatologists should consider topical or oral agents with prominent anti-inflammatory effects to reduce acne-associated inflammation. In addition, in order to avoid exacerbation of PIH, physicians must be cautious with the selection of topical acne agents that are known to cause irritation. Sun protective measures, as well as effective skin lightening agents such as hydroquinone and azelaic acid, are important adjunctive therapies in the treatment of PIH.</p><p>The tendency for skin of color to develop PIH also limits the therapeutic modalities for melasma. Topical and aesthetic procedures are typically used in combination to achieve the best cosmetic outcome. While topical therapies remain the first choice in therapy, chemical peels and lasers are the second and third lines of management, respectively.</p><p>In women of color, particularly African Americans, a basic understanding of the diverse hair care practices is essential as many alopecias in this patient population may be associated with unique culturally-related hair styling methods. CCCA is the most common primary scarring alopecia in African American women. While topical and intralesional corticosteroids, oral anti-inflammatory agents and hair transplantation are potential treatments, patient education is paramount to halt progression of the disease process. As our understanding of these common dermatological disorders in women of color continue to unfold, advances in treatment are likely to develop.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0680"><element-citation publication-type="journal" id="rf0680"><person-group person-group-type="author"><name><surname>Ackerman</surname><given-names>A.B.</given-names></name><name><surname>Walton</surname><given-names>N.W.</given-names></name><name><surname>Jones</surname><given-names>R.E.</given-names></name><name><surname>Charissi</surname><given-names>C.</given-names></name></person-group><article-title>Hot comb alopecia: &#x0201c;follicular degeneration syndrome&#x0201d; in African-American women is traction alopecia!</article-title><source>Dermatopathol Pract Concept</source><volume>6</volume><year>2000</year><fpage>6</fpage><lpage>21</lpage></element-citation></ref><ref id="bb0550"><element-citation publication-type="journal" id="rf0550"><person-group person-group-type="author"><name><surname>Ahdout</surname><given-names>J.</given-names></name><name><surname>Mirmirani</surname><given-names>P.</given-names></name></person-group><article-title>Weft hair extensions causing a distinctive horseshoe pattern of traction alopecia</article-title><source>J Am Acad Dermatol</source><volume>67</volume><year>2012</year><fpage>e294</fpage><lpage>e295</lpage><pub-id pub-id-type="pmid">23158648</pub-id></element-citation></ref><ref id="bb0665"><element-citation publication-type="journal" id="rf0665"><person-group person-group-type="author"><name><surname>Alexis</surname><given-names>A.F.</given-names></name><name><surname>Sergay</surname><given-names>A.B.</given-names></name><name><surname>Taylor</surname><given-names>S.C.</given-names></name></person-group><article-title>Common dermatologic disorders in skin of color: a comparative practice survey</article-title><source>Cutis</source><volume>80</volume><year>2007</year><fpage>387</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">18189024</pub-id></element-citation></ref><ref id="bb0190"><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Alexis</surname><given-names>A.F.</given-names></name><name><surname>Johnson</surname><given-names>L.A.</given-names></name><name><surname>Kerrouche</surname><given-names>N.</given-names></name><name><surname>Callender</surname><given-names>V.D.</given-names></name></person-group><article-title>A subgroup analysis to evaluate the efficacy and safety of adapalene-benzoyl peroxide topical gel in black subjects with moderate acne</article-title><source>J Drugs Dermatol</source><volume>13</volume><year>2014</year><fpage>170</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">24509968</pub-id></element-citation></ref><ref id="bb0330"><element-citation publication-type="journal" id="rf0330"><person-group person-group-type="author"><name><surname>Arellano</surname><given-names>I.</given-names></name><name><surname>Cestari</surname><given-names>T.</given-names></name><name><surname>Ocampo-Candiani</surname><given-names>J.</given-names></name></person-group><article-title>Preventing melasma recurrence: prescribing a maintenance regimen with an effective triple combination cream based on long-lasting clinical severity</article-title><source>J Eur Acad Dermatol Venereol</source><volume>26</volume><year>2012</year><fpage>611</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">21623930</pub-id></element-citation></ref><ref id="bb0370"><element-citation publication-type="journal" id="rf0370"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>P.</given-names></name><name><surname>Sarkar</surname><given-names>R.</given-names></name><name><surname>Garg</surname><given-names>V.K.</given-names></name><name><surname>Arya</surname><given-names>L.</given-names></name></person-group><article-title>Lasers for treatment of melasma and post-inflammatory hyperpigmentation</article-title><source>J Cutan Aesthet Surg</source><volume>5</volume><year>2012</year><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">23060704</pub-id></element-citation></ref><ref id="bb0430"><element-citation publication-type="journal" id="rf0430"><person-group person-group-type="author"><name><surname>Attwa</surname><given-names>E.</given-names></name><name><surname>Khater</surname><given-names>M.</given-names></name><name><surname>Assaf</surname><given-names>M.</given-names></name><name><surname>Haleem</surname><given-names>M.A.</given-names></name></person-group><article-title>Melasma treatment using an erbium:YAG laser: a clinical, immunohistochemical, and ultrastructural study</article-title><source>Int J Dermatol</source><volume>54</volume><year>2014</year><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">25266556</pub-id></element-citation></ref><ref id="bb0040"><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Babiarz-Magee</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Seiberg</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>C.B.</given-names></name></person-group><article-title>The expression and activation of protease-activated receptor-2 correlate with skin color</article-title><source>Pigment Cell Res</source><volume>17</volume><year>2004</year><fpage>241</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">15140069</pub-id></element-citation></ref><ref id="bb0085"><element-citation publication-type="book" id="rf0085"><person-group person-group-type="author"><name><surname>Badreshia-Bansal</surname><given-names>S.</given-names></name><name><surname>Taylor</surname><given-names>S.</given-names></name></person-group><chapter-title>The Structure and Function of Skin of Color</chapter-title><person-group person-group-type="editor"><name><surname>Kelly</surname><given-names>A.P.</given-names></name><name><surname>Taylor</surname><given-names>S.C.</given-names></name></person-group><source>Dermatology for skin of color</source><year>2009</year><publisher-name>McGraw-Hill companies</publisher-name><publisher-loc>New York, NY</publisher-loc><fpage>71</fpage><lpage>77</lpage></element-citation></ref><ref id="bb0775"><element-citation publication-type="journal" id="rf0775"><person-group person-group-type="author"><name><surname>Banka</surname><given-names>N.</given-names></name><name><surname>Mubki</surname><given-names>T.</given-names></name><name><surname>Bunagan</surname><given-names>M.J.</given-names></name><name><surname>McElwee</surname><given-names>K.</given-names></name><name><surname>Shapiro</surname><given-names>J.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: a retrospective clinical review of 62 patients with treatment outcome and long-term follow-up</article-title><source>Int J Dermatol</source><volume>53</volume><year>2014</year><fpage>1324</fpage><lpage>1330</lpage><pub-id pub-id-type="pmid">24738979</pub-id></element-citation></ref><ref id="bb0415"><element-citation publication-type="journal" id="rf0415"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>C.</given-names></name><name><surname>Naik</surname><given-names>H.</given-names></name><name><surname>Kar</surname><given-names>H.K.</given-names></name><name><surname>Chauhan</surname><given-names>A.</given-names></name></person-group><article-title>A Comparison of Low-Fluence 1064-nm Q-Switched Nd: YAG Laser with Topical 20% Azelaic Acid Cream and their Combination in Melasma in Indian Patients</article-title><source>J Cutan Aesthet Surg</source><volume>5</volume><year>2012</year><fpage>266</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">23378709</pub-id></element-citation></ref><ref id="bb0885"><element-citation publication-type="journal" id="rf0885"><person-group person-group-type="author"><name><surname>Berliner</surname><given-names>J.G.</given-names></name><name><surname>McCalmont</surname><given-names>T.H.</given-names></name><name><surname>Price</surname><given-names>V.H.</given-names></name><name><surname>Berger</surname><given-names>T.G.</given-names></name></person-group><article-title>Frontal fibrosing alopecia and lichen planus pigmentosus</article-title><source>J Am Acad Dermatol</source><volume>71</volume><year>2014</year><fpage>e26</fpage><lpage>e27</lpage><pub-id pub-id-type="pmid">24947710</pub-id></element-citation></ref><ref id="bb0625"><element-citation publication-type="journal" id="rf0625"><person-group person-group-type="author"><name><surname>Bolduc</surname><given-names>C.</given-names></name><name><surname>Shapiro</surname><given-names>J.</given-names></name></person-group><article-title>Hair care products: waving, straightening, conditioning, and coloring</article-title><source>Clin Dermatol</source><volume>19</volume><year>2001</year><fpage>431</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">11535384</pub-id></element-citation></ref><ref id="bb0295"><element-citation publication-type="journal" id="rf0295"><person-group person-group-type="author"><name><surname>Boukari</surname><given-names>F.</given-names></name><name><surname>Jourdan</surname><given-names>E.</given-names></name><name><surname>Fontas</surname><given-names>E.</given-names></name><name><surname>Montaudi&#x000e9;</surname><given-names>H.</given-names></name><name><surname>Castela</surname><given-names>E.</given-names></name><name><surname>Lacour</surname><given-names>J.P.</given-names></name><name><surname>Passeron</surname><given-names>T.</given-names></name></person-group><article-title>Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial</article-title><source>J Am Acad Dermatol</source><volume>72</volume><year>2015</year><fpage>189</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">25443629</pub-id></element-citation></ref><ref id="bb0480"><element-citation publication-type="journal" id="rf0480"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name></person-group><article-title>African-American scalp disorders and treatment considerations</article-title><source>Skin Aging</source><volume>10</volume><year>2002</year><fpage>12</fpage><lpage>14</lpage></element-citation></ref><ref id="bb0160"><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name></person-group><article-title>Acne in ethnic skin: special considerations for therapy</article-title><source>Dermatol Ther</source><volume>17</volume><year>2004</year><fpage>184</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">15113286</pub-id></element-citation></ref><ref id="bb0745"><element-citation publication-type="book" id="rf0745"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name></person-group><chapter-title>Hair transplantation for pigmented skins</chapter-title><person-group person-group-type="editor"><name><surname>Halder</surname><given-names>R.M.</given-names></name></person-group><source>Dermatology and Dermatological Therapy of Pigmented Skins</source><year>2006</year><publisher-name>Taylor &#x00026; Francis</publisher-name><publisher-loc>Boca Raton, FL</publisher-loc><fpage>245</fpage><lpage>257</lpage></element-citation></ref><ref id="bb0195"><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name></person-group><article-title>Fitzpatrick Skin Types and Clindamycin Phosphate 1.2%/Benzoyl Peroxide Gel: Efficacy &#x00026; Tolerability of Treatment in Moderate to Severe Acne</article-title><source>J Drugs Dermatol</source><volume>11</volume><year>2012</year><fpage>643</fpage><lpage>648</lpage><pub-id pub-id-type="pmid">22527435</pub-id></element-citation></ref><ref id="bb0705"><element-citation publication-type="journal" id="rf0705"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name><name><surname>Onwudiwe</surname><given-names>O.</given-names></name></person-group><article-title>Prevalence and etiology of central centrifugal cicatricial alopecia</article-title><source>Arch Dermatol</source><volume>147</volume><year>2011</year><fpage>972</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">21844458</pub-id></element-citation></ref><ref id="bb0750"><element-citation publication-type="book" id="rf0750"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name><name><surname>Young</surname><given-names>C.M.</given-names></name></person-group><chapter-title>Alopecias and hair restoration in women</chapter-title><person-group person-group-type="editor"><name><surname>Grimes</surname><given-names>P.E.</given-names></name><name><surname>Soriano</surname><given-names>T.</given-names></name><name><surname>Hexsel</surname><given-names>D.M.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name></person-group><source>Aesthetics and Cosmetic Surgery for Darker Skin Types</source><year>2008</year><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Philadelphia, PA</publisher-loc><fpage>287</fpage><lpage>295</lpage></element-citation></ref><ref id="bb0470"><element-citation publication-type="journal" id="rf0470"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name><name><surname>McMichael</surname><given-names>A.J.</given-names></name><name><surname>Cohen</surname><given-names>G.F.</given-names></name></person-group><article-title>Medical and surgical therapies for alopecias in black women</article-title><source>Dermatol Ther</source><volume>17</volume><year>2004</year><fpage>164</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">15113284</pub-id></element-citation></ref><ref id="bb0200"><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name><name><surname>Young</surname><given-names>C.M.</given-names></name><name><surname>Kindred</surname><given-names>C.</given-names></name><name><surname>Taylor</surname><given-names>S.C.</given-names></name></person-group><article-title>Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne-induced post-inflammatory hyperpigmentation in patients with skin of color</article-title><source>J Clin Aesthet Dermatol</source><volume>5</volume><year>2012</year><fpage>25</fpage><lpage>32</lpage></element-citation></ref><ref id="bb0710"><element-citation publication-type="journal" id="rf0710"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name><name><surname>Wright</surname><given-names>D.R.</given-names></name><name><surname>Davis</surname><given-names>E.C.</given-names></name><name><surname>Sperling</surname><given-names>L.C.</given-names></name></person-group><article-title>Hair breakage as a presenting sign of early or occult central centrifugal cicatricial alopecia: clinicopathologic findings in 9 patients</article-title><source>Arch Dermatol</source><volume>148</volume><year>2012</year><fpage>1047</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">22986858</pub-id></element-citation></ref><ref id="bb0100"><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name><name><surname>Alexis</surname><given-names>A.F.</given-names></name><name><surname>Daniels</surname><given-names>S.R.</given-names></name><name><surname>Kawata</surname><given-names>A.K.</given-names></name><name><surname>Burk</surname><given-names>C.B.</given-names></name><name><surname>Wilcox</surname><given-names>T.K.</given-names></name><name><surname>Taylor</surname><given-names>S.C.</given-names></name></person-group><article-title>Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne</article-title><source>J Clin Aesthet Dermatol</source><volume>7</volume><year>2014</year><fpage>19</fpage><lpage>31</lpage></element-citation></ref><ref id="bb0740"><element-citation publication-type="journal" id="rf0740"><person-group person-group-type="author"><name><surname>Callender</surname><given-names>V.D.</given-names></name><name><surname>Lawson</surname><given-names>C.N.</given-names></name><name><surname>Onwudiwe</surname><given-names>O.C.</given-names></name></person-group><article-title>Hair transplantation in the surgical treatment of central centrifugal cicatricial alopecia</article-title><source>Dermatol Surg</source><volume>40</volume><year>2014</year><fpage>1125</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">25207763</pub-id></element-citation></ref><ref id="bb0855"><element-citation publication-type="journal" id="rf0855"><person-group person-group-type="author"><name><surname>Camacho</surname><given-names>F.M.</given-names></name></person-group><article-title>Lonely hair sign: not specific for frontal fibrosing alopecia</article-title><source>Arch Dermatol</source><volume>148</volume><year>2012</year><fpage>1208</fpage><lpage>1209</lpage></element-citation></ref><ref id="bb0325"><element-citation publication-type="journal" id="rf0325"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>R.</given-names></name><name><surname>Park</surname><given-names>K.C.</given-names></name><name><surname>Lee</surname><given-names>M.H.</given-names></name></person-group><article-title>A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide, 0.01%, hydroquinone, 4%, tretinoin, 0.05%) compared with hydroquinone, 4% cream in Asian patients with moderate to severe melasma</article-title><source>Br J Dermatol</source><volume>159</volume><year>2008</year><fpage>697</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">18616780</pub-id></element-citation></ref><ref id="bb0835"><element-citation publication-type="journal" id="rf0835"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>A.L.</given-names></name><name><surname>Bashir</surname><given-names>S.J.</given-names></name><name><surname>Wain</surname><given-names>E.M.</given-names></name></person-group><article-title>Expanding the spectrum of frontal fibrosing alopecia: a unifying concept</article-title><source>J Am Acad Dermatol</source><volume>63</volume><issue>4</issue><year>2010</year><fpage>653</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">20846567</pub-id></element-citation></ref><ref id="bb0920"><element-citation publication-type="journal" id="rf0920"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>C.</given-names></name><name><surname>Sah</surname><given-names>D.</given-names></name><name><surname>Cho</surname><given-names>B.K.</given-names></name><name><surname>Ochoa</surname><given-names>B.E.</given-names></name><name><surname>Price</surname><given-names>V.H.</given-names></name></person-group><article-title>Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system</article-title><source>J Am Acad Dermatol</source><volume>62</volume><year>2010</year><fpage>387</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">20061052</pub-id></element-citation></ref><ref id="bb0925"><element-citation publication-type="journal" id="rf0925"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>B.K.</given-names></name><name><surname>Sah</surname><given-names>D.</given-names></name><name><surname>Chwalek</surname><given-names>J.</given-names></name><name><surname>Roseborough</surname><given-names>I.</given-names></name><name><surname>Ochoa</surname><given-names>B.</given-names></name><name><surname>Chiang</surname><given-names>C.</given-names></name><name><surname>Price</surname><given-names>V.H.</given-names></name></person-group><article-title>Efficacy and safety of mycophenolate mofetil for lichen planopilaris</article-title><source>J Am Acad Dermatol</source><volume>62</volume><year>2010</year><fpage>393</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">20061053</pub-id></element-citation></ref><ref id="bb0030"><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>W.</given-names></name><name><surname>Kolbe</surname><given-names>L.</given-names></name><name><surname>Hearing</surname><given-names>V.J.</given-names></name></person-group><article-title>Characterization of the bioactive motif of neuregulin-1, a fibroblast-derived paracrine factor that regulates the constitutive color and the function of melanocytes in human skin</article-title><source>Pigment Cell Melanoma Res</source><volume>25</volume><year>2012</year><fpage>477</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">22494484</pub-id></element-citation></ref><ref id="bb0050"><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>M.</given-names></name><name><surname>Kollias</surname><given-names>N.</given-names></name></person-group><article-title>Documentation of normal stratum corneum scaling in an average population: Features of differences among age, ethnicity and body site</article-title><source>Br J Dermatol</source><volume>164</volume><year>2011</year><fpage>497</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">21054338</pub-id></element-citation></ref><ref id="bb0095"><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>E.C.</given-names></name><name><surname>Callender</surname><given-names>V.D.</given-names></name></person-group><article-title>A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies</article-title><source>J Clin Aesthet Dermatol</source><volume>3</volume><year>2010</year><fpage>24</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">20725545</pub-id></element-citation></ref><ref id="bb0015"><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>S.A.</given-names></name><name><surname>Narahari</surname><given-names>S.</given-names></name><name><surname>Feldman</surname><given-names>S.R.</given-names></name><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Pichardo-Geisinger</surname><given-names>R.O.</given-names></name><name><surname>McMichael</surname><given-names>A.J.</given-names></name></person-group><article-title>Top dermatologic conditions in patients of color: An analysis of nationally representative data</article-title><source>J Drugs Dermatol</source><volume>11</volume><year>2012</year><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">22453583</pub-id></element-citation></ref><ref id="bb0890"><element-citation publication-type="journal" id="rf0890"><person-group person-group-type="author"><name><surname>Del Rei</surname><given-names>M.</given-names></name><name><surname>Pirmez</surname><given-names>R.</given-names></name><name><surname>Sodr&#x000e9;</surname><given-names>C.T.</given-names></name><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>Coexistence of frontal fibrosing alopecia and discoid lupus erythematosus of the scalp in 7 patients: just a coincidence?</article-title><source>J Eur Acad Dermatol Venereol</source><year>2014</year><comment>[Published Jul 30, 2014, Epub ahead of print]</comment></element-citation></ref><ref id="bb0635"><element-citation publication-type="journal" id="rf0635"><person-group person-group-type="author"><name><surname>Detwiler</surname><given-names>S.P.</given-names></name><name><surname>Carson</surname><given-names>J.L.</given-names></name><name><surname>Woosley</surname><given-names>J.T.</given-names></name><name><surname>Gambling</surname><given-names>T.M.</given-names></name><name><surname>Briggaman</surname><given-names>R.A.</given-names></name></person-group><article-title>Bubble hair: case caused by an overheating hair dryer and reproducibility in normal hair with heat</article-title><source>J Am Acad Dermatol</source><volume>30</volume><year>1994</year><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8277032</pub-id></element-citation></ref><ref id="bb0900"><element-citation publication-type="journal" id="rf0900"><person-group person-group-type="author"><name><surname>Dlova</surname><given-names>N.C.</given-names></name></person-group><article-title>Frontal fibrosing alopecia and lichen planus pigmentosus: is there a link?</article-title><source>Br J Dermatol</source><volume>168</volume><year>2013</year><fpage>439</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">22803712</pub-id></element-citation></ref><ref id="bb0690"><element-citation publication-type="journal" id="rf0690"><person-group person-group-type="author"><name><surname>Dlova</surname><given-names>N.C.</given-names></name><name><surname>Forder</surname><given-names>M.</given-names></name></person-group><article-title>Central centrifugal cicatricial alopecia: possible familial aetiology in two African families from South Africa</article-title><source>Int J Dermatol</source><volume>51</volume><issue>S1</issue><year>2012</year><fpage>17</fpage><lpage>20</lpage><comment>[20-3]</comment><pub-id pub-id-type="pmid">23210944</pub-id></element-citation></ref><ref id="bb0800"><element-citation publication-type="journal" id="rf0800"><person-group person-group-type="author"><name><surname>Dlova</surname><given-names>N.C.</given-names></name><name><surname>Goh</surname><given-names>C.L.</given-names></name></person-group><article-title>Frontal fibrosing alopecia in an African man</article-title><source>Int J Dermatol</source><volume>54</volume><year>2013</year><fpage>81</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">23968222</pub-id></element-citation></ref><ref id="bb0815"><element-citation publication-type="journal" id="rf0815"><person-group person-group-type="author"><name><surname>Dlova</surname><given-names>N.C.</given-names></name><name><surname>Jordaan</surname><given-names>H.F.</given-names></name><name><surname>Skenjane</surname><given-names>A.</given-names></name><name><surname>Khoza</surname><given-names>N.</given-names></name><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: a clinical review of 20 black patients from South Africa</article-title><source>Br J Dermatol</source><volume>169</volume><year>2013</year><fpage>939</fpage><lpage>941</lpage><pub-id pub-id-type="pmid">23647261</pub-id></element-citation></ref><ref id="bb0695"><element-citation publication-type="journal" id="rf0695"><person-group person-group-type="author"><name><surname>Dlova</surname><given-names>N.C.</given-names></name><name><surname>Jordaan</surname><given-names>F.H.</given-names></name><name><surname>Sarig</surname><given-names>O.</given-names></name><name><surname>Sprecher</surname><given-names>E.</given-names></name></person-group><article-title>Autosomal dominant inheritance of central centrifugal cicatricial alopecia in black South Africans</article-title><source>J Am Acad Dermatol</source><volume>70</volume><year>2014</year><fpage>679</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">24480456</pub-id></element-citation></ref><ref id="bb0210"><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Draelos</surname><given-names>Z.D.</given-names></name><name><surname>Carter</surname><given-names>E.</given-names></name><name><surname>Maloney</surname><given-names>J.M.</given-names></name><name><surname>Elewski</surname><given-names>B.</given-names></name><name><surname>Poulin</surname><given-names>Y.</given-names></name><name><surname>Lynde</surname><given-names>C.</given-names></name><name><surname>Garrett</surname><given-names>S.</given-names></name><collab>United States/Canada Dapsone Gel Study Group</collab></person-group><article-title>Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris</article-title><source>J Am Acad Dermatol</source><volume>56</volume><year>2007</year><fpage>439.e1</fpage><lpage>439.e10</lpage><pub-id pub-id-type="pmid">17208334</pub-id></element-citation></ref><ref id="bb0400"><element-citation publication-type="journal" id="rf0400"><person-group person-group-type="author"><name><surname>Fabi</surname><given-names>S.G.</given-names></name><name><surname>Friedmann</surname><given-names>D.P.</given-names></name><name><surname>Niwa Massaki</surname><given-names>A.B.</given-names></name><name><surname>Goldman</surname><given-names>M.P.</given-names></name></person-group><article-title>A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma</article-title><source>Lasers Surg Med</source><volume>46</volume><year>2014</year><fpage>531</fpage><lpage>537</lpage><pub-id pub-id-type="pmid">24895301</pub-id></element-citation></ref><ref id="bb0770"><element-citation publication-type="journal" id="rf0770"><person-group person-group-type="author"><name><surname>Faulkner</surname><given-names>C.F.</given-names></name><name><surname>Wilson</surname><given-names>N.J.</given-names></name><name><surname>Jones</surname><given-names>S.K.</given-names></name></person-group><article-title>Frontal fibrosing alopecia associated with cutaneous lichen planus in a premenopausal woman</article-title><source>Australas J Dermatol</source><volume>43</volume><year>2002</year><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">11869213</pub-id></element-citation></ref><ref id="bb0130"><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Fisk</surname><given-names>W.A.</given-names></name><name><surname>Lev-Tov</surname><given-names>H.A.</given-names></name><name><surname>Sivamani</surname><given-names>R.K.</given-names></name></person-group><article-title>Epidemiology and Management of Acne in Adult Women</article-title><source>Curr Dermatol Rep</source><volume>3</volume><year>2014</year><fpage>29</fpage><lpage>39</lpage></element-citation></ref><ref id="bb0220"><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Fleischer</surname><given-names>A.B.</given-names><suffix>Jr.</suffix></name><name><surname>Dinehart</surname><given-names>S.</given-names></name><name><surname>Stough</surname><given-names>D.</given-names></name><name><surname>Plott</surname><given-names>R.T.</given-names></name><collab>Solodyn Phase 2 Study Group</collab><collab>Solodyn Phase 3 Study Group</collab></person-group><article-title>Safety and efficacy of a new extended-release formulation of minocycline</article-title><source>Cutis</source><volume>78</volume><year>2006</year><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">17436826</pub-id></element-citation></ref><ref id="bb0530"><element-citation publication-type="journal" id="rf0530"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>G.N.</given-names></name><name><surname>Stausmire</surname><given-names>J.M.</given-names></name><name><surname>Mehregan</surname><given-names>D.R.</given-names></name></person-group><article-title>Traction folliculitis: an underreported entity</article-title><source>Cutis</source><volume>79</volume><year>2007</year><fpage>26</fpage><lpage>30</lpage></element-citation></ref><ref id="bb0700"><element-citation publication-type="journal" id="rf0700"><person-group person-group-type="author"><name><surname>Franbourg</surname><given-names>A.</given-names></name><name><surname>Hallegot</surname><given-names>P.</given-names></name><name><surname>Baltenneck</surname><given-names>F.</given-names></name><name><surname>Toutain</surname><given-names>C.</given-names></name><name><surname>Leroy</surname><given-names>F.</given-names></name></person-group><article-title>Current research on ethnic hair</article-title><source>J Am Acad Dermatol</source><volume>48</volume><year>2003</year><fpage>S115</fpage><lpage>S119</lpage><pub-id pub-id-type="pmid">12789163</pub-id></element-citation></ref><ref id="bb0905"><element-citation publication-type="journal" id="rf0905"><person-group person-group-type="author"><name><surname>Gaffney</surname><given-names>D.C.</given-names></name><name><surname>Sinclair</surname><given-names>R.D.</given-names></name><name><surname>Yong-Gee</surname><given-names>S.</given-names></name></person-group><article-title>Discoid lupus alopecia complicated by frontal fibrosing alopecia on a background of androgenetic alopecia</article-title><source>Br J Dermatol</source><volume>169</volume><year>2013</year><fpage>217</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">23448183</pub-id></element-citation></ref><ref id="bb0670"><element-citation publication-type="journal" id="rf0670"><person-group person-group-type="author"><name><surname>Gathers</surname><given-names>R.C.</given-names></name><name><surname>Jankowski</surname><given-names>M.</given-names></name><name><surname>Eide</surname><given-names>M.</given-names></name><name><surname>Lim</surname><given-names>H.W.</given-names></name></person-group><article-title>Hair grooming practices and central centrifugal cicatricial alopecia</article-title><source>J Am Acad Dermatol</source><volume>60</volume><year>2009</year><fpage>574</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">19293007</pub-id></element-citation></ref><ref id="bb0250"><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Geller</surname><given-names>L.</given-names></name><name><surname>Rosen</surname><given-names>J.</given-names></name><name><surname>Frankel</surname><given-names>A.</given-names></name><name><surname>Goldenberg</surname><given-names>G.</given-names></name></person-group><article-title>Perimenstrual flare of adult acne</article-title><source>J Clin Aesthet Dermatol</source><volume>7</volume><year>2014</year><fpage>30</fpage><lpage>34</lpage></element-citation></ref><ref id="bb0065"><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Girardeau-Hubert</surname><given-names>S.</given-names></name><name><surname>Pageon</surname><given-names>H.</given-names></name><name><surname>Asselineau</surname><given-names>D.</given-names></name></person-group><article-title>In vivo and in vitro approaches in understanding the differences between caucasian and african skin types: specific involvement of the papillary dermis</article-title><source>Int J Dermatol</source><volume>51</volume><issue>S1</issue><year>2012</year><fpage>1</fpage><lpage>4</lpage></element-citation></ref><ref id="bb0265"><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>M.H.</given-names></name></person-group><article-title>Clinical evaluation of the safety and efficacy of a novel superficial and deep carbon dioxide fractional system in the treatment of patients with skin of color</article-title><source>J Drugs Dermatol</source><volume>11</volume><year>2012</year><fpage>1331</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">23135084</pub-id></element-citation></ref><ref id="bb0110"><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Goulden</surname><given-names>V.</given-names></name><name><surname>Stables</surname><given-names>G.I.</given-names></name><name><surname>Cunliffee</surname><given-names>W.J.</given-names></name></person-group><article-title>Prevalence of facial acne in adults</article-title><source>J Am Acad Dermatol</source><volume>41</volume><year>1999</year><fpage>577</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">10495379</pub-id></element-citation></ref><ref id="bb0280"><element-citation publication-type="journal" id="rf0280"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>P.E.</given-names></name></person-group><article-title>Melasma: etiologic and therapeutic considerations</article-title><source>Arch Dermatol</source><volume>131</volume><year>1995</year><fpage>1453</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">7492140</pub-id></element-citation></ref><ref id="bb0475"><element-citation publication-type="journal" id="rf0475"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>P.E.</given-names></name></person-group><article-title>Skin and hair cosmetic issues in women of color</article-title><source>Dermatol Clin</source><volume>18</volume><year>2000</year><fpage>659</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">11059374</pub-id></element-citation></ref><ref id="bb0350"><element-citation publication-type="journal" id="rf0350"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>P.E.</given-names></name></person-group><article-title>Novel skin brightener used as monotherapy for moderate melasma in skin of color</article-title><source>J Drugs Dermatol</source><volume>13</volume><year>2014</year><fpage>364</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">24595584</pub-id></element-citation></ref><ref id="bb0185"><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>P.E.</given-names></name><name><surname>Callender</surname><given-names>V.D.</given-names></name></person-group><article-title>Tazarotene Cream for Postinflammatory Hyperpigmentation and Acne Vulgaris in Darker Skin: A Double-Blind, Randomized, Vehicle-Controlled Study</article-title><source>Cutis</source><volume>77</volume><year>2006</year><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">16475496</pub-id></element-citation></ref><ref id="bb0090"><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Halder</surname><given-names>R.M.</given-names></name><name><surname>Grimes</surname><given-names>P.E.</given-names></name><name><surname>McLaurin</surname><given-names>C.L.</given-names></name><name><surname>Kress</surname><given-names>M.A.</given-names></name><name><surname>Kenney</surname><given-names>J.A.</given-names></name></person-group><article-title>Incidence of common dermatoses in a predominantly black dermatology practice</article-title><source>Cutis</source><volume>32</volume><year>1983</year><fpage>388</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">6226496</pub-id></element-citation></ref><ref id="bb0660"><element-citation publication-type="journal" id="rf0660"><person-group person-group-type="author"><name><surname>Halder</surname><given-names>R.M.</given-names></name><name><surname>Grimes</surname><given-names>P.E.</given-names></name><name><surname>McLaurin</surname><given-names>C.I.</given-names></name><name><surname>Kress</surname><given-names>M.A.</given-names></name><name><surname>Kenney</surname><given-names>J.A.</given-names></name></person-group><article-title>Incidence of common dermatoses in a predominantly black dermatologic practice</article-title><source>Cutis</source><volume>32</volume><year>1983</year><fpage>388</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">6226496</pub-id></element-citation></ref><ref id="bb0155"><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Halder</surname><given-names>R.M.</given-names></name><name><surname>Holmes</surname><given-names>Y.C.</given-names></name><name><surname>Bridgeman-Shah</surname><given-names>S.</given-names></name><name><surname>Kligman</surname><given-names>A.M.</given-names></name></person-group><article-title>A clinicohistopathologic study of acne vulgaris in black females</article-title><source>J Invest Dermatol</source><volume>106</volume><year>1996</year><fpage>888</fpage></element-citation></ref><ref id="bb0495"><element-citation publication-type="journal" id="rf0495"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>R.R.</given-names></name><name><surname>Francis</surname><given-names>S.</given-names></name><name><surname>Whitt-Glover</surname><given-names>M.</given-names></name><name><surname>Loftin-Bell</surname><given-names>K.</given-names></name><name><surname>Swett</surname><given-names>K.</given-names></name><name><surname>McMichael</surname><given-names>A.J.</given-names></name></person-group><article-title>Hair care practices as a barrier to physical activity in African American women</article-title><source>JAMA Dermatol</source><volume>149</volume><year>2013</year><fpage>310</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">23682367</pub-id></element-citation></ref><ref id="bb0565"><element-citation publication-type="journal" id="rf0565"><person-group person-group-type="author"><name><surname>Heath</surname><given-names>C.R.</given-names></name><name><surname>Taylor</surname><given-names>S.C.</given-names></name></person-group><article-title>Alopecia in an ophiasis pattern: traction alopecia versus alopecia areata</article-title><source>Cutis</source><volume>89</volume><year>2012</year><fpage>213</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">22768432</pub-id></element-citation></ref><ref id="bb0395"><element-citation publication-type="journal" id="rf0395"><person-group person-group-type="author"><name><surname>Hilton</surname><given-names>S.</given-names></name><name><surname>Heise</surname><given-names>H.</given-names></name><name><surname>Buhren</surname><given-names>B.A.</given-names></name><name><surname>Schrumpf</surname><given-names>H.</given-names></name><name><surname>B&#x000f6;lke</surname><given-names>E.</given-names></name><name><surname>Gerber</surname><given-names>P.A.</given-names></name></person-group><article-title>Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laser</article-title><source>Eur J Med Res</source><volume>18</volume><year>2013</year><fpage>43</fpage><pub-id pub-id-type="pmid">24225160</pub-id></element-citation></ref><ref id="bb0865"><element-citation publication-type="journal" id="rf0865"><person-group person-group-type="author"><name><surname>Inui</surname><given-names>S.</given-names></name><name><surname>Nakajima</surname><given-names>T.</given-names></name><name><surname>Shono</surname><given-names>F.</given-names></name><name><surname>Itami</surname><given-names>S.</given-names></name></person-group><article-title>Dermoscopic findings in frontal fibrosing alopecia: report of four cases</article-title><source>Int J Dermatol</source><volume>47</volume><year>2008</year><fpage>796</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">18717858</pub-id></element-citation></ref><ref id="bb0440"><element-citation publication-type="journal" id="rf0440"><person-group person-group-type="author"><name><surname>Jalaly</surname><given-names>N.Y.</given-names></name><name><surname>Valizadeh</surname><given-names>N.</given-names></name><name><surname>Barikbin</surname><given-names>B.</given-names></name><name><surname>Yousefi</surname><given-names>M.</given-names></name></person-group><article-title>Low-power fractional CO<sub>2</sub> laser versus low-fluence Q-switch 1,064 nm Nd:YAG laser for treatment of melasma: a randomized, controlled, split-face study</article-title><source>Am J Clin Dermatol</source><volume>15</volume><year>2014</year><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">24858737</pub-id></element-citation></ref><ref id="bb0570"><element-citation publication-type="journal" id="rf0570"><person-group person-group-type="author"><name><surname>James</surname><given-names>J.</given-names></name><name><surname>Saladi</surname><given-names>R.N.</given-names></name><name><surname>Fox</surname><given-names>J.L.</given-names></name></person-group><article-title>Traction alopecia in Sikh male patients</article-title><source>J Am Board Fam Med</source><volume>20</volume><year>2007</year><fpage>497</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">17823469</pub-id></element-citation></ref><ref id="bb0380"><element-citation publication-type="journal" id="rf0380"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>W.S.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Kim</surname><given-names>B.J.</given-names></name><name><surname>Kim</surname><given-names>M.N.</given-names></name></person-group><article-title>Efficacy of 694-nm Q-switched ruby fractional laser treatment of melasma in female Korean patients</article-title><source>Dermatol Surg</source><volume>37</volume><year>2011</year><fpage>1133</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">21585597</pub-id></element-citation></ref><ref id="bb0070"><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>J.H.</given-names></name><name><surname>Park</surname><given-names>T.S.</given-names></name><name><surname>Lee</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>Y.D.</given-names></name><name><surname>Pi</surname><given-names>L.Q.</given-names></name><name><surname>Jin</surname><given-names>X.H.</given-names></name><name><surname>Lee</surname><given-names>W.S.</given-names></name></person-group><article-title>The ethnic differences of the damage of hair and integral hair lipid after ultra violet radiation</article-title><source>Ann Dermatol</source><volume>25</volume><year>2013</year><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">23467772</pub-id></element-citation></ref><ref id="bb0055"><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Jungersted</surname><given-names>J.M.</given-names></name><name><surname>Hogh</surname><given-names>J.K.</given-names></name><name><surname>Hellgren</surname><given-names>L.I.</given-names></name><name><surname>Jemec</surname><given-names>G.B.</given-names></name><name><surname>Agner</surname><given-names>T.</given-names></name></person-group><article-title>Ethnicity and stratum corneum ceramides</article-title><source>Br J Dermatol</source><volume>163</volume><year>2010</year><fpage>1169</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">21039401</pub-id></element-citation></ref><ref id="bb0140"><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Kamangar</surname><given-names>F.</given-names></name><name><surname>Shinkai</surname><given-names>K.</given-names></name></person-group><article-title>Acne in the adult female patient: a practical approach</article-title><source>Int J Dermatol</source><volume>51</volume><year>2012</year><fpage>1162</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">22994662</pub-id></element-citation></ref><ref id="bb0275"><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name><surname>Karnik</surname><given-names>J.</given-names></name><name><surname>Baumann</surname><given-names>L.</given-names></name><name><surname>Bruce</surname><given-names>S.</given-names></name><name><surname>Callender</surname><given-names>V.</given-names></name><name><surname>Cohen</surname><given-names>S.</given-names></name><name><surname>Grimes</surname><given-names>P.</given-names></name><name><surname>Joseph</surname><given-names>J.</given-names></name><name><surname>Shamban</surname><given-names>A.</given-names></name><name><surname>Spencer</surname><given-names>J.</given-names></name><name><surname>Teldaldi</surname><given-names>R.</given-names></name><name><surname>Werschler</surname><given-names>W.</given-names></name><name><surname>Smith</surname><given-names>S.</given-names></name></person-group><article-title>A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars</article-title><source>J Am Acad Dermatol</source><volume>71</volume><year>2014</year><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">24725475</pub-id></element-citation></ref><ref id="bb0915"><element-citation publication-type="journal" id="rf0915"><person-group person-group-type="author"><name><surname>Katoulis</surname><given-names>A.</given-names></name><name><surname>Georgala</surname><given-names>S.</given-names></name><name><surname>Bozi</surname><given-names>E.</given-names></name><name><surname>Papadavid</surname><given-names>E.</given-names></name><name><surname>Kalogeromitros</surname><given-names>D.</given-names></name><name><surname>Stavrianeas</surname><given-names>N.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus</article-title><source>J Eur Acad Dermatol Venereol</source><volume>23</volume><year>2009</year><fpage>580</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">19415810</pub-id></element-citation></ref><ref id="bb0255"><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>A.P.</given-names></name><name><surname>Sampson</surname><given-names>D.D.</given-names></name></person-group><article-title>Recalcitrant nodulocystic acne in black Americans: treatment with isotretinoin</article-title><source>J Natl Med Assoc</source><volume>79</volume><year>1987</year><fpage>1266</fpage><lpage>1270</lpage><pub-id pub-id-type="pmid">2963137</pub-id></element-citation></ref><ref id="bb0895"><element-citation publication-type="journal" id="rf0895"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Fenton</surname><given-names>D.A.</given-names></name><name><surname>Stefanato</surname><given-names>C.M.</given-names></name></person-group><article-title>Frontal fibrosing alopecia and lupus overlap in a man: guilt by association?</article-title><source>Int J Trichol</source><volume>5</volume><year>2013</year><fpage>217</fpage><lpage>219</lpage></element-citation></ref><ref id="bb0575"><element-citation publication-type="journal" id="rf0575"><person-group person-group-type="author"><name><surname>Khumalo</surname><given-names>N.P.</given-names></name><name><surname>Ngwanya</surname><given-names>R.M.</given-names></name></person-group><article-title>Traction alopecia: 2% topical minoxidil shows promise. Report of two cases</article-title><source>J Eur Acad Dermatol Venereol</source><volume>21</volume><year>2007</year><fpage>433</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">17309495</pub-id></element-citation></ref><ref id="bb0505"><element-citation publication-type="journal" id="rf0505"><person-group person-group-type="author"><name><surname>Khumalo</surname><given-names>N.P.</given-names></name><name><surname>Jessop</surname><given-names>S.</given-names></name><name><surname>Gumedze</surname><given-names>F.</given-names></name><name><surname>Ehrlich</surname><given-names>R.</given-names></name></person-group><article-title>Hairdressing and the prevalence of scalp disease in African adults</article-title><source>Br J Dermatol</source><volume>157</volume><year>2007</year><fpage>981</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">17725667</pub-id></element-citation></ref><ref id="bb0510"><element-citation publication-type="journal" id="rf0510"><person-group person-group-type="author"><name><surname>Khumalo</surname><given-names>N.P.</given-names></name><name><surname>Jessop</surname><given-names>S.</given-names></name><name><surname>Gumedze</surname><given-names>F.</given-names></name><name><surname>Ehrlich</surname><given-names>R.</given-names></name></person-group><article-title>Hairdressing is associated with scalp disease in African schoolchildren</article-title><source>Br J Dermatol</source><volume>157</volume><year>2007</year><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">17553035</pub-id></element-citation></ref><ref id="bb0540"><element-citation publication-type="journal" id="rf0540"><person-group person-group-type="author"><name><surname>Khumalo</surname><given-names>N.P.</given-names></name><name><surname>Jessop</surname><given-names>S.</given-names></name><name><surname>Gumedze</surname><given-names>F.</given-names></name><name><surname>Ehrlich</surname><given-names>R.</given-names></name></person-group><article-title>Determinants of marginal traction alopecia in African girls and women</article-title><source>J Am Acad Dermatol</source><volume>59</volume><year>2008</year><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">18694677</pub-id></element-citation></ref><ref id="bb0615"><element-citation publication-type="journal" id="rf0615"><person-group person-group-type="author"><name><surname>Khumalo</surname><given-names>N.P.</given-names></name><name><surname>Stone</surname><given-names>J.</given-names></name><name><surname>Gumedze</surname><given-names>F.</given-names></name><name><surname>McGrath</surname><given-names>E.</given-names></name><name><surname>Ngwanya</surname><given-names>M.R.</given-names></name><name><surname>de Berker</surname><given-names>D.</given-names></name></person-group><article-title>'Relaxers' damage hair: evidence from amino acid analysis</article-title><source>J Am Acad Dermatol</source><volume>62</volume><year>2010</year><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">20159306</pub-id></element-citation></ref><ref id="bb0105"><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Khunger</surname><given-names>N.</given-names></name><name><surname>Kumar</surname><given-names>C.</given-names></name></person-group><article-title>A clinico-epidemiological study of adult acne: is it different from adolescent acne?</article-title><source>Indian J Dermatol Venereol Leprol</source><volume>78</volume><year>2012</year><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">22565434</pub-id></element-citation></ref><ref id="bb0260"><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name><surname>Khunger</surname><given-names>N.</given-names></name><name><surname>Bhardwaj</surname><given-names>D.</given-names></name><name><surname>Khunger</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of CROSS technique with 100% TCA in the management of ice pick acne scars in darker skin types</article-title><source>J Cosmet Dermatol</source><volume>10</volume><year>2011</year><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">21332915</pub-id></element-citation></ref><ref id="bb0235"><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Kircik</surname><given-names>L.H.</given-names></name></person-group><article-title>Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications</article-title><source>J Drugs Dermatol</source><volume>9</volume><year>2010</year><fpage>1407</fpage><lpage>1411</lpage><pub-id pub-id-type="pmid">21061764</pub-id></element-citation></ref><ref id="bb0205"><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Kircik</surname><given-names>L.H.</given-names></name></person-group><article-title>Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study</article-title><source>J Drugs Dermatol</source><volume>10</volume><year>2011</year><fpage>586</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">21637899</pub-id></element-citation></ref><ref id="bb0045"><element-citation publication-type="book" id="rf0045"><person-group person-group-type="author"><name><surname>Kligman</surname><given-names>A.M.</given-names></name></person-group><chapter-title>Solar elastosis in relation to pigmentation</chapter-title><person-group person-group-type="editor"><name><surname>Fitzpatrick</surname><given-names>T.B.</given-names></name><name><surname>Pathak</surname><given-names>M.A.</given-names></name><name><surname>Harber</surname><given-names>L.C.</given-names></name><name><surname>Seiji</surname><given-names>M.</given-names></name><name><surname>Kukita</surname><given-names>A.</given-names></name></person-group><source>Sunlight and Man: Normal and Abnormal Photobiologic Response</source><year>1994</year><publisher-name>University of Tokyo Press</publisher-name><publisher-loc>Tokyo</publisher-loc><fpage>157</fpage><lpage>163</lpage></element-citation></ref><ref id="bb0755"><element-citation publication-type="journal" id="rf0755"><person-group person-group-type="author"><name><surname>Kossard</surname><given-names>S.</given-names></name></person-group><article-title>Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution</article-title><source>Arch Dermatol</source><volume>130</volume><year>1994</year><fpage>770</fpage><lpage>774</lpage><comment>[Erratum in: Arch Dermatol. 1994;130:1407]</comment><pub-id pub-id-type="pmid">8002649</pub-id></element-citation></ref><ref id="bb0785"><element-citation publication-type="journal" id="rf0785"><person-group person-group-type="author"><name><surname>Kossard</surname><given-names>S.</given-names></name><name><surname>Shiell</surname><given-names>R.C.</given-names></name></person-group><article-title>Frontal fibrosing alopecia developing after hair transplantation for androgenetic alopecia</article-title><source>Int J Dermatol</source><volume>44</volume><year>2005</year><fpage>321</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">15811087</pub-id></element-citation></ref><ref id="bb0760"><element-citation publication-type="journal" id="rf0760"><person-group person-group-type="author"><name><surname>Kossard</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>M.S.</given-names></name><name><surname>Wilkinson</surname><given-names>B.</given-names></name></person-group><article-title>Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris</article-title><source>J Am Acad Dermatol</source><volume>36</volume><year>1997</year><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">8996262</pub-id></element-citation></ref><ref id="bb0725"><element-citation publication-type="journal" id="rf0725"><person-group person-group-type="author"><name><surname>Kyei</surname><given-names>A.</given-names></name><name><surname>Bergfeld</surname><given-names>W.F.</given-names></name><name><surname>Piliang</surname><given-names>M.</given-names></name><name><surname>Summers</surname><given-names>P.</given-names></name></person-group><article-title>Medical and environmental risk factors for the development of central centrifugal cicatricial alopecia: a population study</article-title><source>Arch Dermatol</source><volume>147</volume><year>2011</year><fpage>909</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">21482861</pub-id></element-citation></ref><ref id="bb0080"><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Laatsch</surname><given-names>C.N.</given-names></name><name><surname>Durbin-Johnson</surname><given-names>B.P.</given-names></name><name><surname>Rocke</surname><given-names>D.M.</given-names></name><name><surname>Mukwana</surname><given-names>S.</given-names></name><name><surname>Newland</surname><given-names>A.B.</given-names></name><name><surname>Flagler</surname><given-names>M.J.</given-names></name><name><surname>Davis</surname><given-names>M.G.</given-names></name><name><surname>Eigenheer</surname><given-names>R.A.</given-names></name><name><surname>Phinney</surname><given-names>B.S.</given-names></name><name><surname>Rice</surname><given-names>R.H.</given-names></name></person-group><article-title>Human hair shaft proteomic profiling: Individual differences, site specificity and cuticle analysis</article-title><source>PeerJ</source><volume>2</volume><year>2014</year><fpage>e506</fpage><pub-id pub-id-type="pmid">25165623</pub-id></element-citation></ref><ref id="bb0820"><element-citation publication-type="journal" id="rf0820"><person-group person-group-type="author"><name><surname>Ladizinski</surname><given-names>B.</given-names></name><name><surname>Bazakas</surname><given-names>A.</given-names></name><name><surname>Selim</surname><given-names>M.A.</given-names></name><name><surname>Olsen</surname><given-names>E.A.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University</article-title><source>J Am Acad Dermatol</source><volume>68</volume><year>2013</year><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">23375454</pub-id></element-citation></ref><ref id="bb9010"><element-citation publication-type="journal" id="rf9010"><person-group person-group-type="author"><name><surname>La Ruche</surname><given-names>G.</given-names></name><name><surname>Cesarini</surname><given-names>J.</given-names></name></person-group><article-title>Histology and physiology of black skin</article-title><source>Ann Dermatol Venerol</source><volume>119</volume><year>1992</year><fpage>567</fpage><lpage>574</lpage></element-citation></ref><ref id="bb0075"><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W.S.</given-names></name><name><surname>Oh</surname><given-names>T.H.</given-names></name><name><surname>Chun</surname><given-names>S.H.</given-names></name><name><surname>Jeon</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>E.Y.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>W.S.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name></person-group><article-title>Integral lipid in human hair follicle</article-title><source>J Investig Dermatol Symp Proc</source><volume>10</volume><year>2005</year><fpage>234</fpage><lpage>237</lpage></element-citation></ref><ref id="bb0340"><element-citation publication-type="journal" id="rf0340"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J.T.</given-names></name></person-group><article-title>Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid</article-title><source>Dermatol Surg</source><volume>25</volume><year>1999</year><fpage>282</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">10417583</pub-id></element-citation></ref><ref id="bb9005"><element-citation publication-type="journal" id="rf9005"><person-group person-group-type="author"><name><surname>Lindelof</surname><given-names>B.</given-names></name><name><surname>Forslind</surname><given-names>B.</given-names></name><name><surname>Hedblad</surname><given-names>M.</given-names></name></person-group><article-title>Human hair form morphology revealed by light and scanning electron microscopy and computer aided three-dimensional reconstruction</article-title><source>Arch Dermatol</source><volume>124</volume><year>1998</year><fpage>1359</fpage><lpage>1362</lpage></element-citation></ref><ref id="bb0485"><element-citation publication-type="journal" id="rf0485"><person-group person-group-type="author"><name><surname>LoPresti</surname><given-names>P.</given-names></name><name><surname>Papa</surname><given-names>C.M.</given-names></name><name><surname>Kligman</surname><given-names>A.M.</given-names></name></person-group><article-title>Hot comb alopecia</article-title><source>Arch Dermatol</source><volume>98</volume><year>1968</year><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">5673883</pub-id></element-citation></ref><ref id="bb0610"><element-citation publication-type="journal" id="rf0610"><person-group person-group-type="author"><name><surname>Lurie</surname><given-names>R.</given-names></name><name><surname>Hodak</surname><given-names>E.</given-names></name><name><surname>Ginzburg</surname><given-names>A.</given-names></name><name><surname>David</surname><given-names>M.</given-names></name></person-group><article-title>Trichorrhexis nodosa: a manifestation of hypothyroidism</article-title><source>Cutis</source><volume>57</volume><year>1996</year><fpage>358</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">8726720</pub-id></element-citation></ref><ref id="bb0875"><element-citation publication-type="journal" id="rf0875"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>A.</given-names></name><name><surname>Clark</surname><given-names>C.</given-names></name><name><surname>Holmes</surname><given-names>S.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: A review of 60 cases</article-title><source>J Am Acad Dermatol</source><volume>67</volume><year>2012</year><fpage>955</fpage><lpage>961</lpage><pub-id pub-id-type="pmid">22503342</pub-id></element-citation></ref><ref id="bb0345"><element-citation publication-type="journal" id="rf0345"><person-group person-group-type="author"><name><surname>Makino</surname><given-names>E.T.</given-names></name><name><surname>Mehta</surname><given-names>R.C.</given-names></name><name><surname>Garruto</surname><given-names>J.</given-names></name><name><surname>Gotz</surname><given-names>V.</given-names></name><name><surname>Sigler</surname><given-names>M.L.</given-names></name><name><surname>Herndon</surname><given-names>J.H.</given-names></name></person-group><article-title>Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone</article-title><source>J Drugs Dermatol</source><volume>12</volume><year>2013</year><fpage>s21</fpage><lpage>s26</lpage><pub-id pub-id-type="pmid">23545929</pub-id></element-citation></ref><ref id="bb0435"><element-citation publication-type="journal" id="rf0435"><person-group person-group-type="author"><name><surname>Manaloto</surname><given-names>R.M.</given-names></name><name><surname>Alster</surname><given-names>T.</given-names></name></person-group><article-title>Erbium:YAG laser resurfacing for refractory melasma</article-title><source>Dermatol Surg</source><volume>25</volume><year>1999</year><fpage>121</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">10037517</pub-id></element-citation></ref><ref id="bb0585"><element-citation publication-type="journal" id="rf0585"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>A.M.</given-names></name><name><surname>Sugathan</surname><given-names>P.</given-names></name></person-group><article-title>Localised acquired trichorrhexis nodosa of the scalp hair induced by a specific comb and combing habit - a report of three cases</article-title><source>Int J Trichol</source><volume>3</volume><year>2011</year><fpage>34</fpage><lpage>37</lpage></element-citation></ref><ref id="bb0590"><element-citation publication-type="journal" id="rf0590"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez de Lagr&#x000e1;n</surname><given-names>Z.</given-names></name><name><surname>Gonz&#x000e1;lez-Hermosa</surname><given-names>M.R.</given-names></name><name><surname>D&#x000ed;az-P&#x000e9;rez</surname><given-names>J.L.</given-names></name></person-group><article-title>Localized trichorrhexis nodosa</article-title><source>Actas Dermosifiliogr</source><volume>100</volume><year>2009</year><fpage>522</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">19709565</pub-id></element-citation></ref><ref id="bb0500"><element-citation publication-type="journal" id="rf0500"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>A.J.</given-names></name></person-group><article-title>Ethnic hair update: past and present</article-title><source>J Am Acad Dermatol</source><volume>48</volume><year>2003</year><fpage>S127</fpage><lpage>S133</lpage><pub-id pub-id-type="pmid">12789165</pub-id></element-citation></ref><ref id="bb0620"><element-citation publication-type="journal" id="rf0620"><person-group person-group-type="author"><name><surname>Mirmirani</surname><given-names>P.</given-names></name></person-group><article-title>Ceramic flat irons: improper use leading to acquired trichorrhexis nodosa</article-title><source>J Am Acad Dermatol</source><volume>62</volume><year>2010</year><fpage>145</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">20082891</pub-id></element-citation></ref><ref id="bb0545"><element-citation publication-type="journal" id="rf0545"><person-group person-group-type="author"><name><surname>Mirmirani</surname><given-names>P.</given-names></name><name><surname>Khumalo</surname><given-names>N.P.</given-names></name></person-group><article-title>Traction alopecia: how to translate study data for public education&#x02013;closing the KAP gap?</article-title><source>Dermatol Clin</source><volume>32</volume><year>2014</year><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">24680002</pub-id></element-citation></ref><ref id="bb0930"><element-citation publication-type="journal" id="rf0930"><person-group person-group-type="author"><name><surname>Miteva</surname><given-names>M.</given-names></name><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>The follicular triad: a pathological clue to the diagnosis of early frontal fibrosing alopecia</article-title><source>Br J Dermatol</source><volume>166</volume><year>2012</year><fpage>440</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">21787366</pub-id></element-citation></ref><ref id="bb0720"><element-citation publication-type="journal" id="rf0720"><person-group person-group-type="author"><name><surname>Miteva</surname><given-names>M.</given-names></name><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>Dermoscopy guided scalp biopsy in cicatricial alopecia</article-title><source>J Eur Acad Dermatol Venereol</source><volume>27</volume><year>2013</year><fpage>1299</fpage><lpage>1303</lpage><pub-id pub-id-type="pmid">22449222</pub-id></element-citation></ref><ref id="bb0715"><element-citation publication-type="journal" id="rf0715"><person-group person-group-type="author"><name><surname>Miteva</surname><given-names>M.</given-names></name><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>Dermatoscopic features of central centrifugal cicatricial alopecia</article-title><source>J Am Acad Dermatol</source><volume>71</volume><year>2014</year><fpage>443</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">24929886</pub-id></element-citation></ref><ref id="bb0880"><element-citation publication-type="journal" id="rf0880"><person-group person-group-type="author"><name><surname>Miteva</surname><given-names>M.</given-names></name><name><surname>Aber</surname><given-names>C.</given-names></name><name><surname>Torres</surname><given-names>F.</given-names></name><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>Frontal fibrosing alopecia occurring on scalp vitiligo: report of four cases</article-title><source>Br J Dermatol</source><volume>165</volume><year>2011</year><fpage>445</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">21517796</pub-id></element-citation></ref><ref id="bb0810"><element-citation publication-type="journal" id="rf0810"><person-group person-group-type="author"><name><surname>Miteva</surname><given-names>M.</given-names></name><name><surname>Whiting</surname><given-names>D.</given-names></name><name><surname>Harries</surname><given-names>M.</given-names></name><name><surname>Bernardes</surname><given-names>A.</given-names></name><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>Frontal fibrosing alopecia in black patients</article-title><source>Br J Dermatol</source><volume>167</volume><year>2012</year><fpage>208</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">22229387</pub-id></element-citation></ref><ref id="bb0600"><element-citation publication-type="journal" id="rf0600"><person-group person-group-type="author"><name><surname>Miyamoto</surname><given-names>M.</given-names></name><name><surname>Tsuboi</surname><given-names>R.</given-names></name><name><surname>Oh-I</surname><given-names>T.</given-names></name></person-group><article-title>Case of acquired trichorrhexis nodosa: scanning electron microscopic observation</article-title><source>J Dermatol</source><volume>36</volume><year>2009</year><fpage>109</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">19284457</pub-id></element-citation></ref><ref id="bb0840"><element-citation publication-type="journal" id="rf0840"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>L.</given-names></name><name><surname>Doche</surname><given-names>I.</given-names></name></person-group><article-title>Facial papules in frontal fibrosing alopecia: evidence of vellus follicle involvement</article-title><source>Arch Dermatol</source><volume>147</volume><issue>12</issue><year>2011</year><fpage>1424</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">22184764</pub-id></element-citation></ref><ref id="bb0685"><element-citation publication-type="journal" id="rf0685"><person-group person-group-type="author"><name><surname>Montagna</surname><given-names>W.</given-names></name><name><surname>Carlisle</surname><given-names>K.</given-names></name></person-group><article-title>The architecture of black and white facial skin</article-title><source>J Am Acad Dermatol</source><volume>24</volume><year>1991</year><fpage>929</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">1714469</pub-id></element-citation></ref><ref id="bb0765"><element-citation publication-type="journal" id="rf0765"><person-group person-group-type="author"><name><surname>Moreno-Ramirez</surname><given-names>D.</given-names></name><name><surname>Camacho Martinez</surname><given-names>F.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: a survey in 16 patients</article-title><source>J Eur Acad Dermatol Venereol</source><volume>19</volume><year>2005</year><fpage>700</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">16268874</pub-id></element-citation></ref><ref id="bb0240"><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Mouton</surname><given-names>R.W.</given-names></name><name><surname>Jordaan</surname><given-names>H.F.</given-names></name><name><surname>Schneider</surname><given-names>J.W.</given-names></name></person-group><article-title>A new type of minocycline-induced cutaneous hyperpigmentation</article-title><source>Clin Exp Dermatol</source><volume>29</volume><year>2004</year><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">14723711</pub-id></element-citation></ref><ref id="bb0060"><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Muizzuddin</surname><given-names>N.</given-names></name><name><surname>Hellemans</surname><given-names>L.</given-names></name><name><surname>Van Overloop</surname><given-names>L.</given-names></name><name><surname>Corstjens</surname><given-names>H.</given-names></name><name><surname>Declercq</surname><given-names>L.</given-names></name><name><surname>Maes</surname><given-names>D.</given-names></name></person-group><article-title>Structural and functional differences in barrier properties of African American, Caucasian and East Asian skin</article-title><source>J Dermatol Sci</source><volume>59</volume><year>2010</year><fpage>123</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">20654785</pub-id></element-citation></ref><ref id="bb0515"><element-citation publication-type="journal" id="rf0515"><person-group person-group-type="author"><name><surname>Mulinari-Brenner</surname><given-names>F.</given-names></name><name><surname>Bregfeld</surname><given-names>F.</given-names></name></person-group><article-title>Hair loss: an overview</article-title><source>Dermatol Nurs</source><volume>13</volume><year>2001</year><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">11917783</pub-id></element-citation></ref><ref id="bb0365"><element-citation publication-type="journal" id="rf0365"><person-group person-group-type="author"><name><surname>Nanda</surname><given-names>S.</given-names></name><name><surname>Grover</surname><given-names>C.</given-names></name><name><surname>Reddy</surname><given-names>B.S.</given-names></name></person-group><article-title>Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma</article-title><source>Dermatol Surg</source><volume>30</volume><year>2004</year><fpage>385</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">15008866</pub-id></element-citation></ref><ref id="bb0445"><element-citation publication-type="journal" id="rf0445"><person-group person-group-type="author"><name><surname>Neeley</surname><given-names>M.R.</given-names></name><name><surname>Pearce</surname><given-names>F.B.</given-names></name><name><surname>Collawn</surname><given-names>S.S.</given-names></name></person-group><article-title>Successful treatment of malar dermal melasma with a fractional ablative CO<sub>2</sub> laser in a patient with type V skin</article-title><source>J Cosmet Laser Ther</source><volume>12</volume><year>2010</year><fpage>258</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">21142733</pub-id></element-citation></ref><ref id="bb0650"><element-citation publication-type="journal" id="rf0650"><person-group person-group-type="author"><name><surname>Nicholson</surname><given-names>A.G.</given-names></name><name><surname>Harland</surname><given-names>C.C.</given-names></name><name><surname>Bull</surname><given-names>R.H.</given-names></name><name><surname>Mortimer</surname><given-names>P.S.</given-names></name><name><surname>Cook</surname><given-names>M.G.</given-names></name></person-group><article-title>Chemically induced cosmetic alopecia</article-title><source>Br J Dermatol</source><volume>128</volume><year>1993</year><fpage>537</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">8504045</pub-id></element-citation></ref><ref id="bb0675"><element-citation publication-type="journal" id="rf0675"><person-group person-group-type="author"><name><surname>Nnoruka</surname><given-names>E.N.</given-names></name></person-group><article-title>Hair loss: is there a relationship with hair care practices in Nigeria?</article-title><source>Int J Dermatol</source><volume>44</volume><issue>S1</issue><year>2005</year><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16187950</pub-id></element-citation></ref><ref id="bb0790"><element-citation publication-type="journal" id="rf0790"><person-group person-group-type="author"><name><surname>Nusbaum</surname><given-names>B.P.</given-names></name><name><surname>Nusbaum</surname><given-names>A.G.</given-names></name></person-group><article-title>Frontal fibrosing alopecia in a man: results of follicular unit test grafting</article-title><source>Dermatol Surg</source><volume>36</volume><year>2010</year><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">20482728</pub-id></element-citation></ref><ref id="bb0605"><element-citation publication-type="journal" id="rf0605"><person-group person-group-type="author"><name><surname>Ogunbiyi</surname><given-names>A.</given-names></name><name><surname>Ogun</surname><given-names>O.</given-names></name><name><surname>Enechukwu</surname><given-names>N.</given-names></name></person-group><article-title>Recurrent hair loss resulting from generalized proximal trichorrhexis nodosa in a nigerian female</article-title><source>Int J Trichol</source><volume>6</volume><year>2014</year><fpage>83</fpage><lpage>84</lpage></element-citation></ref><ref id="bb0465"><element-citation publication-type="journal" id="rf0465"><person-group person-group-type="author"><name><surname>Ogunleye</surname><given-names>T.A.</given-names></name><name><surname>McMichael</surname><given-names>A.</given-names></name><name><surname>Olsen</surname><given-names>E.A.</given-names></name></person-group><article-title>Central centrifugal cicatricial alopecia: what has been achieved, current clues for future research</article-title><source>Dermatol Clin</source><volume>32</volume><year>2014</year><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">24680004</pub-id></element-citation></ref><ref id="bb0655"><element-citation publication-type="journal" id="rf0655"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>E.A.</given-names></name><name><surname>Bergfeld</surname><given-names>W.F.</given-names></name><name><surname>Cotsarelis</surname><given-names>G.</given-names></name><name><surname>Price</surname><given-names>V.H.</given-names></name><name><surname>Shapiro</surname><given-names>J.</given-names></name><name><surname>Sinclair</surname><given-names>R.</given-names></name><name><surname>Solomon</surname><given-names>A.</given-names></name><name><surname>Sperling</surname><given-names>L.</given-names></name><name><surname>Stenn</surname><given-names>K.</given-names></name><name><surname>Whiting</surname><given-names>D.A.</given-names></name><name><surname>Bernado</surname><given-names>O.</given-names></name><name><surname>Bettencourt</surname><given-names>M.</given-names></name><name><surname>Bolduc</surname><given-names>C.</given-names></name><name><surname>Callender</surname><given-names>V.</given-names></name><name><surname>Elston</surname><given-names>D.</given-names></name><name><surname>Hickman</surname><given-names>J.</given-names></name><name><surname>Ioffreda</surname><given-names>M.</given-names></name><name><surname>King</surname><given-names>L.</given-names></name><name><surname>Linzon</surname><given-names>C.</given-names></name><name><surname>McMichael</surname><given-names>A.</given-names></name><name><surname>Miller</surname><given-names>J.</given-names></name><name><surname>Mulinari</surname><given-names>F.</given-names></name><name><surname>Trancik</surname><given-names>R.</given-names></name><collab>Members of the Workshop on Cicatricial Alopecia</collab></person-group><article-title>Summary of North American Hair Research Society (NAHRS)-sponsored Work- Shop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001</article-title><source>J Am Acad Dermatol</source><volume>48</volume><issue>1</issue><year>2003</year><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">12522378</pub-id></element-citation></ref><ref id="bb0730"><element-citation publication-type="journal" id="rf0730"><person-group person-group-type="author"><name><surname>Olsen</surname><given-names>E.A.</given-names></name><name><surname>Callender</surname><given-names>V.D.</given-names></name><name><surname>McMichael</surname><given-names>A.</given-names></name><name><surname>Sperling</surname><given-names>L.</given-names></name><name><surname>Anstrom</surname><given-names>K.J.</given-names></name><name><surname>Shapiro</surname><given-names>J.</given-names></name><name><surname>Roberts</surname><given-names>J.</given-names></name><name><surname>Durden</surname><given-names>F.</given-names></name><name><surname>Whiting</surname><given-names>D.</given-names></name><name><surname>Bergfeld</surname><given-names>W.</given-names></name></person-group><article-title>Central hair loss in African American women: incidence and potential risk factors</article-title><source>J Am Acad Dermatol</source><volume>64</volume><year>2011</year><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">21075478</pub-id></element-citation></ref><ref id="bb0580"><element-citation publication-type="journal" id="rf0580"><person-group person-group-type="author"><name><surname>Ozcelik</surname><given-names>D.</given-names></name></person-group><article-title>Extensive traction alopecia attributable to ponytail hairstyle and its treatment with hair transplantation</article-title><source>Aesthet Plast Surg</source><volume>29</volume><year>2005</year><fpage>325</fpage><lpage>327</lpage></element-citation></ref><ref id="bb0450"><element-citation publication-type="journal" id="rf0450"><person-group person-group-type="author"><name><surname>Passeron</surname><given-names>T.</given-names></name><name><surname>Fontas</surname><given-names>E.</given-names></name><name><surname>Kang</surname><given-names>H.Y.</given-names></name><name><surname>Bahadoran</surname><given-names>P.</given-names></name><name><surname>Lacour</surname><given-names>J.P.</given-names></name><name><surname>Ortonne</surname><given-names>J.P.</given-names></name></person-group><article-title>Melasma treatment with pulsed-dye laser and triple combination cream: A prospective, randomized, single-blind, split-face study</article-title><source>Arch Dermatol</source><volume>147</volume><year>2011</year><fpage>1106</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">21931054</pub-id></element-citation></ref><ref id="bb0115"><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>A.C.</given-names></name><name><surname>Cheng</surname><given-names>C.E.</given-names></name><name><surname>Hillebrand</surname><given-names>G.G.</given-names></name><name><surname>Miyamoto</surname><given-names>K.</given-names></name><name><surname>Kimball</surname><given-names>A.B.</given-names></name></person-group><article-title>Comparison of the epidemiology of acne vulgaris among Caucasians, Asian, Continental Indian and African American women</article-title><source>J Eur Acad Dermatol Venereol</source><volume>25</volume><year>2011</year><fpage>1054</fpage><lpage>1060</lpage><pub-id pub-id-type="pmid">21108671</pub-id></element-citation></ref><ref id="bb0215"><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Piette</surname><given-names>W.W.</given-names></name><name><surname>Taylor</surname><given-names>S.</given-names></name><name><surname>Pariser</surname><given-names>D.</given-names></name><name><surname>Jarratt</surname><given-names>M.</given-names></name><name><surname>Sheth</surname><given-names>P.</given-names></name><name><surname>Wilson</surname><given-names>D.</given-names></name></person-group><article-title>Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris</article-title><source>Arch Dermatol</source><volume>144</volume><year>2008</year><fpage>1564</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">19075138</pub-id></element-citation></ref><ref id="bb0845"><element-citation publication-type="journal" id="rf0845"><person-group person-group-type="author"><name><surname>Pirmez</surname><given-names>R.</given-names></name><name><surname>Donati</surname><given-names>A.</given-names></name><name><surname>Valente</surname><given-names>N.S.</given-names></name><name><surname>Sodr&#x000e9;</surname><given-names>C.T.</given-names></name><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>Glabellar red dots in frontal fibrosing alopecia: a further clinical sign of vellus follicle involvement</article-title><source>Br J Dermatol</source><volume>170</volume><year>2014</year><fpage>745</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">24116835</pub-id></element-citation></ref><ref id="bb0460"><element-citation publication-type="journal" id="rf0460"><person-group person-group-type="author"><name><surname>Polder</surname><given-names>K.D.</given-names></name><name><surname>Bruce</surname><given-names>S.</given-names></name></person-group><article-title>Treatment of melasma using a novel 1,927-nm fractional thulium fiber laser: a pilot study</article-title><source>Dermatol Surg</source><volume>38</volume><year>2012</year><fpage>199</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">22093448</pub-id></element-citation></ref><ref id="bb0630"><element-citation publication-type="journal" id="rf0630"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>C.R.</given-names></name><name><surname>Quinn</surname><given-names>T.M.</given-names></name><name><surname>Kelly</surname><given-names>A.P.</given-names></name></person-group><article-title>Hair care practices in African American women</article-title><source>Cutis</source><volume>72</volume><year>2003</year><fpage>280</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">14604079</pub-id></element-citation></ref><ref id="bb0935"><element-citation publication-type="journal" id="rf0935"><person-group person-group-type="author"><name><surname>Racz</surname><given-names>E.</given-names></name><name><surname>Gho</surname><given-names>C.</given-names></name><name><surname>Moorman</surname><given-names>P.W.</given-names></name><name><surname>Noordhoek Hegt</surname><given-names>V.</given-names></name><name><surname>Neumann</surname><given-names>H.A.</given-names></name></person-group><article-title>Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review</article-title><source>J Eur Acad Dermatol Venereol</source><volume>27</volume><year>2013</year><fpage>1461</fpage><lpage>1470</lpage><pub-id pub-id-type="pmid">23531029</pub-id></element-citation></ref><ref id="bb0805"><element-citation publication-type="journal" id="rf0805"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>P.</given-names></name><name><surname>Mendese</surname><given-names>G.</given-names></name><name><surname>Goldberg</surname><given-names>L.J.</given-names></name></person-group><article-title>Scarring alopecia of the sideburns: a unique presentation of frontal fibrosing alopecia in men</article-title><source>Arch Dermatol</source><volume>148</volume><year>2012</year><fpage>1095</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">22986881</pub-id></element-citation></ref><ref id="bb0300"><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name><surname>Rivas</surname><given-names>S.</given-names></name><name><surname>Pandya</surname><given-names>A.</given-names></name></person-group><article-title>Treatment of melasma with topical agents, peels and lasers: An evidence-based review</article-title><source>Am J Clin Dermatol</source><volume>14</volume><year>2013</year><fpage>359</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">23881551</pub-id></element-citation></ref><ref id="bb0525"><element-citation publication-type="journal" id="rf0525"><person-group person-group-type="author"><name><surname>Rollins</surname><given-names>T.G.</given-names></name></person-group><article-title>Traction folliculitis with hair casts and alopecia</article-title><source>Am J Dis Child</source><volume>101</volume><year>1961</year><fpage>639</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">13742951</pub-id></element-citation></ref><ref id="bb0595"><element-citation publication-type="journal" id="rf0595"><person-group person-group-type="author"><name><surname>Rudnicka</surname><given-names>L.</given-names></name><name><surname>Rakowska</surname><given-names>A.</given-names></name><name><surname>Kerzeja</surname><given-names>M.</given-names></name><name><surname>Olszewska</surname><given-names>M.</given-names></name></person-group><article-title>Hair shafts in trichoscopy: clues for diagnosis of hair and scalp diseases</article-title><source>Dermatol Clin</source><volume>31</volume><year>2013</year><fpage>695</fpage><lpage>708</lpage><pub-id pub-id-type="pmid">24075554</pub-id></element-citation></ref><ref id="bb0640"><element-citation publication-type="journal" id="rf0640"><person-group person-group-type="author"><name><surname>Ruetsch</surname><given-names>S.B.</given-names></name><name><surname>Kamath</surname><given-names>Y.K.</given-names></name></person-group><article-title>Effects of thermal treatments with a curling iron on hair fiber</article-title><source>J Cosmet Sci</source><volume>55</volume><year>2004</year><fpage>13</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">15037918</pub-id></element-citation></ref><ref id="bb0405"><element-citation publication-type="journal" id="rf0405"><person-group person-group-type="author"><name><surname>Rusciani</surname><given-names>A.</given-names></name><name><surname>Motta</surname><given-names>A.</given-names></name><name><surname>Rusciani</surname><given-names>L.</given-names></name><name><surname>Alfano</surname><given-names>C.</given-names></name></person-group><article-title>Q-switched alexandrite laser-assisted treatment of melasma: 2-year follow-up monitoring</article-title><source>J Drugs Dermatol</source><volume>4</volume><year>2005</year><fpage>770</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">16302566</pub-id></element-citation></ref><ref id="bb0360"><element-citation publication-type="journal" id="rf0360"><person-group person-group-type="author"><name><surname>Salam</surname><given-names>A.</given-names></name><name><surname>Dadzie</surname><given-names>O.E.</given-names></name><name><surname>Galadari</surname><given-names>H.</given-names></name></person-group><article-title>Chemical peeling in ethnic skin: an update</article-title><source>Br J Dermatol</source><volume>169</volume><issue>S3</issue><year>2013</year><fpage>82</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">24098904</pub-id></element-citation></ref><ref id="bb0560"><element-citation publication-type="journal" id="rf0560"><person-group person-group-type="author"><name><surname>Samrao</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Zedek</surname><given-names>D.</given-names></name><name><surname>Price</surname><given-names>V.H.</given-names></name></person-group><article-title>Traction alopecia in a ballerina: clincopathologic features</article-title><source>Arch Dermatol</source><volume>146</volume><year>2010</year><fpage>930</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">20713841</pub-id></element-citation></ref><ref id="bb0830"><element-citation publication-type="journal" id="rf0830"><person-group person-group-type="author"><name><surname>Samrao</surname><given-names>A.</given-names></name><name><surname>Chew</surname><given-names>A.L.</given-names></name><name><surname>Price</surname><given-names>V.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: a clinical review of 36 patients</article-title><source>Br J Dermatol</source><volume>163</volume><year>2010</year><fpage>1296</fpage><lpage>1300</lpage><pub-id pub-id-type="pmid">20698851</pub-id></element-citation></ref><ref id="bb0520"><element-citation publication-type="journal" id="rf0520"><person-group person-group-type="author"><name><surname>Samrao</surname><given-names>A.</given-names></name><name><surname>Price</surname><given-names>V.H.</given-names></name><name><surname>Zedek</surname><given-names>D.</given-names></name><name><surname>Mirmirani</surname><given-names>P.</given-names></name></person-group><article-title>The "Fringe Sign" - A useful clinical finding in traction alopecia of the marginal hair line</article-title><source>Dermatol Online J</source><volume>17</volume><year>2011</year><fpage>1</fpage></element-citation></ref><ref id="bb0375"><element-citation publication-type="journal" id="rf0375"><person-group person-group-type="author"><name><surname>Sardana</surname><given-names>K.</given-names></name><name><surname>Garg</surname><given-names>V.K.</given-names></name></person-group><article-title>Lasers are not effective for melasma in darkly pigmented skin</article-title><source>J Cutan Aesthet Surg</source><volume>7</volume><year>2014</year><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">24761105</pub-id></element-citation></ref><ref id="bb0290"><element-citation publication-type="journal" id="rf0290"><person-group person-group-type="author"><name><surname>Sardesai</surname><given-names>V.R.</given-names></name><name><surname>Kolte</surname><given-names>J.N.</given-names></name><name><surname>Srinivas</surname><given-names>B.N.</given-names></name></person-group><article-title>A clinical study of melasma and a comparison of the therapeutic effect of certain currently available topical modalities for its treatment</article-title><source>Indian J Dermatol</source><volume>58</volume><year>2013</year><fpage>239</fpage></element-citation></ref><ref id="bb0355"><element-citation publication-type="journal" id="rf0355"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>R.</given-names></name><name><surname>Bansal</surname><given-names>S.</given-names></name><name><surname>Garg</surname><given-names>V.K.</given-names></name></person-group><article-title>Chemical peels for melasma in dark-skinned patients</article-title><source>J Cutan Aesthet Surg</source><volume>5</volume><year>2012</year><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">23378706</pub-id></element-citation></ref><ref id="bb0150"><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Savory</surname><given-names>S.A.</given-names></name><name><surname>Agim</surname><given-names>N.G.</given-names></name><name><surname>Mao</surname><given-names>R.</given-names></name><name><surname>Peter</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Maldonado</surname><given-names>G.</given-names></name><name><surname>Dietert</surname><given-names>J.B.</given-names></name><name><surname>Lieu</surname><given-names>T.J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Pretzlaff</surname><given-names>K.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name><name><surname>Vandergriff</surname><given-names>T.</given-names></name><name><surname>Lopez</surname><given-names>I.E.</given-names></name><name><surname>Litzner</surname><given-names>B.R.</given-names></name><name><surname>Hynan</surname><given-names>L.S.</given-names></name><name><surname>Arellano-Mendoza</surname><given-names>M.I.</given-names></name><name><surname>Bergstresser</surname><given-names>P.R.</given-names></name><name><surname>Pandya</surname><given-names>A.G.</given-names></name></person-group><article-title>Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris</article-title><source>J Am Acad Dermatol</source><volume>70</volume><year>2014</year><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">24176524</pub-id></element-citation></ref><ref id="bb0270"><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name><surname>Semchyshyn</surname><given-names>N.</given-names></name><name><surname>Prodanovic</surname><given-names>E.</given-names></name><name><surname>Varade</surname><given-names>R.</given-names></name></person-group><article-title>Treating acne scars in patients with Fitzpatrick skin types IV to VI using the 1450-nm diode laser</article-title><source>Cutis</source><volume>92</volume><year>2013</year><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">23961527</pub-id></element-citation></ref><ref id="bb0165"><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>S.K.</given-names></name><name><surname>Alexis</surname><given-names>A.F.</given-names></name></person-group><article-title>Acne in skin of color: practical approaches to treatment</article-title><source>J Dermatolog Treat</source><volume>21</volume><year>2010</year><fpage>206</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">20132053</pub-id></element-citation></ref><ref id="bb0285"><element-citation publication-type="journal" id="rf0285"><person-group person-group-type="author"><name><surname>Sheth</surname><given-names>V.M.</given-names></name><name><surname>Pandya</surname><given-names>A.G.</given-names></name></person-group><article-title>Melasma: a comprehensive update: part I</article-title><source>J Am Acad Dermatol</source><volume>65</volume><year>2011</year><fpage>689</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">21920241</pub-id></element-citation></ref><ref id="bb0305"><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name><surname>Sheth</surname><given-names>V.M.</given-names></name><name><surname>Pandya</surname><given-names>A.G.</given-names></name></person-group><article-title>Melasma: a comprehensive update: part II</article-title><source>J Am Acad Dermatol</source><volume>65</volume><year>2011</year><fpage>699</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">21920242</pub-id></element-citation></ref><ref id="bb0420"><element-citation publication-type="journal" id="rf0420"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>J.H.</given-names></name><name><surname>Park</surname><given-names>Y.L.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Choi</surname><given-names>W.B.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name></person-group><article-title>Treatment of melasma by low-fluence 1064 nm Q-switched Nd:YAG laser</article-title><source>J Dermatolog Treat</source><volume>25</volume><year>2014</year><fpage>212</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">23030603</pub-id></element-citation></ref><ref id="bb0245"><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Soung</surname><given-names>J.</given-names></name><name><surname>Cohen</surname><given-names>J.</given-names></name><name><surname>Phelps</surname><given-names>R.</given-names></name><name><surname>Cohen</surname><given-names>S.</given-names></name></person-group><article-title>Case reports: minocycline-induced hyperpigmentation resolves during oral isotretinoin therapy</article-title><source>J Drugs Dermatol</source><volume>6</volume><year>2007</year><fpage>1232</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">18189065</pub-id></element-citation></ref><ref id="bb0645"><element-citation publication-type="journal" id="rf0645"><person-group person-group-type="author"><name><surname>Sperling</surname><given-names>L.C.</given-names></name><name><surname>Sau</surname><given-names>P.</given-names></name></person-group><article-title>The follicular degeneration syndrome in black patients: &#x02018;hot comb alopecia&#x02019; revisited and revised</article-title><source>Arch Dermatol</source><volume>128</volume><year>1992</year><fpage>68</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">1739290</pub-id></element-citation></ref><ref id="bb0795"><element-citation publication-type="journal" id="rf0795"><person-group person-group-type="author"><name><surname>Stockmeier</surname><given-names>M.</given-names></name><name><surname>Kunte</surname><given-names>C.</given-names></name><name><surname>Sander</surname><given-names>C.A.</given-names></name><name><surname>Wolff</surname><given-names>H.</given-names></name></person-group><article-title>Kossard frontal fibrosing alopecia in a man</article-title><source>Hautarzt</source><volume>53</volume><year>2002</year><fpage>409</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">12132298</pub-id></element-citation></ref><ref id="bb0735"><element-citation publication-type="journal" id="rf0735"><person-group person-group-type="author"><name><surname>Summers</surname><given-names>P.</given-names></name><name><surname>Kyei</surname><given-names>A.</given-names></name><name><surname>Bergfeld</surname><given-names>W.</given-names></name></person-group><article-title>Central centrifugal cicatricial alopecia - an approach to diagnosis and management</article-title><source>Int J Dermatol</source><volume>50</volume><year>2011</year><fpage>1457</fpage><lpage>1464</lpage><pub-id pub-id-type="pmid">22097988</pub-id></element-citation></ref><ref id="bb0490"><element-citation publication-type="journal" id="rf0490"><person-group person-group-type="author"><name><surname>Swee</surname><given-names>W.</given-names></name><name><surname>Klontz</surname><given-names>K.C.</given-names></name><name><surname>Lambert</surname><given-names>L.A.</given-names></name></person-group><article-title>A nationwide outbreak of alopecia associated with the use of a hair-relaxing formulation</article-title><source>Arch Dermatol</source><volume>136</volume><year>2000</year><fpage>1104</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">10987865</pub-id></element-citation></ref><ref id="bb0825"><element-citation publication-type="journal" id="rf0825"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>K.T.</given-names></name><name><surname>Messenger</surname><given-names>A.G.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: clinical presentations and prognosis</article-title><source>Br J Dermatol</source><volume>160</volume><year>2009</year><fpage>75</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">18811690</pub-id></element-citation></ref><ref id="bb0910"><element-citation publication-type="journal" id="rf0910"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>E.</given-names></name><name><surname>Martinka</surname><given-names>M.</given-names></name><name><surname>Ball</surname><given-names>N.</given-names></name><name><surname>Shapiro</surname><given-names>J.</given-names></name></person-group><article-title>Primary cicatricial alopecias: clinicopathology of 112 cases</article-title><source>J Am Acad Dermatol</source><volume>50</volume><year>2004</year><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">14699361</pub-id></element-citation></ref><ref id="bb0230"><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J.</given-names></name><name><surname>Humphrey</surname><given-names>S.</given-names></name><name><surname>Vender</surname><given-names>R.</given-names></name><name><surname>Barankin</surname><given-names>B.</given-names></name><name><surname>Gooderham</surname><given-names>M.</given-names></name><name><surname>Kerrouche</surname><given-names>N.</given-names></name><name><surname>Audibert</surname><given-names>F.</given-names></name><name><surname>Lynde</surname><given-names>C.</given-names></name><collab>POWER study group</collab></person-group><article-title>A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin</article-title><source>Br J Dermatol</source><volume>171</volume><year>2014</year><fpage>1508</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">24934963</pub-id></element-citation></ref><ref id="bb0125"><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Tanghetti</surname><given-names>E.A.</given-names></name><name><surname>Kawata</surname><given-names>A.K.</given-names></name><name><surname>Daniels</surname><given-names>S.R.</given-names></name><name><surname>Yeomans</surname><given-names>K.</given-names></name><name><surname>Burk</surname><given-names>C.T.</given-names></name><name><surname>Callender</surname><given-names>V.D.</given-names></name></person-group><article-title>Understanding the burden of adult female acne</article-title><source>J Clin Aesthet Dermatol</source><volume>7</volume><year>2014</year><fpage>22</fpage><lpage>30</lpage></element-citation></ref><ref id="bb0020"><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>S.C.</given-names></name></person-group><article-title>Skin of color: Biology, structure, function, and implications for dermatologic disease</article-title><source>J Am Acad Dermatol</source><volume>46</volume><year>2002</year><fpage>S41</fpage><lpage>S62</lpage><pub-id pub-id-type="pmid">11807469</pub-id></element-citation></ref><ref id="bb0010"><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>S.C.</given-names></name></person-group><article-title>Epidemiology of skin diseases in people of color</article-title><source>Cutis</source><volume>71</volume><year>2003</year><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">12729089</pub-id></element-citation></ref><ref id="bb0175"><element-citation publication-type="book" id="rf0175"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>S.</given-names></name><name><surname>Summers</surname><given-names>P.</given-names></name></person-group><chapter-title>Acne</chapter-title><person-group person-group-type="editor"><name><surname>Kelly</surname><given-names>A.P.</given-names></name><name><surname>Taylor</surname><given-names>S.C.</given-names></name></person-group><source>Dermatology for skin of color</source><year>2009</year><publisher-name>McGraw-Hill Companies</publisher-name><publisher-loc>New York, NY</publisher-loc><fpage>269</fpage><lpage>274</lpage></element-citation></ref><ref id="bb0310"><element-citation publication-type="journal" id="rf0310"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>S.C.</given-names></name><name><surname>Torok</surname><given-names>H.</given-names></name><name><surname>Jones</surname><given-names>T.</given-names></name><name><surname>Lowe</surname><given-names>N.</given-names></name><name><surname>Rich</surname><given-names>P.</given-names></name><name><surname>Tschen</surname><given-names>E.</given-names></name></person-group><article-title>Efficacy and safety of a new triple-combination agent for the treatment of facial melasma</article-title><source>Cutis</source><volume>72</volume><year>2003</year><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">12889718</pub-id></element-citation></ref><ref id="bb0170"><element-citation publication-type="book" id="rf0170"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>S.</given-names></name><name><surname>Badreshia-Bansal</surname><given-names>S.</given-names></name><name><surname>Callender</surname><given-names>V.</given-names></name><name><surname>Gathers</surname><given-names>R.</given-names></name></person-group><chapter-title>Treatments for Skin of Color</chapter-title><year>2011</year><publisher-name>Saunders</publisher-name><publisher-loc>Edinburgh</publisher-loc></element-citation></ref><ref id="bb0180"><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Tirado-Sanchez</surname><given-names>A.</given-names></name><name><surname>Espindola</surname><given-names>Y.S.</given-names></name><name><surname>Ponce-Olivera</surname><given-names>R.M.</given-names></name><name><surname>Bonifaz</surname><given-names>A.</given-names></name></person-group><article-title>Efficacy and safety of adapalene gel 0.1% and 0.3% and tretinoin gel 0.05% for acne vulgaris: results of a single-center, randomized, double-blinded, placebo-controlled clinical trial on Mexican patients (skin type III-IV)</article-title><source>J Cosmet Dermatol</source><volume>12</volume><year>2013</year><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">23725303</pub-id></element-citation></ref><ref id="bb0870"><element-citation publication-type="journal" id="rf0870"><person-group person-group-type="author"><name><surname>Toledo-Pastrana</surname><given-names>T.</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>M.J.</given-names></name><name><surname>Camacho Mart&#x000ed;nez</surname><given-names>F.M.</given-names></name></person-group><article-title>Perifollicular erythema as a trichoscopy sign of progression in frontal fibrosing alopecia</article-title><source>Int J Trichol</source><volume>5</volume><year>2013</year><fpage>151</fpage><lpage>153</lpage></element-citation></ref><ref id="bb0315"><element-citation publication-type="journal" id="rf0315"><person-group person-group-type="author"><name><surname>Torok</surname><given-names>H.M.</given-names></name></person-group><article-title>A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream</article-title><source>Am J Clin Dermatol</source><volume>7</volume><year>2006</year><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">16901182</pub-id></element-citation></ref><ref id="bb0320"><element-citation publication-type="journal" id="rf0320"><person-group person-group-type="author"><name><surname>Torok</surname><given-names>H.M.</given-names></name><name><surname>Jones</surname><given-names>T.</given-names></name><name><surname>Rich</surname><given-names>P.</given-names></name></person-group><article-title>Hydroquinone, 4%, tretinoin, 0.05%, fluocinolone acetonide, 0.01%: A safe and efficacious 12-month treatment for Melasma</article-title><source>Cutis</source><volume>75</volume><year>2005</year><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15732437</pub-id></element-citation></ref><ref id="bb0335"><element-citation publication-type="journal" id="rf0335"><person-group person-group-type="author"><name><surname>Torok</surname><given-names>H.</given-names></name><name><surname>Taylor</surname><given-names>S.</given-names></name><name><surname>Baumann</surname><given-names>L.</given-names></name><name><surname>Jones</surname><given-names>T.</given-names></name><name><surname>Wieder</surname><given-names>J.</given-names></name><name><surname>Lowe</surname><given-names>N.</given-names></name><name><surname>Jarret</surname><given-names>M.</given-names></name><name><surname>Rich</surname><given-names>P.</given-names></name><name><surname>Pariser</surname><given-names>D.</given-names></name><name><surname>Tschen</surname><given-names>E.</given-names></name><name><surname>Martin</surname><given-names>D.</given-names></name><name><surname>Menter</surname><given-names>A.</given-names></name><name><surname>Weiss</surname><given-names>J.</given-names></name></person-group><article-title>A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads</article-title><source>J Drugs Dermatol</source><volume>4</volume><year>2005</year><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">16167418</pub-id></element-citation></ref><ref id="bb0860"><element-citation publication-type="journal" id="rf0860"><person-group person-group-type="author"><name><surname>Tosti</surname><given-names>A.</given-names></name></person-group><article-title>Lonely hair sign: not specific for frontal fibrosing alopecia-reply</article-title><source>Arch Dermatol</source><volume>148</volume><year>2012</year><fpage>1208</fpage><lpage>1209</lpage></element-citation></ref><ref id="bb0535"><element-citation publication-type="journal" id="rf0535"><person-group person-group-type="author"><name><surname>Tosti</surname><given-names>A.</given-names></name><name><surname>Miteva</surname><given-names>M.</given-names></name><name><surname>Torres</surname><given-names>F.</given-names></name><name><surname>Vincenzi</surname><given-names>C.</given-names></name><name><surname>Romanelli</surname><given-names>P.</given-names></name></person-group><article-title>Hair casts are a dermoscopic clue for the diagnosis of traction alopecia</article-title><source>Br J Dermatol</source><volume>163</volume><year>2010</year><fpage>1353</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">20716211</pub-id></element-citation></ref><ref id="bb0850"><element-citation publication-type="journal" id="rf0850"><person-group person-group-type="author"><name><surname>Tosti</surname><given-names>A.</given-names></name><name><surname>Miteva</surname><given-names>M.</given-names></name><name><surname>Torres</surname><given-names>F.</given-names></name></person-group><article-title>Lonely hair: a clue to the diagnosis of frontal fibrosing alopecia</article-title><source>Arch Dermatol</source><volume>147</volume><year>2011</year><fpage>1240</fpage><pub-id pub-id-type="pmid">22006155</pub-id></element-citation></ref><ref id="bb0555"><element-citation publication-type="journal" id="rf0555"><person-group person-group-type="author"><name><surname>Trueb</surname><given-names>R.M.</given-names></name></person-group><article-title>"Chignon alopecia": a distinctive type of nonmarginal traction alopecia</article-title><source>Cutis</source><volume>55</volume><year>1995</year><fpage>178</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">7634850</pub-id></element-citation></ref><ref id="bb0225"><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Ullah</surname><given-names>G.</given-names></name><name><surname>Noor</surname><given-names>S.M.</given-names></name><name><surname>Bhatti</surname><given-names>Z.</given-names></name><name><surname>Ahmad</surname><given-names>M.</given-names></name><name><surname>Bangash</surname><given-names>A.R.</given-names></name></person-group><article-title>Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris</article-title><source>Br J Dermatol</source><volume>171</volume><year>2014</year><fpage>1508</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">24934963</pub-id></element-citation></ref><ref id="bb0005"><element-citation publication-type="other" id="rf0005"><person-group person-group-type="author"><name><surname>US Census Bureau</surname></name></person-group><article-title>Overview of Race and Hispanic Origin</article-title><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf" id="ir0010">http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf</ext-link><year>2010</year><comment>[Accessed October 13, 2014]</comment></element-citation></ref><ref id="bb0780"><element-citation publication-type="journal" id="rf0780"><person-group person-group-type="author"><name><surname>Va&#x000f1;&#x000f3;-Galv&#x000e1;n</surname><given-names>S.</given-names></name><name><surname>Molina-Ruiz</surname><given-names>A.M.</given-names></name><name><surname>Serrano-Falc&#x000f3;n</surname><given-names>C.</given-names></name><name><surname>Arias-Santiago</surname><given-names>S.</given-names></name><name><surname>Rodrigues-Barata</surname><given-names>A.R.</given-names></name><name><surname>Garnacho-Saucedo</surname><given-names>G.</given-names></name><name><surname>Martorell-Calatayud</surname><given-names>A.</given-names></name><name><surname>Fern&#x000e1;ndez-Crehuet</surname><given-names>P.</given-names></name><name><surname>Grimalt</surname><given-names>R.</given-names></name><name><surname>Aranegui</surname><given-names>B.</given-names></name><name><surname>Grillo</surname><given-names>E.</given-names></name><name><surname>Diaz-Ley</surname><given-names>B.</given-names></name><name><surname>Salido</surname><given-names>R.</given-names></name><name><surname>P&#x000e9;rez-Gala</surname><given-names>S.</given-names></name><name><surname>Serrano</surname><given-names>S.</given-names></name><name><surname>Moreno</surname><given-names>J.C.</given-names></name><name><surname>Ja&#x000e9;n</surname><given-names>P.</given-names></name><name><surname>Camacho</surname><given-names>F.M.</given-names></name></person-group><article-title>Frontal fibrosing alopecia: a multicenter review of 355 patients</article-title><source>J Am Acad Dermatol</source><volume>70</volume><year>2014</year><fpage>670</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">24508293</pub-id></element-citation></ref><ref id="bb0025"><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Wakamatsu</surname><given-names>K.</given-names></name><name><surname>Kavanagh</surname><given-names>R.</given-names></name><name><surname>Kadekaro</surname><given-names>A.L.</given-names></name><name><surname>Terzieva</surname><given-names>S.</given-names></name><name><surname>Sturm</surname><given-names>R.A.</given-names></name><name><surname>Leachman</surname><given-names>S.</given-names></name><name><surname>Abdel-Malek</surname><given-names>Z.</given-names></name><name><surname>Ito</surname><given-names>S.</given-names></name></person-group><article-title>Diversity of pigmentation in cultured human melanocytes is due to differences in the type as well as quantity of melanin</article-title><source>Pigment Cell Res</source><volume>19</volume><year>2006</year><fpage>154</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">16524431</pub-id></element-citation></ref><ref id="bb0385"><element-citation publication-type="journal" id="rf0385"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.C.</given-names></name><name><surname>Hui</surname><given-names>C.Y.</given-names></name><name><surname>Sue</surname><given-names>Y.M.</given-names></name><name><surname>Wong</surname><given-names>W.R.</given-names></name><name><surname>Hong</surname><given-names>H.S.</given-names></name></person-group><article-title>Intense pulsed light for the treatment of refractory melasma in Asian persons</article-title><source>Dermatol Surg</source><volume>30</volume><year>2004</year><fpage>1196</fpage><lpage>1200</lpage><pub-id pub-id-type="pmid">15355358</pub-id></element-citation></ref><ref id="bb0135"><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Warrier</surname><given-names>A.G.</given-names></name><name><surname>Kligman</surname><given-names>A.M.</given-names></name><name><surname>Harper</surname><given-names>R.A.</given-names></name><name><surname>Bowman</surname><given-names>J.</given-names></name><name><surname>Wickett</surname><given-names>R.R.</given-names></name></person-group><article-title>A comparison of black and white skin using non-invasive methods</article-title><source>J Soc Cosmet Chem</source><volume>47</volume><year>1996</year><fpage>229</fpage><lpage>240</lpage></element-citation></ref><ref id="bb0410"><element-citation publication-type="journal" id="rf0410"><person-group person-group-type="author"><name><surname>Wattanakrai</surname><given-names>P.</given-names></name><name><surname>Mornchan</surname><given-names>R.</given-names></name><name><surname>Eimpunth</surname><given-names>S.</given-names></name></person-group><article-title>Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians</article-title><source>Dermatol Surg</source><volume>36</volume><year>2010</year><fpage>76</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">20298254</pub-id></element-citation></ref><ref id="bb0390"><element-citation publication-type="journal" id="rf0390"><person-group person-group-type="author"><name><surname>Wattanakrai</surname><given-names>P.</given-names></name><name><surname>Mornchan</surname><given-names>R.</given-names></name><name><surname>Eimputh</surname><given-names>S.</given-names></name></person-group><article-title>Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians</article-title><source>Dermatol Surg</source><volume>36</volume><year>2012</year><fpage>76</fpage><lpage>87</lpage></element-citation></ref><ref id="bb9000"><element-citation publication-type="journal" id="rf9000"><person-group person-group-type="author"><name><surname>Weigand</surname><given-names>D.</given-names></name><name><surname>Haygood</surname><given-names>C.</given-names></name><name><surname>Gaylor</surname><given-names>J.</given-names></name></person-group><article-title>Cell layers and density of Negro and Caucasian stratum corneum</article-title><source>J Invest Dermatol</source><volume>62</volume><year>1974</year><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">4835777</pub-id></element-citation></ref><ref id="bb0455"><element-citation publication-type="journal" id="rf0455"><person-group person-group-type="author"><name><surname>Wind</surname><given-names>B.S.</given-names></name><name><surname>Kroon</surname><given-names>M.W.</given-names></name><name><surname>Meesters</surname><given-names>A.A.</given-names></name><name><surname>Beek</surname><given-names>J.F.</given-names></name><name><surname>van der Veen</surname><given-names>J.P.</given-names></name><name><surname>Nieuweboer-Krobotov&#x000e1;</surname><given-names>L.</given-names></name><name><surname>Bos</surname><given-names>J.D.</given-names></name><name><surname>Wolkerstorfer</surname><given-names>A.</given-names></name></person-group><article-title>Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study</article-title><source>Lasers Surg Med</source><volume>42</volume><year>2010</year><fpage>607</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">20806385</pub-id></element-citation></ref><ref id="bb0120"><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Yentzer</surname><given-names>B.A.</given-names></name><name><surname>Hick</surname><given-names>J.</given-names></name><name><surname>Reese</surname><given-names>E.L.</given-names></name><name><surname>Uhas</surname><given-names>A.</given-names></name><name><surname>Feldman</surname><given-names>S.R.</given-names></name><name><surname>Balkrishnan</surname><given-names>R.</given-names></name></person-group><article-title>Acne vulgaris in the United States: a descriptive epidemiology</article-title><source>Cutis</source><volume>86</volume><year>2010</year><fpage>94</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">20919604</pub-id></element-citation></ref><ref id="bb0145"><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>N.C.</given-names></name><name><surname>McMichael</surname><given-names>A.J.</given-names></name></person-group><article-title>Acne in patients with skin of color: practical management</article-title><source>Am J Clin Dermatol</source><volume>15</volume><year>2014</year><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">24190453</pub-id></element-citation></ref><ref id="bb0035"><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Yoshida-Amano</surname><given-names>Y.</given-names></name><name><surname>Hachiya</surname><given-names>A.</given-names></name><name><surname>Ohuchi</surname><given-names>A.</given-names></name><name><surname>Kobinger</surname><given-names>G.P.</given-names></name><name><surname>Kitahara</surname><given-names>T.</given-names></name><name><surname>Takema</surname><given-names>Y.</given-names></name><name><surname>Fukuda</surname><given-names>M.</given-names></name></person-group><article-title>Essential role of RAB27A in determining constitutive human skin color</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e41160</fpage><pub-id pub-id-type="pmid">22844437</pub-id></element-citation></ref><ref id="bb0425"><element-citation publication-type="journal" id="rf0425"><person-group person-group-type="author"><name><surname>Zaleski</surname><given-names>L.</given-names></name><name><surname>Fabi</surname><given-names>S.</given-names></name><name><surname>Goldman</surname><given-names>M.P.</given-names></name></person-group><article-title>Treatment of melasma and the use of intense pulsed light: a review</article-title><source>J Drugs Dermatol</source><volume>11</volume><year>2012</year><fpage>1316</fpage><lpage>1320</lpage><pub-id pub-id-type="pmid">23135081</pub-id></element-citation></ref></ref-list><sec id="s0135"><label>Appendix A</label><title>US Preventive Services Task Force levels of evidence for grading clinical trials (<xref rid="bb0305" ref-type="bibr">Sheth and Pandya, 2011b</xref>)</title><p><table-wrap id="t0030" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left">Level of evidence</th><th align="left">Quality of evidence</th></tr></thead><tbody><tr><td align="left">I</td><td align="left">Evidence obtained from at least one properly designed, randomized controlled trial</td></tr><tr><td align="left">II-i</td><td align="left">Evidence obtained from well designed controlled trials without randomization</td></tr><tr><td align="left">II-ii</td><td align="left">Evidence obtained from well designed cohort or case control analytical studies, preferably from more than one center or research group</td></tr><tr><td align="left">II-iii</td><td align="left">Evidence obtained from multiple time series with or without the intervention; dramatic results in uncontrolled experiments could also be regarded as this type of evidence</td></tr><tr><td align="left">III</td><td align="left">Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees</td></tr><tr><td align="left">IV</td><td align="left">Evidence inadequate because of problems of methodology (eg, sample size or length of comprehensiveness of follow-up or conflicts in evidence)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="left">Strength of recommendations</th></tr></thead><tbody><tr><td align="left">A</td><td align="left">There is good evidence to support the use of the procedure</td></tr><tr><td align="left">B</td><td align="left">There is fair evidence to support the use of the procedure</td></tr><tr><td align="left">C</td><td align="left">There is poor evidence to support the use of the procedure</td></tr><tr><td align="left">D</td><td align="left">There is fair evidence to support the rejection of the use of the procedure</td></tr><tr><td align="left">E</td><td align="left">There is good evidence to support the rejection of the use of the procedure</td></tr></tbody></table></table-wrap></p></sec><fn-group><fn id="d31e994"><label>&#x02606;</label><p id="np0005">This article has no funding source.</p></fn><fn id="d31e999"><label>&#x02606;&#x02606;</label><p id="np0010">We declare the following conflicts of interest: Dr. Valerie Callender is a Consultant and Speaker for Allergan, Inc. The remaining authors do not have any conflicts of interest to disclose.</p></fn><fn id="d31e1004"><label>&#x02605;</label><p id="np1005">This article is a reprint of a previously published article. For citation purposes, please use the original publication details; International Journal of Women's Dermatology 1 (2015) 59-75. DOI of original item: 10.1016/j.ijwd.2015.04.002.</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Fig.&#x000a0;1</label><caption><p>Acne in an African American female (Courtesy of Susan C. Taylor, MD, et al; from <italic>Treatments for Skin of Color</italic>, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Fig.&#x000a0;2</label><caption><p>Acne and Postinflammatory Hyperpigmentation (Courtesy of Valerie Callender, MD; Callender Dermatology &#x00026; Cosmetic Center, Glenn Dale, MD).</p></caption><graphic xlink:href="gr2"/></fig><fig id="f0015"><label>Fig.&#x000a0;3</label><caption><p>Pomade acne. Note the closed comedones on the forehead and temples. (Courtesy of Valerie Callender, MD; from <italic>Treatments for Skin of Color</italic> by Susan C. Taylor, MD, et al, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr3"/></fig><fig id="f0020"><label>Fig.&#x000a0;4</label><caption><p>Acne and PIH algorithm (Modified from <italic>Treatments for Skin of Color</italic> by Susan C. Taylor, MD, et al, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr4"/></fig><fig id="f0025"><label>Fig.&#x000a0;5</label><caption><p>Melasma, malar variant (Courtesy of Jean Bolognia, MD; from <italic>Dermatology</italic>, copyright Elsevier, 3rd ed., 2012).</p></caption><graphic xlink:href="gr5"/></fig><fig id="f0030"><label>Fig.&#x000a0;6</label><caption><p>Melasma, centrofacial variant with sparing of the philtrum (Courtesy of Jean Bolognia, MD; from <italic>Dermatology</italic>, copyright Elsevier, 3rd ed., 2012).</p></caption><graphic xlink:href="gr6"/></fig><fig id="f0035"><label>Fig.&#x000a0;7</label><caption><p>(Left to right) Electric curling iron, hot comb and ceramic flat iron (Courtesy of Valerie Callender, MD; from <italic>Treatments for Skin of Color</italic> by Susan C. Taylor, MD, et al, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr7"/></fig><fig id="f0040"><label>Fig.&#x000a0;8</label><caption><p>Chemical relaxer application to hair (Courtesy of Susan C. Taylor, MD, et al; from <italic>Treatments for Skin of Color</italic>, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr8"/></fig><fig id="f0045"><label>Fig.&#x000a0;9</label><caption><p>Traction alopecia (Courtesy of Valerie Callender, MD; from <italic>Treatments for Skin of Color</italic> by Susan C. Taylor, MD, et al, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr9"/></fig><fig id="f0050"><label>Fig.&#x000a0;10</label><caption><p>Trichorrhexis nodosa in the temporal scalp region (Courtesy of Valerie Callender, MD; from <italic>Treatments for Skin of Color</italic> by Susan C. Taylor, MD, et al, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr10"/></fig><fig id="f0055"><label>Fig.&#x000a0;11</label><caption><p>Early stage CCCA (Courtesy of Susan C. Taylor, MD, et al; from <italic>Treatments for Skin of Color</italic>, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr11"/></fig><fig id="f0060"><label>Fig.&#x000a0;12</label><caption><p>CCCA (Courtesy of Susan C. Taylor, MD, et al; from <italic>Treatments for Skin of Color</italic>, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr12"/></fig><fig id="f0065"><label>Fig.&#x000a0;13</label><caption><p>CCCA in an African American woman (Courtesy of Jean Bolognia, MD; from <italic>Dermatology</italic>, copyright Elsevier, 3rd ed., 2012).</p></caption><graphic xlink:href="gr13"/></fig><fig id="f0070"><label>Fig.&#x000a0;14</label><caption><p>Late stage CCCA (Courtesy of Susan C. Taylor, MD, et al; from <italic>Treatments for Skin of Color</italic>, copyright Elsevier 2011).</p></caption><graphic xlink:href="gr14"/></fig><fig id="f0075"><label>Fig.&#x000a0;15</label><caption><p>FFA in an African American female. Note the symmetrical band-like loss of hair on the frontotemporal hairline and scalp. (Courtesy of Valerie Callender, MD; Callender Dermatology &#x00026; Cosmetic Center, Glenn Dale, MD).</p></caption><graphic xlink:href="gr15"/></fig><table-wrap id="t0005" position="float"><label>Table&#x000a0;1</label><caption><p>Top Ten Dermatologic Conditions Among Caucasian Versus Skin of Color Patients in the United States.<xref rid="tf0005" ref-type="table-fn">&#x0204e;</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Caucasians</th><th align="left">African Americans</th><th align="left">Asian or Pacific Islanders</th><th align="left">Hispanics or Latinos</th></tr></thead><tbody><tr><td align="left">Actinic keratosis</td><td align="left">Acne vulgaris</td><td align="left">Acne vulgaris</td><td align="left">Acne vulgaris</td></tr><tr><td align="left">Acne vulgaris</td><td align="left">Unspecified dermatitis or eczema</td><td align="left">Unspecified dermatitis or eczema</td><td align="left">Unspecified dermatitis or eczema</td></tr><tr><td align="left">Benign neoplasm of the skin</td><td align="left">Seborrheic dermatitis</td><td align="left">Benign neoplasm of the skin</td><td align="left">Psoriasis</td></tr><tr><td align="left">Unspecified dermatitis or eczema</td><td align="left">Atopic dermatitis</td><td align="left">Psoriasis</td><td align="left">Benign neoplasm of the skin</td></tr><tr><td align="left">Non-melanoma skin cancer</td><td align="left">Dyschromia</td><td align="left">Seborrheic keratosis</td><td align="left">Viral warts</td></tr><tr><td align="left">Seborrheic keratosis</td><td align="left">Psoriasis</td><td align="left">Atopic dermatitis</td><td align="left">Actinic keratosis</td></tr><tr><td align="left">Viral warts</td><td align="left">Alopecia</td><td align="left">Viral warts</td><td align="left">Seborrheic keratosis</td></tr><tr><td align="left">Psoriasis</td><td align="left">Keloid scar</td><td align="left">Urticaria</td><td align="left">Sebaceous cyst</td></tr><tr><td align="left">Rosacea</td><td align="left">Viral warts</td><td align="left">Sebaceous cyst</td><td align="left">Rosacea</td></tr><tr><td align="left">Sebaceous cyst</td><td align="left">Sebaceous cyst</td><td align="left">Seborrheic dermatitis</td><td align="left">Dyschromia</td></tr></tbody></table><table-wrap-foot><fn id="tf0005"><label>&#x0204e;</label><p id="np0015">Listed in order of decreasing frequency. Table adapted from Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. <italic>J Drugs Dermatol</italic>. 2012;11:466-73.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table&#x000a0;2</label><caption><p>Comparison of the Structure and Function of Skin and Hair Between Caucasians and African Americans.<xref rid="tf0010" ref-type="table-fn">&#x0204e;</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Caucasians</th><th align="left">African Americans</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">Stratum corneum thickness</td><td align="left">Equal</td><td align="left">Equal</td><td align="left"><xref rid="bb9000" ref-type="bibr">Weigand et al. (1974)</xref></td></tr><tr><td align="left">Stratum corneum layers</td><td align="left">Less</td><td align="left">More</td><td align="left"><xref rid="bb9000" ref-type="bibr">Weigand et al. (1974)</xref></td></tr><tr><td align="left">Stratum corneum lipids</td><td align="left">Low</td><td align="left">High</td><td align="left"><xref rid="bb9010" ref-type="bibr">La Ruche and Cesarini (1992)</xref></td></tr><tr><td align="left">Corneocyte detachment</td><td align="left">High</td><td align="left">Low</td><td align="left"><xref rid="bb0050" ref-type="bibr">Chu and Kollias (2011)</xref></td></tr><tr><td align="left">Ceramide concentration</td><td align="left">High</td><td align="left">Low</td><td align="left"><xref rid="bb0055" ref-type="bibr">Jungersted et al. (2010)</xref></td></tr><tr><td align="left">Melanin content</td><td align="left">Low</td><td align="left">High</td><td align="left"><xref rid="bb0025" ref-type="bibr">Wakamatsu et al. (2006)</xref></td></tr><tr><td align="left">Melanosomes</td><td align="left">Small, aggregated</td><td align="left">Large, dispersed; higher number transferred to keratinocytes</td><td align="left"><xref rid="bb0035" ref-type="bibr">Yoshida-Amano et al. (2012)</xref></td></tr><tr><td align="left">Dermis</td><td align="left">Thin, less compact</td><td align="left">Thick, more compact</td><td align="left"><xref rid="bb0065" ref-type="bibr">Girardeau-Hubert et al. (2012)</xref></td></tr><tr><td align="left">Papillary and reticular layers</td><td align="left">More distinct</td><td align="left">Less distinct</td><td align="left"><xref rid="bb0065" ref-type="bibr">Girardeau-Hubert et al. (2012)</xref></td></tr><tr><td align="left">Collagen fiber bundles</td><td align="left">Larger</td><td align="left">Smaller, closely stacked</td><td align="left"><xref rid="bb0065" ref-type="bibr">Girardeau-Hubert et al. (2012)</xref></td></tr><tr><td align="left">Fiber fragments</td><td align="left">Sparse</td><td align="left">Prominent, numerous</td><td align="left"><xref rid="bb0065" ref-type="bibr">Girardeau-Hubert et al. (2012)</xref></td></tr><tr><td align="left">Hair shaft structure</td><td align="left">Straight or slightly curved</td><td align="left">Tightly coiled, spiral</td><td align="left"><xref rid="bb9005" ref-type="bibr">Lindelof et al. (1998)</xref></td></tr><tr><td align="left">Cross-section of hair</td><td align="left">Slightly less round than Asian hair</td><td align="left">Oval or elliptical shape</td><td align="left"><xref rid="bb9005" ref-type="bibr">Lindelof et al. (1998)</xref></td></tr><tr><td align="left">Tensile strength of hair</td><td align="left">Higher</td><td align="left">Lower</td><td align="left"><xref rid="bb0070" ref-type="bibr">Ji et al. (2013)</xref></td></tr></tbody></table><table-wrap-foot><fn id="tf0010"><label>&#x0204e;</label><p id="np0020">Table modified from Badreshia-Bansal S, Taylor S. The Structure and Function of Skin of Color. In: Kelly AP, Taylor SC, eds. <italic>Dermatology for skin of color</italic>. New York, NY: McGraw-Hill companies. 2009:71-77.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0015" position="float"><label>Table&#x000a0;3</label><caption><p>Review of Acne in Skin of Color.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Authors</th><th align="left">Study Design</th><th align="left">Total # of Subjects (N)</th><th align="left">Summary of Results</th><th align="left">Level of Evidence</th><th align="left">Strength of Recommendation</th></tr></thead><tbody><tr><td align="left"><xref rid="bb0180" ref-type="bibr">Tirado-Sanchez et al. (2013)</xref></td><td align="left">Single-center, randomized, double-blinded placebo-controlled study</td><td align="left">171 subjects (F=94; M =&#x000a0;77)</td><td align="left">At 90 days of treatment, the efficacy rates of tretinoin 0.05% gel, adapalene 0.3% gel and adapalene 0.1% gel were 80%, 70%, and 59% respectively.<break/>Tolerance was better with adapalene 0.1% gel than with adapalene 0.3% and tretinoin 0.05% gel (P = 0.001).</td><td align="left">I</td><td align="left">A</td></tr><tr><td align="left"><xref rid="bb0185" ref-type="bibr">Grimes and Callender (2006)</xref></td><td align="left">Multicenter, randomized, double-blinded, vehicle-controlled study</td><td align="left">74 subjects (F=65; M=9)</td><td align="left">Once-daily tazarotene 0.1% cream was significantly more effective than vehicle in lessening PIH overall (P = 0.010), and in reducing the intensity (P = 0.044) and area of hyperpigmented lesions (P = 0.026) within 18 weeks.</td><td align="left">I</td><td align="left">A</td></tr><tr><td align="left"><xref rid="bb0190" ref-type="bibr">Alexis et al. (2014)</xref></td><td align="left">Multicenter, randomized, double-blinded, placebo-controlled study</td><td align="left">238 subjects (F=166; M=72)</td><td align="left">After 12 weeks, significant reductions in total, inflammatory and noninflammatory lesion counts were observed with adapalene 0.1%/BPO 2.5% gel than vehicle.<break/>After 12 weeks, most subjects reported no dryness (&#x0003e;&#x000a0;89.9%), no erythema (&#x0003e;&#x000a0;90.9%), no scaling (&#x0003e;&#x000a0;96.0%), or no stinging/burning (&#x0003e;&#x000a0;94.9) with adapalene-BPO treatment.</td><td align="left">I</td><td align="left">A</td></tr><tr><td align="left"><xref rid="bb0195" ref-type="bibr">Callender (2012)</xref></td><td align="left">Multicenter, randomized, double-blinded, vehicle-controlled study</td><td align="left">797 subjects (F=408; M=389)</td><td align="left">Treatment success with clindamycin phosphate 1.2%/BPO 2.5% gel was comparable between FST I-III and FST IV-VI at week 12.<break/>Patients with FST IV-VI were not found to be more susceptible to cutaneous irritation than patients with FST I-III.</td><td align="left">I</td><td align="left">A</td></tr><tr><td align="left"><xref rid="bb0200" ref-type="bibr">Callender et al. (2012a)</xref></td><td align="left">Multicenter, randomized, double-blinded, placebo-controlled study</td><td align="left">33 subjects (F=26; M=7)</td><td align="left">Clindamycin phosphate 1.2%/tretinoin 0.025% gel-treated patients had a greater decrease in inflammatory lesion counts from baseline than vehicle group at week 12 (P = 0.05).</td><td align="left">I</td><td align="left">B</td></tr><tr><td align="left"><xref rid="bb0205" ref-type="bibr">Kircik (2011)</xref></td><td align="left">Single-center, open-label pilot study</td><td align="left">20 subjects (F=15; M=5)</td><td align="left">At week 16, azelaic acid 15% gel applied twice daily resulted in 92% of subjects with at least a one-point improvement in IGA for acne and 100% of subjects had at least a 2-point improvement in IGA for PIH.</td><td align="left">II-iii</td><td align="left">B</td></tr><tr><td align="left"><xref rid="bb0215" ref-type="bibr">Piette et al. (2008)</xref></td><td align="left">Multicenter, randomized, double-blinded, vehicle-controlled crossover study</td><td align="left">64 subjects (F=35; M=29)</td><td align="left">Subjects with glucose-6-phosphate dehydrogenase deficiency (G6PD) treated with dapsone 5% gel had only a 0.32 g/dL decrease in hemoglobin levels from baseline to 2 weeks; however, no changes were noted in reticulocytes, haptoglobin, bilirubin or lactate dehydrogenase levels.</td><td align="left">I</td><td align="left">A</td></tr><tr><td align="left"><xref rid="bb0220" ref-type="bibr">Fleischer et al. (2006)</xref></td><td align="left">Multicenter, randomized, double-blinded, placebo-controlled study</td><td align="left">1038 subjects (F=449; M=589)</td><td align="left">An extended release formulation of minocycline hydrochloride was evaluated in subjects with moderate to severe acne in a phase 2 dose finding study and two phase 3 safety and efficacy trials. Study participants received minocycline 1 mg/kg daily or placebo over 12 weeks.<break/>The number of inflammatory lesions was reduced and significant improvement was noted in the Evaluator&#x02019;s Global Severity Assessment scores. In both the placebo and treatment groups, acute vestibular adverse events (AVAEs) were comparable. The authors concluded that extended release minocycline reduces dose dependent AVAEs, inflammatory lesions, and improves overall appearance of acne patients.</td><td align="left">I</td><td align="left">A</td></tr><tr><td align="left"><xref rid="bb0225" ref-type="bibr">Ullah et al. (2014)</xref></td><td align="left">Single-center, randomized controlled study</td><td align="left">386 subjects (F=215; M=171)</td><td align="left">Subjects with moderate acne received either azithromycin 500 mg daily before meals for 4 consecutive days monthly for 3 months or doxycycline 100 mg daily after meals for 3 months and followed up after 3 months. An excellent response was noted in 3.1% and a good response was observed in 22.8% in the azithromycin group. In the doxycycline group, 11.4% had excellent and 55.4% had a good response. The authors concluded that doxycycline is the better treatment option for acne.</td><td align="left">I</td><td align="left">A</td></tr><tr><td align="left"><xref rid="bb0230" ref-type="bibr">Tan et al. (2014)</xref></td><td align="left">Multicenter, randomized, controlled, noninferiority, investigator-blinded study</td><td align="left">266 subjects (F=39; M=227)</td><td align="left">The efficacy and safety of oral isotretinoin versus doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) was compared in subjects with severe nodular acne over 20 weeks. The authors found that D+A/BPO showed a favorable composite efficacy/safety profile compared with isotretinoin and concluded that this combination can be used as an alternative to isotretinoin in severe nodular acne.</td><td align="left">I</td><td align="left">A</td></tr><tr><td align="left"><xref rid="bb0255" ref-type="bibr">Kelly and Sampson (1987)</xref></td><td align="left">Case series</td><td align="left">10 subjects</td><td align="left">10 African American subjects with recalcitrant nodulocystic acne treated with isotretinoin developed an early onset flare of nodulocystic lesions at sites initially devoid of acne lesions at weeks 2-4.<break/>At completion of the study, an improvement in PIH was noted.<break/>Between weeks 2-8, most subjects developed a reversible ashen or grayish facial hue (due to the drying and desquamative effects of isotretinoin).</td><td align="left">II-iii</td><td align="left">B</td></tr><tr><td align="left"><xref rid="bb0260" ref-type="bibr">Khunger et al. (2011)</xref></td><td align="left">Case series</td><td align="left">30 subjects (F=20; M=10)</td><td align="left">Subjects with FST IV and V with atrophic ice pick acne scars were primed for 2 weeks (with hydroquinone 4% cream in the morning and tretinoin 0.025% cream at night) prior to receiving focal application of 100% trichloroacetic acid (TCA) to each scar at 2-week intervals for 4 sessions.<break/>Excellent improvement was seen in 73.3% of subjects, while 20% showed good improvement and 6.7% had fair results. Transient hypopigmentation was observed in 1 patient and hyperpigmentation was observed in 2 patients. No significant prolonged pigmentary changes or scarring were noted at 3 month follow-up.</td><td align="left">II-iii</td><td align="left">C</td></tr><tr><td align="left"><xref rid="bb0265" ref-type="bibr">Gold (2012)</xref></td><td align="left">Case series</td><td align="left">5 subjects (F=3; M=2)</td><td align="left">Subjects with FST IV and V treated with a novel superficial and deep AcuPulse MultiMode carbon dioxide (CO2) fractional laser had clinically significant improvement in acne and no reports of PIH were noted.</td><td align="left">II-iii</td><td align="left">C</td></tr><tr><td align="left"><xref rid="bb0270" ref-type="bibr">Semchyshyn et al. (2013)</xref></td><td align="left">Case series</td><td align="left">20 subjects</td><td align="left">Subjects with FST IV through VI treated with a nonablative 450-nm diode laser found it to be effective in improving the appearance of atrophic acne scars, however, PIH was common in 56% of subjects.</td><td align="left">II-iii</td><td align="left">C</td></tr><tr><td align="left"><xref rid="bb0275" ref-type="bibr">Karnik et al. (2014)</xref></td><td align="left">Multicenter, randomized, double-blinded, controlled study</td><td align="left">147 subjects (F&#x000a0;= 90; M =&#x000a0;57)</td><td align="left">Subjects with at least 4 moderate to severe rolling, atrophic scars randomly received polymethylmethacrylate (PMMA) suspended in bovine collagen (PMMA-collagen) or saline injections. Subjects underwent up to 2 injection sessions and were followed up for 6 months. Success was achieved by 64% of those treated with PMMA-collagen compared with 33% of control subjects (P = .0005). The treatment showed excellent safety with generally mild, reversible adverse events. No significant differences in efficacy or safety were noted between genders, for darker skin types, or in older age groups.</td><td align="left">I</td><td align="left">B</td></tr></tbody></table><table-wrap-foot><fn id="sp0025"><p>* In accordance with the US Preventive Services Task Force levels of evidence for grading clinical trials (<xref rid="bb0305" ref-type="bibr">Sheth and Pandya, 2011b</xref>), (see <xref rid="s0135" ref-type="sec">Appendix A</xref>).</p></fn><fn id="sp0030"><p>Abbreviations: F, female; M, male; BPO, benzoyl peroxide; PIH, postinflammatory hyperpigmentation; FST, Fitzpatrick skin type; IGA, investigator global assessment.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0020" position="float"><label>Table&#x000a0;4</label><caption><p>Levels of evidence and strength of recommendations for various peeling agents in ethnic skin (<xref rid="bb0355" ref-type="bibr">Sarkar et al., 2012</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Peeling agent</th><th align="left">Level of evidence</th><th align="left">Strength of recommendation</th></tr></thead><tbody><tr><td align="left">Glycolic acid peel</td><td align="left">II-i</td><td align="left">A</td></tr><tr><td align="left">Lactic acid peel</td><td align="left">II-iii</td><td align="left">B</td></tr><tr><td align="left">Salicylic acid peel</td><td align="left">II-iii</td><td align="left">B</td></tr><tr><td align="left">Trichloroacetic acid peel</td><td align="left">II-iii</td><td align="left">B</td></tr><tr><td align="left">Jessner&#x02019;s solution</td><td align="left">II-iii</td><td align="left">B</td></tr><tr><td align="left">Phytic acid peel</td><td align="left">III</td><td align="left">C</td></tr><tr><td align="left">Pyruvic acid peel</td><td align="left">III</td><td align="left">C</td></tr></tbody></table><table-wrap-foot><fn><p>* In accordance with the US Preventive Services Task Force levels of evidence for grading clinical trials (<xref rid="bb0305" ref-type="bibr">Sheth and Pandya, 2011b</xref>), (see <xref rid="s0135" ref-type="sec">Appendix A</xref>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0025" position="float"><label>Table&#x000a0;5</label><caption><p>Levels of evidence and strength of recommendations for lasers and light based devices for treating melasma in skin of color.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Type of laser</th><th align="left"/><th align="left">Level of evidence</th><th align="left">Strength of recommendation</th><th align="left">Side effects and complications</th></tr></thead><tbody><tr><td rowspan="6" align="left">Q switched lasers</td><td rowspan="2" align="left">Q switched Ruby (<xref rid="bb0380" ref-type="bibr">Jang et al., 2011</xref>, <xref rid="bb0395" ref-type="bibr">Hilton et al., 2013</xref>)</td><td rowspan="2" align="left">II-iii</td><td rowspan="2" align="left">C</td><td align="left">PIH and recurrence of melasma</td></tr><tr><td align="left">Post operative discomfort</td></tr><tr><td align="left">Q switched Alexandrite (<xref rid="bb0400" ref-type="bibr">Fabi et al., 2014</xref>, <xref rid="bb0405" ref-type="bibr">Rusciani et al., 2005</xref>)</td><td align="left">II-iii</td><td align="left">C</td><td align="left">PIH</td></tr><tr><td rowspan="3" align="left">Q switched Nd:Yag-&#x0201c;laser toning/laser facial&#x0201d; (<xref rid="bb0410" ref-type="bibr">Wattanakrai et al., 2010</xref>, <xref rid="bb0415" ref-type="bibr">Bansal et al., 2012</xref>, <xref rid="bb0420" ref-type="bibr">Sim et al., 2014</xref>)</td><td rowspan="3" align="left">I</td><td rowspan="3" align="left">B</td><td align="left">Erythema, burning, swelling, whitening of hair Spotty depigmentation</td></tr><tr><td align="left">Rebound hyperpigmentation</td></tr><tr><td align="left">Recurrence of melasma</td></tr><tr><td rowspan="3" align="left">Light devices</td><td rowspan="3" align="left">IPL (<xref rid="bb0425" ref-type="bibr">Zaleski et al., 2012</xref>)</td><td rowspan="3" align="left">II-iii</td><td rowspan="3" align="left">C</td><td align="left">Erythema</td></tr><tr><td align="left">Pain</td></tr><tr><td align="left">PIH</td></tr><tr><td rowspan="3" align="left">Fractional Ablative lasers</td><td align="left">Erbium:YAG (<xref rid="bb0430" ref-type="bibr">Attwa et al., 2014</xref>, <xref rid="bb0435" ref-type="bibr">Manaloto and Alster, 1999</xref>)</td><td align="left">II-iii</td><td align="left">C</td><td align="left">PIH</td></tr><tr><td rowspan="2" align="left">CO2 (<xref rid="bb0440" ref-type="bibr">Jalaly et al., 2014</xref>, <xref rid="bb0445" ref-type="bibr">Neeley et al., 2010</xref>)</td><td rowspan="2" align="left">II-iii</td><td rowspan="2" align="left">C</td><td align="left">PIH</td></tr><tr><td align="left">Rebound melasma</td></tr><tr><td align="left">Vascular lasers</td><td align="left">PDL (<xref rid="bb0450" ref-type="bibr">Passeron et al., 2011</xref>)</td><td align="left">II-iii</td><td align="left">C</td><td align="left">PIH</td></tr><tr><td rowspan="2" align="left">Fractional lasers<break/>Non- ablative (<xref rid="bb0455" ref-type="bibr">Wind et al., 2010</xref>)</td><td align="left">Non-ablative 1,550 nm fractional laser therapy</td><td align="left">I</td><td align="left">C</td><td align="left">Erythema, burning sensation, edema, pain and PIH</td></tr><tr><td align="left">1,927-nm thulium fiber laser (<xref rid="bb0460" ref-type="bibr">Polder and Bruce, 2012</xref>)</td><td align="left">II-iii</td><td align="left">C</td><td align="left">Moderate erythema and mild edema</td></tr></tbody></table><table-wrap-foot><fn id="sp0050"><p>* In accordance with the US Preventive Services Task Force levels of evidence for grading clinical trials (<xref rid="bb0305" ref-type="bibr">Sheth and Pandya, 2011b</xref>), (see <xref rid="s0135" ref-type="sec">Appendix A</xref>).</p></fn><fn id="sp0055"><p>Abbreviations: IPL, intense pulsed light; PDL, pulsed dye laser; PIH, postinflammatory hyperpigmentation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>